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1
CHAPTER 1
INTRODUCTION
1.1 Biology of the Nervous System
The nervous system can be broken down into two parts, the central nervous system (CNS)
which is composed of the brain and spinal cord, and the peripheral nervous system (PNS),
consisting of nerves, ganglia, and the enteric nervous system which controls the gastrointestinal
system (Chapman & Silkwood-Sherer 2000). These two parts of the nervous system come
together where nerves enter and exit the spinal cord and the brain, in spinal and cranial nerves
respectively. Spinal nerves enter and exit the spinal cord through openings between adjacent
vertebrae and correspond roughly to segments of the vertebral column. Figure 1.1.1 (A) shows
how the spinal cord is encased in the vertebral column and where spinal nerves join the
periphery. Sensory information comes into the spinal cord from the periphery through nerves
entering dorsal roots, while motor information leaves the spinal cord through nerves exiting
ventral roots, sending motor signals to the periphery (Chapman & Silkwood-Sherer 2000; Squire
et al 2008). Spinal nerves handle sensory and motor information from the limbs and trunk.
Figure 1.1.1 (B) shows the basic structure of the spinal cord and how dorsal and ventral roots
leave the spinal cord and come together to form spinal nerves. Cranial nerves, which emerge
from the brain directly, deal with sensory and motor information from the head and neck
(Chapman & Silkwood-Sherer 2000; McNeill 1997).
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Figure 1.1.1 Overview of spinal cord structure and spinal nerves.
A. The general structure of the spinal column. The spinal cord is encased by the vertebrae with
spinal nerves roughly corresponing to each vertebrae, entering the periphery through spaces
between them. B. The general structure of the spinal cord. Grey matter is found in the center
of the spinal cord and consists of neuronal cell bodies that receive sensory information that
enters through dorsal roots. Motor information exits the spinal cord through ventral roots. White
matter surrounds the grey matter and consists of tracts of myelinated axons that send
information up and down the spinal cord.
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Both the CNS and the PNS are composed of a variety of cell types that work cooperatively
to maintain homeostasis and allow for intercellular communication through electrochemical
signaling. There are two main types of cells that make up the nervous system, neurons and
glial cells.
Neurons are polarized cells that can be divided into distinct sub cellular regions, each of
which carries out a different set of functions (Cooper et al 2003; Nestler et al 2001; Squire et al
2008). They come in a variety of shapes and sizes but can be broken down into a basic
morphology consisting of three regions: 1) the soma (cell body), containing the nucleus and
cytoplasmic organelles; 2) dendrites, which branch from the soma and vary in size, shape, and
number depending upon the type of neuron; and 3) a single axon, which is rich in
neurofilaments, extending a distance from the cell body to make contacts with other neurons
(Cooper et al 2003; Nestler et al 2001; Squire et al 2008). These three basic compartments of a
neuron can be seen in Figure 1.1.2. Dendrites, neuronal cell bodies, and unmyelinated axons
make up grey matter.
Dendrites receive electrochemical signals from other neurons, which are integrated at the
cell body and passed down the axon in the form of action potentials to signal other neurons or
organs. In order to send these signals, neurons express a variety of ion channels and pumps to
maintain an electrochemical gradient across the membrane. They also express a variety of
neurotransmitter receptors coupled to ion channels, which alter the electrochemical gradient for
signaling. The connections between pre- and post-synaptic neurons are dynamic, with the
formation of new synapses and the removal of unused synapses occurring constantly.
Maintaining and resetting electrochemical gradients after an action potential, and synaptic
restructuring both require a significant amount of energy which is provided by supporting cells.
Glial cells are a broad category of cells that serve structural and supportive functions in the
nervous system. In the CNS there are three main types of glia, oligodendrocytes, astrocytes,
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Figure 1.1.2 Basic cellular interactions in the central nervous system.
There is a complex set of interactions that occur between neurons, astrocytes, and
oligodendrocytes in the central nervous system. Astrocytes can make several connections with
neurons - at the soma, at nodes of Ranvier (between myelin sheaths), and at synapses – while
also making connections with blood vessels and other astrocytes. Oligodendrocytes (OL) send
out several processes to myelinate multiple axons.
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and microglia, whereas the PNS has only one major type of glial cell, Schwann cells (Chapman
& Silkwood-Sherer 2000; Squire et al 2008).

Both oligodendrocytes and Schwann cells

synthesize myelin, a fatty substance that wraps around axons to accelerate the propagation of
action potentials. Although they are similar in function, oligodendrocytes and Schwann cells
have very different morphological features. Oligodendrocytes have a cell body that gives rise to
several processes, each of which is composed of a long, extremely thin layer of plasma
membrane that wraps around a portion of an axon to produce myelin. A single oligodendrocyte
produces and maintains several myelin sheaths, myelinating segments of multiple axons.
Figure 1.1.2 illustrates an oligodendrocyte myelinating an axon in the CNS. Schwann cells, on
the other hand, are very thin, pancake-shaped cells that wrap their entire cell body around a
single axon segment to produce myelin.

As a result, it takes multiple Schwann cells to

myelinate a single axon in the PNS. Axons are myelinated in small segments, with gaps called
nodes of Ranvier between segments of myelin (Chapman & Silkwood-Sherer 2000; Nestler et al
2001; Squire et al 2008). Myelinated axons have a characteristic white color and make up the
portion of the CNS referred to as white matter.
Astrocytes and microglia are two very different types of cells that also serve supporting
roles in the CNS. In most areas of the brain, astrocytes make up 20-50% of the volume (Squire
et al 2008). They are star-shaped cells, and like oligodendrocytes, extend several processes
from their cell bodies.

These processes branch out and serve a variety of structural and

supportive functions throughout the CNS, and are extremely important in maintaining
homeostasis and supporting neuron function (Squire et al 2008). They help form barriers within
the CNS, the glia limitans (Squire et al 2008) as well as the blood-brain, blood-cerebrospinal
fluid, and blood-spinal cord barriers (BBB, BCSFB, and BSCB respectively), providing protection
from pathogens and other types of insults (Abbott 2002; Engelhardt & Coisne 2011). They also
extend processes to nodes of Ranvier, synapses, dendrites, and neuronal cell bodies where
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they help to buffer ion fluxes during action potentials, remove excess neurotransmitters, and
provide much needed metabolic intermediates to active neurons (Fields & Stevens-Graham
2002; Prebil et al 2011; Squire et al 2008; Turner & Adamson 2011). Astrocytes are connected
to one another by gap junctions, which allows for the movement of small molecules and ions
across the brain parenchyma. Figure 1.1.2 shows some of the interactions that astrocytes can
make within the CNS. Astrocytes also produce growth factors and extracellular matrix proteins
which act to regulate survival, proliferation, differentiation, and the morphology of other cell
types in the nervous system. In addition, astrocytes have the potential to become activated and
produce cytokines during injury and infection playing an immunological role as well (Dong &
Benveniste 2001; Squire et al 2008).
Microglia are considered to be the resident macrophages of the CNS, which has
traditionally been thought of as an immunologically privileged tissue (Murphy et al 2008). The
physical barriers produced by astrocytes make it difficult for antibodies and peripheral immune
cells, such as natural killer cells, T-cells, and macrophages, to infiltrate the CNS to fight
infection. Microglia, which develop from monocytes derived from bone-marrow, have the ability
to phagocytose apoptotic cells (Murphy et al 2008; Nicklin et al 2009) and provide the first line of
defense during infection. In the case of injury or infection, microglia become reactive, changing
their morphology and upregulating molecules involved in immune responses. They can divide
and behave like macrophages, secrete cytokines and growth factors, and present antigens to Tcells (Murphy et al 2008; Squire et al 2008; Town et al 2005).

Microglia react quickly in

response to alterations in their environment and can act in conjunction with astrocytes to regain
homeostasis.
In the healthy nervous system, there is a delicate interplay between all of the various cell
types which allows for rapid transmission of signals between neurons and a quick response of
the person to environmental factors. Astrocytes maintain barriers which separate the CNS from
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the circulating blood, selectively allowing the entry of nutrients and peripheral immune cells and
the exit of waste, while blocking the entry of pathogens (Abbott 2002; Engelhardt & Coisne
2011; Fields & Stevens-Graham 2002; Redzic 2011; Squire et al 2008).

Neurons with

myelinated axons communicate quickly with each other through electrochemical signals, which
are regulated by astrocytes. During neuronal signaling, astrocytes maintain ion homeostasis at
the nodes of Ranvier and at synapses, where they also aid in the removal of excess
neurotransmitter to prevent over-signaling (Nestler et al 2001; Squire et al 2008). They are
capable of interacting with neurons by expressing neurotransmitter receptors that detect signals
from neurons, allowing them to adjust their metabolism accordingly to keep active neurons
functioning efficiently (Nestler et al 2001; Prebil et al 2011).

Astrocytes, with the help of

microglia, monitor the environment and respond accordingly to maintain homeostasis. Neurons
are delicate cells and when this homeostasis is disrupted by chemical insult, pathogen
infiltration, or other injuries, a cascade of events can occur that result in neuron death,
inflammation, and overall dysfunction within the nervous system.
1.2 Amyotrophic Lateral Sclerosis
1.2.1

Amyotrophic Lateral Sclerosis in General

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which
the primary target is the motor neuron. Amyotrophy refers to the atrophy of skeletal muscle
fibers that occurs when motor neurons die and muscle innervation is lost. Lateral sclerosis
refers to the degeneration of neurons in the anterior horn and lateral corticospinal tracts and the
gliosis that accompanies this (Wijesekera & Leigh 2009). The disease is commonly referred to
as Lou Gehrig’s disease after New York Yankee, Lou Gherig, who died of the disease in 1941.
The axons of motor neurons gradually die back from the skeletal muscles they innervate,
leading to a loss of neuromuscular connections and muscle atrophy.

Patients experience
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muscle weakness which rapidly turns into paralysis, and eventually succumb to respiratory
complications within one to five years of disease onset (Bruijn et al 2004).
ALS is a relatively rare disease, with an overall incidence of about 2 in 100,000 people per
year (Alonso et al 2009; Logroscino et al 2008) and a prevalence of about 5 in 100,000 people
(Haverkamp et al 1995). The low incidence rate makes it difficult to collect epidemiological data
from large numbers of patients, but with better diagnostic and communication technologies, data
collection is improving.

The incidence of the disease increases after age 40 and peaks

somewhere between the late 60s and early 70s, after which the incidence seems to decline
(Logroscino et al 2008). The typical age of onset of ALS is between 50 and 60 years of age
(Bruijn et al 2004), but there are some rare forms with juvenile onset (Beghi et al 2007). There
tends to be a slight male prevalence in the disease, with a male to female ratio of about 3:2
(Wijesekera & Leigh 2009).

This gender difference decreases with increasing age and

approaches a ratio of 1:1 after age 60 (Haverkamp et al 1995).
The phenotypic characterization of ALS is inconsistent across patients (Logroscino et al
2008). The symptoms of the disease vary, depending upon the area in which motor neurons
are affected. Most patients, about 75%, develop early symptoms in the limbs in what is referred
to as limb or spinal onset ALS. This can begin in the arms or legs, with the most common
symptoms being muscle weakness and wasting. Involuntary muscle twitching and cramping
can occur prior to muscle weakness (Wijesekera & Leigh 2009). When symptoms begin in the
leg patients may experience some problems walking, whereas patients with arm symptoms
have difficulty performing tasks requiring manual dexterity.

Typically symptom onset is

asymmetrical, affecting only one side of the body, however most patients eventually experience
symptoms in other limbs (Wijesekera & Leigh 2009). The remaining 25% of patients have
symptom onset occurring in the head or neck, which is referred to as bulbar onset ALS. These
symptoms typically present themselves as difficulty swallowing or speaking, due to problems
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with tongue mobility, and may progress to include facial weakness (Wijesekera & Leigh 2009).
Patients with bulbar onset ALS may experience limb symptoms simultaneously, and most
patients with limb onset eventually develop bulbar symptoms as well. It is important to note that
there is significant heterogeneity in the symptoms of ALS (Beghi et al 2007), which makes the
disease difficult to diagnose.
Patients with ALS suffer from degeneration of both upper and lower motor neurons.
Upper motor neurons are neurons whose cell bodies reside in the primary motor cortex of the
brain, sending their axons down the spinal cord. Lower motor neurons have axons that project
into the ventral root and through a spinal nerve to innervate skeletal muscle, with their cell
bodies remaining in the ventral horn of the spinal cord (Chapman & Silkwood-Sherer 2000).
Upper motor neurons in the primary cortex send signals down the spinal cord and synapse on
lower motor neurons, which then send signals to skeletal muscles in the periphery (Chapman &
Silkwood-Sherer 2000). When either type of motor neuron is affected by the disease, there is a
loss of trophic factor signaling between synapsing neurons, which can result in dying back of all
of the motor neurons in the pathway leading to paralysis.
1.2.2

Causes of ALS
ALS is a heterogeneous disorder with a variety of factors, both genetic and

environmental, believed to play a role in pathogenesis of the disease. Patients with ALS can be
broken down into two groups, those with a hereditary form of ALS, Familial ALS (FALS), and
those with no known family history of ALS, referred to as Sporadic ALS (SALS). SALS is much
more common, accounting for the majority of ALS cases, while FALS accounts for only 5-10%
of all cases of the disease (Bruijn et al 2004; Wijesekera & Leigh 2009).

The pathological and

clinical characteristics of FALS and SALS are strikingly similar, making it very difficult to
distinguish between the two (Beghi et al 2007). Genetic forms of ALS show a great deal of
heterogeneity, with a variety of gene mutations implicated in the cause.
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Mutations in 13 genes have been found to be associated with FALS (Table 1.2.2.1). All
of these genes are inherited in an autosomal dominant fashion, with the exception of three that
are recessive and two with unknown inheritance patterns. The genetic loci of all of these
mutations have been determined, however only seven gene products have been positively
identified in ALS: 1) superoxide dismutase-1 (SOD1); 2) alsin; 3) senataxin (SETX); 4) vesicle
associated protein B (VAPB); 5) angiogenin (ANG); 6) TAR-DNA binding protein-43 (TDP43);
and 7) fused in sarcoma (FUS) (Beghi et al 2007; Belzil et al 2009; Bruijn et al 2004; Pasinelli &
Brown 2006; Wijesekera & Leigh 2009). Two genes, with unknown products, produce a form of
ALS that is associated with frontotemporal dementia (FTD) (Beghi et al 2007; Wijesekera &
Leigh 2009).

Mutations in chromatin-modifying protein 2B (CHMP2B; also called charged

multivesicular body protein 2B) have been found in two ALS patients and seem to be primarily
associated with a form of FTD accompanied by ALS, however more research must be done in
order to characterize the inheritance pattern of these mutations and their involvement in the
disease (Beghi et al 2007; Parkinson et al 2006). Mutations in dynactin (DCTN1), a protein
involved in axonal transport, have been associated with a form of lower motor neuron disease
and their presence in the genome may increase a person’s susceptibility to motor neuron
degeneration and the development of ALS (Beghi et al 2007; Wijesekera & Leigh 2009).
Another axonal protein, microtubule-associated protein tau (MAPT), is commonly associated
with FTD and may also increase the risk of developing ALS.
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Table 1.2.2.1 List of genetic mutations associated with ALS

AD = autosomal dominant
AR = autosomal recessive
* The SOD1 D90A mutation is the only recessive mutation (Al-Chalabi et al 1998).
GEF = guanine nucleotide exchange factor
ESCRT-III = endosomal sorting complex required for transport-III
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Of the seven positively identified genes involved in FALS, superoxide dismutase-1
(SOD1) is probably the most well studied protein, although its involvement in neurodegeneration
is still a mystery. SOD1 is a ubiquitously expressed copper/zinc-binding protein that is involved
in scavenging reactive oxygen species (ROS) produced during oxidative phosphorylation.
Superoxide dismutase catalyzes the reaction between two molecules of superoxide and two
protons to produce hydrogen peroxide and oxygen, preventing oxidative damage within the cell
(Nelson & Cox 2008). Approximately 15-20% of FALS cases are associated with mutations in
the gene encoding SOD1, accounting for only a small portion of all cases of ALS (Beghi et al
2007; Bruijn et al 2004; Orrell et al 1996; Wijesekera & Leigh 2009; Zoccolella et al 2006). Over
100 different ALS-associated mutations have been found in the gene encoding SOD1, most of
which are autosomal dominant (Beghi et al 2007; Wijesekera & Leigh 2009). These mutations
result in a variety of alterations to the protein, most of which are single-amino acid substitutions
that may alter the protein structure to decrease metal binding and increase protein aggregation
(Hayward et al 2002; Johnston et al 2000; Rumfeldt et al 2009; Shinder et al 2001; Tiwari &
Hayward 2005). Figure 1.2.2.1 shows the amino acid sequence of the SOD1 protein, with the
amino acids that can undergo mutations highlighted in green. The enzyme can be mutated in
several locations throughout its sequence, including introns (Turner & Talbot 2008).

The

mechanism by which mutations in the SOD1 protein lead to motor neuron death remain unclear,
since the enzyme appears to retain its normal function with most mutations, but are believed to
involve a toxic gain of function (Harraz et al 2008; Mali & Zisapels 2008) and the combined
effects of its expression in neurons, microglia, and astrocytes (Boillee et al 2006; Yamanaka et
al 2008a).
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Figure 1.2.2.1 Amino acid sequence of the SOD1 protein.
SOD1 mRNA consists of five exons and four introns and the final protein-product is 153 amino
acids in length. The protein can undergo a wide variety of mutations and the amino acids that
can be mutated are highlighted in green with the substitutions listed below them. Amino acids
involved in Cu/Zn binding are indicated with red lines and the cysteine residues involved in
disulfide bond formation are indicated with blue lines. Introns and the 3’ untranslated region are
shown in purple and the asterisks indicate those that can contain mutations.
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The remaining six genes involved in ALS encode an array of proteins involved in a
variety of cellular processes. Alsin, a protein containing three guanine nucleotide exchange
factor domains (Yang et al 2001), is a cytosolic protein capable of associating with membrane
structures believed to be involved with actin cytoskeleton remodeling and vesicular trafficking
(Topp et al 2004). Senataxin, which has been linked to an early onset form of ALS (Chance et
al 1998), was discovered to be the ortholog of a yeast RNA helicase (Moreira et al 2004) and is
believed to play a role in RNA processing in humans (Beghi et al 2007). Vesicle associated
protein B (VAPB) is an integral membrane protein found on the membrane of the endoplasmic
reticulum, which is believed to exert its negative effects in ALS by promoting protein aggregation
and ER stress (Langou et al 2010; Moumen et al 2011; Nachreiner et al 2010). Angiogenin is a
protein involved in angiogenesis that plays a variety of roles within the cell. Under normal
conditions angiogenin acts as a ribonuclease, regulating rRNA transcription (Li & Hu 2010),
attenuates apoptotic signals (Li et al 2012), and can bind to actin to alter polymerization
(Pyatibratov & Kostyukova 2012; Pyatibratov et al 2010). TDP43 is a DNA/RNA-binding protein
found in glia and neurons (Swarup et al 2011b) that plays a role in the maintenance of
autophagy (Bose et al 2011), regulation of splicing RNA transcripts and the production of micro
RNAs (Lee et al 2012a), and may associate with mutant forms of VAPB in ALS (Suzuki &
Matsuoka 2011).

Like TDP43, FUS (also called TLS for translocated in liposarcoma) is also a

DNA/RNA-binding protein. It is found primarily in the nucleus of normal cells but is transported
to dendritic spines and is involved in transcription, splicing, and mRNA transport from the
nucleus to the cytoplasm (Fujii et al 2005; Wang et al 2008; Yang et al 1998; Zinszner et al
1997). Despite its rare occurrence and the variety of genetic factors involved, studies of FALS
have offered insight into the molecular mechanisms underlying motor neuron death and
provided potential therapeutic targets and biomarkers of the disease.
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FALS research has been able to shed some light on SALS, as some of the mutations
involved in hereditary forms of the disease have also been identified in sporadic ALS patients.
Table 1.2.2.1 lists the cellular function of the proteins SOD1, ANG, TDP43, and FUS that have
been found to undergo mutations and become involved in some cases of SALS. In addition to
these, mutations in APEX1 (Hayward et al 1999), HFE (Goodall et al 2005; He et al 2011;
Sutedja et al 2007a; Wang et al 2004b), PON (Cronin et al 2007; Slowik et al 2006; Ticozzi et al
2010; Valdmanis et al 2008), PRPH (Corrado et al 2011; Gros-Louis et al 2004; Leung et al
2004), and PGRN (Sleegers et al 2008; Talbot & Ansorge 2006) have also been found to be
associated with SALS (Table 1.2.2.2). It is unknown as to whether or not these mutations cause
the disease, or if their presence increases the risk of developing ALS (Schymick et al 2007).
The association of certain genes with SALS provides some hope that there may be a genetic
component to sporadic forms of the disease.
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Table 1.2.2.2 List of genes found to have SALS-associated mutations.
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There are a large number of genetic mutations associated with FALS that have the
ability to alter a variety of proteins with roles in a multitude of cellular processes which lead to a
significant amount of heterogeneity in the disease.

To complicate matters further, the

inheritance patterns of FALS genes are not strictly followed in all cases and multiple mutations
can occur within the same individual (Andersen 2006; Andersen et al 1996; Orrell et al 1996).
This had led to the belief that ALS develops through a complex interaction between genetic and
environmental factors.
Since most cases of ALS are sporadic and have no known genetic component, exposure
to environmental toxins and head injuries are believed to be potential risk factors for developing
ALS. Examining patients’ occupations has typically been used as a way to evaluate exposure
to toxins that may be associated with development of the disease. Workplace exposure to lead,
with elevated lead levels found in bone and blood of ALS patients, has been suggested to play a
role in the etiology of ALS (Kamel et al 2005; Kamel et al 2002). People exposed to other
chemicals commonly associated with construction work, such as paint strippers, lubricating oils,
coolants, metals and metal fumes, also show an increased risk in developing ALS (Binazzi et al
2009; Fang et al 2009). One study conducted in Italy showed that professional soccer players
had an increased risk of developing the disease (Chio et al 2005), suggesting that head injuries
lead to an increased risk of ALS. Patients who had experienced multiple head injuries or who
had been injured within a ten year period prior to diagnosis were found to have a threefold
higher risk of developing ALS. It was also found that people with head injuries were more likely
to have bulbar onset ALS and an earlier age of diagnosis (Chen et al 2007).
Most often the types of studies used to evaluate chemical exposures and injuries
associated with ALS involve the use of questionnaires, which also take into consideration other
means of exposure to toxins, such as smoking and diet.

Several studies have found that

smokers have an increased risk in developing ALS (Binazzi et al 2009; Nelson et al 2000;
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Sutedja et al 2007b; Weisskopf et al 2004). One study determined that female smokers have a
greater risk of developing ALS than male smokers (Weisskopf et al 2004), while another study
detected a link between cigarette smoking and bulbar onset ALS (Binazzi et al 2009).
Interestingly, an interaction between cigarette smoking and chemical exposure was also
observed (Fang et al 2009). This increased risk in ALS with smoking could be directly due to
the chemicals found within cigarettes, or chemicals in the cigarettes could induce the expression
of metabolic enzymes that alter metabolism in such a way that smokers become more sensitive
to other chemicals.

With respect to diet, it was found that bulbar onset patients showed an

increase in the consumption of cold cuts and a decrease in the consumption of vegetables
(Binazzi et al 2009). In a small population of people in Guam, where the incidence of ALS is
higher than that of Europe and North America, β-methyl-amino-L-alanine is found in low levels
in the diet and has been found in brain tissue of ALS patients and is believed to play a role in
the disease (Banack & Murch 2009).
1.2.3

Molecular Mechanisms Underlying ALS Pathogenesis
Genetic analyses of patients with both hereditary and sporadic forms of ALS have

identified a wide variety of genes that can be involved in the development of the disease. These
genes encode proteins that are involved in several different cellular processes and implicate an
array of cellular mechanisms that may become dysfunctional during the disease.
Understanding the molecular mechanisms behind the disease is the primary goal of ALS
research, as it will aid in the development of pharmacological treatments and possibly uncover
biomarkers that may allow for early detection of the disease. There are believed to be six major
mechanisms underlying ALS pathogenesis: glutamate excitotoxicity; mitochondrial dysfunction
and oxidative stress; dysfunctional protein quality control mechanisms; aberrant RNA
processing; neurotrophic factor dysregulation; and neuroinflammation.

These mechanisms
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overlap to some extent and involve several different cell types. Experimental evidence suggests
that these mechanisms may converge at some point to initiate the programmed cell death
pathway, as the final mechanism of cell death seems to resemble apoptosis.
1.2.3.1 Glutamate Excitotoxicity
The amino acid glutamate acts as the major excitatory neurotransmitter in the central
nervous system where it is released from electrically stimulated neurons in a calcium-dependent
fashion (Cooper et al 2003; Nestler et al 2001; Squire et al 2008). Upon stimulation, glutamate
is released from the pre-synaptic nerve terminal into the synaptic cleft where it: 1) stimulates
the post-synaptic neuron by binding to glutamate receptors; 2) is taken up by astrocytes; and 3)
may be taken back up by the pre-synaptic neuron for recycling (Figure 1.2.3.1). In healthy
individuals, glutamate binds to a variety of glutamate receptors on post-synaptic neurons, some
of which are coupled to ion channels that when stimulated, allow for an influx of calcium to
induce an action potential. Since overstimulation of these receptors can lead to a massive influx
of calcium resulting in apoptosis, there are mechanisms in place to remove glutamate from the
synapse. Both pre-synaptic neurons and astrocytes express excitatory amino acid transporters
(EAATs) which remove excess glutamate from the synapse.

Glutamate taken up by pre-

synaptic neurons can be repackaged into vesicles for later use or converted to aspartate by the
mitochondrial enzyme aspartate transaminase (Nestler et al 2001).

The majority of the

glutamate in the synapse is taken up by astrocytes where it is converted to glutamine by the
enzyme glutamine synthetase (GS) (Cooper et al 2003; Nestler et al 2001; Squire et al 2008).
GS plays an extremely important role in the central nervous system as it not only detoxifies
glutamate, but it removes ammonia as well. The glutamine produced in astrocytes is then
passed back to neurons where it is converted to glutamate by mitochondrial glutaminase and
then packaged into vesicles for later use. This process of astrocytic removal of glutamate, its
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conversion to glutamine by GS, and the transport of glutamine back to neurons is referred to as
the glutamate-glutamine cycle and its importance in the CNS is illustrated in Figure 1.2.3.1.
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Figure 1.2.3.1.1 Glutamatergic signaling in the central nervous system.
Once released from the pre-synaptic neuron, there are three possible fates of glutamate in the
synapse. A. Glutamate can interact with ionotropic glutamate receptors (NMDA, AMPA, or
kainate receptors) on the post-synaptic neuron, which are coupled to ion channels and allow
calcium to flow into the cell. Glutamate can also bind to metabotropic receptors which are
coupled to g-proteins and produce their effects more slowly. B. Glutamate can be taken up by
the pre-synaptic cell where it is recycled for subsequent action potentials. C. The majority of
the glutamate is taken up by astrocytes, where glutamine synthetase (GS) converts it to
glutamine. The glutamine is then transported back to the pre-synaptic neuron through SN1
transporters where it is converted back to glutamate by mitochondrial glutaminase and
packaged into vesicles.

EAAT = excitatory amino acid transporter
SN1 = glutamine transporter
AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazole
NMDA = N-methyl-D-aspartate
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Experimental evidence suggests that the glutamate-glutamine cycle is disrupted in ALS.
Glutamate levels were found to be elevated in the cerebrospinal fluid (CSF) of ALS patients
(Rothstein et al 1990) and glutamate signaling defects were found in neuronal tissue from
patients who had died of ALS (Rothstein et al 1992). Western blot analysis of post-mortem
motor cortex tissue

indicated that the major astrocytic glutamate transporter EAAT2 was

significantly decreased in patients with ALS, and that a splice variant of this transporter,
EAAT2b,

was

increased

when

compared

to

controls

(Maragakis

et

al

2004).

Immunohistochemical analysis of lumbar spinal cord samples from patients with motor neuron
disease showed a decrease in EAAT2 density in the grey matter (Fray et al 1998). In a rat
model of ALS, immunohistochemical analysis of spinal cord sections showed a focal loss of
EAAT2 in the ventral horn region that coincided with gliosis but occurred prior to motor neuron
degeneration. As the disease progressed the loss of EAAT2 and reactive gliosis increased,
suggesting that these processes worsen with disease progression (Howland et al 2002).
Studies in which excitatory amino acid transporters were selectively knocked down, in
both cell culture and animal models, showed that glutamate uptake was impaired and that
animals developed a motor neuron syndrome that resulted in paralysis similar to ALS (Rothstein
et al 1996). In mouse models of ALS, it was shown that overexpression of EAAT2 was able to
slow motor neuron loss and grip strength decline (Guo et al 2003) and treatment with drugs that
increase the expression of glutamate transporters also slow disease progression and increase
survival (Rothstein et al 1995). Taken together, these results suggest that there may be a
decrease in glutamate uptake by astrocytes due to down-regulation of transporters which in turn
leads to an increase in glutamate in the CSF. Excessive glutamate in the synapse may lead to
increased calcium influx into motor neurons, resulting in caspase activation and apoptosis.
Caspase activation has been observed in mouse models of ALS (Li et al 2000; Pasinelli et al
2000), lending support for this method of motor neuron death. However, the order in which

23
these mechanisms occur during pathogenesis remains unclear as the dysfunction of other
cellular mechanisms may play a role in glutamate transporter expression.

For example,

analysis of post-mortem spinal cord tissue collected from ALS patients indicated that mRNA
levels of EAAT2 were normal (Bristol & Rothstein 1996) and aberrant EAAT2 mRNA has been
detected in affected areas in ALS patients (Lin et al 1998), indicating that dysfunctional mRNA
processing may lead to a decrease in transporter expression. Caspase-3 has also been shown
to cleave and inhibit EAAT2 function (Boston-Howes et al 2006), suggesting that decreased
transporter function may occur secondary to excitotoxic mechanisms.
1.2.3.2 Mitochondrial Dysfunction and Oxidative Stress
Mitochondria are mobile, plastic organelles that occupy a significant volume of
eukaryotic cells.

They are capable of associating with microtubules, which carry them to

different locations within a cell and allow the mitochondria to take on unique distributions and
orientations depending upon the cell type (Alberts et al 2002). Mitochondria play many roles
within the cell, but they primarily function as energy producing organelles. Glycolysis alone is
not sufficient to meet the energy demands of most animals and the pyruvate produced is taken
up by the mitochondria (along with the carbon skeletons of fatty acids and amino acids) where it
is oxidized by molecular oxygen (Alberts et al 2002; Nelson & Cox 2008).

High energy

electrons are produced which drive the electron transport chain to form the ATP that fuels the
cell (Nelson & Cox 2008). If not channeled properly these electrons can become involved in
aberrant reactions and damage cellular components, but healthy cells have mechanisms in
place to help prevent oxidative damage.
In addition to their role as energy producers, mitochondria play an extensive role in
calcium signaling and homeostasis. Mitochondria can store calcium and take it up from the
cytosol to maintain intracellular calcium concentrations and modulate calcium signaling. They
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can also interact directly with endoplasmic reticulum (ER) membranes through a structure called
the mitochondria-associated ER membrane (MAM), which is involved in phospholipid exchange
(Vance 1990), may play a role in the secretory pathway (Rusinol et al 1994), and also plays a
role in calcium signaling (Rizzuto et al 2009). Through this interaction the ER can send calcium
directly to the mitochondria to stimulate oxidative metabolism, allowing the cell to integrate
signal transduction and metabolic pathways (Hayashi et al 2009).

Regardless of how the

calcium enters mitochondria, it can increase the production of ROS and once a calcium
threshold is surpassed the intrinsic apoptotic pathway can be initiated resulting in cell death
(Green 1998).
In patients with ALS, as well as in cell culture and animal models of the disease,
experimental evidence suggests that at some point during disease pathogenesis mitochondria
become dysfunctional and cells experience and increase in oxidative stress. In mouse models
of ALS morphological abnormalities in motor neuron mitochondria, such as swelling and
vacuolization, can be seen as early as two weeks of age, well before symptom onset (Bendotti
et al 2001). These abnormal mitochondria can be found in the dendrites and axons of motor
neurons and appear to be undergoing degeneration (Wong et al 1995).

Mitochondrial

vacuolization is associated with an increase in immunoreactivity for mutatant SOD1 (Bendotti et
al 2001; Jaarsma et al 2000), which appears to associate with the outer mitochondrial
membrane, the intermembrane space and the matrix (Higgins et al 2003; Mattiazzi et al 2002;
Vijayvergiya et al 2005). Mitochondrial accumulation in the axon terminals of motor neurons is
associated with an increase in ROS and RNS, and these mitochondrial show an accumulation
of nitrated proteins (Martin et al 2007). Single-stranded, followed by double-stranded, DNA
breaks in nuclear and mitochondrial DNA accompany morphological changes in mitochondria
(Martin et al 2007). Abnormalities in mitochondrial DNA, such as alterations in gene copy
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number as well as gene deletions, have been seen in spinal motor neurons of ALS patients
(Keeney & Bennett 2010).
In addition to morphological changes in mitochondria, alterations in mitochondrial
proteins and enzyme activities have been associated with disease pathogenesis. Mitochondria
isolated from the brain and spinal cord of mouse models of ALS show an overall decrease in
state three respiration, suggesting a decrease in the rate at which oxygen can be utilized for
ATP synthesis in symptomatic animals (Mattiazzi et al 2002). While mitochondria isolated from
the spinal cords of ALS patients showed an overall decrease in activity of all of the enzymes of
the respiratory chain (Wiedemann et al 2002). When oxygen consumed by the whole animal
was measured in mouse models, there was an increase in the total oxygen consumption as well
as energy expenditure at rest, which was attributed to greater energy usage by the muscle
(Dupuis et al 2004).

These results were preceded by alterations in leptin, insulin, and

corticosterone signaling prior to the development of symptoms (Dupuis et al 2004). In addition,
presymptomatic mice have shown depletion of ATP in the cortex along with impaired glucose
utilization in bulbospinal and corticospinal motor tracts (Browne et al 2006). Mutant SOD1
protein has been shown to interact with cytosolic malate dehydrogenase, an enzyme involved in
the malate-aspartate shuttle important for transporting electrons produced during glycolysis
across the mitochondrial inner membrane, in neuronal cell culture experiments (Mali & Zisapels
2008). Neuron-like cells stably expressing mutant SOD1 have shown an overall decrease in
glutathione levels (D'Alessandro et al 2011), with a corresponding decrease in mitochondrial
glutathione pools which make these cells more susceptible to oxidative stress (Muyderman et al
2009). In post-mortem brain tissue of SALS patients, an increase in the level of protein carbonyl
groups was found suggesting an increase in oxidative damage to proteins (Bowling et al 1993).
Similar results were found in mouse models of the disease, in which increased levels of
oxidative damage were found in mitochondrial proteins and lipids (Mattiazzi et al 2002).
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It is important to note that these alterations to mitochondria and mitochondrial proteins in
ALS are not limited to motor neurons, but have been seen in liver, lymphocytes, muscle, and
astrocytes. Hepatocytes from liver biopsy samples collected from ALS patients have shown
defects in mitochondrial morphology, exhibiting enlarged mitochondria containing protein
inclusions, that were associated with liver dysfunction (Nakano et al 1987). Mouse models of
the disease also show a decrease in liver mitochondrial respiration and oxidative damage to
proteins and lipids within the mitochondria at the time of symptom onset (Mattiazzi et al 2002).
In circulating lymphocytes isolated from SALS patients, mitochondria showed a decrease in
complex I activity and an increase in free cytosolic calcium levels (Curti et al 1996).
Abnormalities in muscle mitochondrial DNA from SALS patients have been associated with
decreased activity in NADH dehydrogenase and cytochrome c oxidase (Vielhaber et al 2000).
In astrocytes isolated from a rat model of ALS, mitochondria showed defective respiratory
function, a decrease in membrane potential, and an increase in ROS production and protein
nitration.

When these cells were co-cultured with motor neurons and preincubated with

antioxidants and nitric oxide synthase inhibitors, motor neuron loss was prevented suggesting
that dysfunctions in other cell types contribute to motor neuron death (Cassina et al 2008).
1.2.3.3 Dysfunctional Protein Quality Control Mechanisms
In healthy cells there are several quality control mechanisms in place to aid in the
refolding of misfolded proteins, and quickly degrade misfolded proteins that cannot be repaired
to prevent their accumulation and stress on cells. Often times when proteins are misfolded,
hydrophobic amino acid residues, which are normally found inside of proteins, are exposed and
signal quality control machinery to aid in protein refolding or removal. Chaperon proteins, like
the heat shock protein families hsp60 and hsp70, can be found in the cytosol, mitochondria, and
the ER to aid in proper protein folding (Alberts et al 2002). When proper folding cannot be
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accomplished proteins are degraded through two major mechanisms, ER associated
degradation and the ubiquitin-proteosome pathway, which function cooperatively to maintain
homeostasis within the cell.
The endoplasmic reticulum is found in two forms within the cell, a smooth form
containing a variety of enzymes and proteins which is involved in the secretory pathway and
calcium homeostasis; and a rough form containing ribosomes on the cytosolic side of the
membrane and different types of proteins and enzymes inside which are involved in protein
synthesis, folding, post-translational modification, and transport (Alberts et al 2002). When new
proteins are misfolded and accumulate within the ER, the unfolded protein response (UPR) is
initiated and there is an increase in ER chaperones and enzymes that degrade misfolded
proteins within the ER (Alberts et al 2002). When refolding within the ER fails, proteins can be
transported back into the cytosol for degradation through the ubiquitin-proteosome pathway.
Dysfunction or overloading of ER associated protein degradation machinery can lead to ER
stress, disruption of protein synthesis and transport, and calcium homeostasis, resulting in
mitochondrial dependent or independent forms of cell death.
There is evidence to suggest that the UPR is activated during ALS and that there are
abnormalities in ER associated degradation of misfolded proteins. Spinal cords from patients
with SALS also show signs of the UPR, with induction of kinases, chaperones, and other
proteins involved in ER stress (Atkin et al 2008; Ilieva et al 2007; Sasaki 2010). Transgenic
mouse models of ALS in which mutant SOD1 protein is overexpressed show early upregulation
of ER stress markers well before symptom onset, and an ER-stress protective agent has been
shown to slow progression of the disease in these animals (Saxena et al 2009). Studies using
ALS mice have shown that mutant forms of SOD1 accumulate in ER lumen to form high
molecular weight aggregates that interact with immunoglobulin-binding protein (BiP), an ER
chaperone, in affected spinal cord regions (Kikuchi et al 2006). Mutant forms of SOD1 have
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also been shown to directly interact with derlin-1, a protein component of ERAD machinery,
which causes ER stress in motor neurons and leads to activation of the apoptosis-signal
regulating 1 (ASK1) cell death pathway (Nishitoh et al 2008). Mutant forms of VAPB, an ER
protein which has recently been associated with ALS, also show the ability to trigger ER stress
and activate the UPR. In cell culture models, mutant forms of VAPB form aggregates that colocalize with other ER proteins, initiating upregulation of ER stress related proteins (Moumen et
al 2011). Viral-mediated expression of mutant forms of VAPB in primary mouse motor neuron
cultures also showed evidence of ER stress, as well as impaired calcium homeostasis,
providing further support for ER stress in ALS pathogenesis (Langou et al 2010).
The proteosome is an ATP-dependent protease that works to degrade proteins in the
cytoplasm and aids the ER in removal of improperly assembled proteins. The proteosome is a
large, multisubunit complex that specifically targets, with a few exceptions, proteins that have
been tagged with ubiquitin. Once inside the active site, proteins are cleaved into several short
peptide fragments about seven to eight amino acids long that can then go on to be degraded
further into individual amino acids.

In addition to the removal of misfolded proteins, the

proteosome also degrades normal proteins to regulate their concentrations within the cell and
maintain homeostasis. As with ERAD, dysfunction or overloading of the proteosome can lead to
increased cellular stress and result in cell death.
The presence of cytosolic protein aggregates, as well as ubiquitin-positive protein
aggregates, in the spinal cords of ALS patients has provided evidence suggesting that protein
aggregation and dysfunction of the proteosome play a role in disease pathogenesis (Redler &
Dokholyan 2012; Wijesekera & Leigh 2009). Several different proteins have been found to
aggregate in motor neurons during ALS, such as neurofilaments, mutant SOD1 protein, and
TDP43. Mutations in the KSP region of the neurofilament heavy chain, a region involved in
neurofilament cross-linking, have been found in patients with sporadic and familial ALS (Al-
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Chalabi et al 1999; Figlewicz et al 1994; Tomkins et al 1998).

In addition, peripherin, an

intermediate filament found primarily in motor neurons, has been found in axonal aggregates in
ALS patients and mouse models of the disease (Corbo & Hays 1992; Robertson et al 2003).
The aggregation of neurofilaments in the axons of motor neurons may slow anterograde and
retrograde transport of proteins and organelles, disrupt homeostasis, and alter the neuron’s
ability to send signals to other cells. As previously mentioned, mitochondria have been found to
accumulate in axon terminals in mouse models of ALS (Martin et al 2007). This accumulation
may be due to neurofilament aggregates which block the axon and prevent retrograde transport
back to the cell body. In the same respect, blockage of axons may impair anterograde transport
of proteins to the axon terminal and may play a role in the dysregulation of neurotrophic factor
signaling. Both retrograde and anterograde transport along axons have been shown to be
slowed in mouse models of ALS (Borchelt et al 1998; De Vos et al 2008; Murakami et al 2001;
Williamson & Cleveland 1999).
In addition to neurofilaments, mutant forms of the SOD1 protein have been found in
protein aggregates in ALS patients, mouse models, and cell culture models of the disease
(Deng et al 2006; Gruzman et al 2007; Johnston et al 2000; Matsumoto et al 1996; Shibata et al
1996a; Shibata et al 1994; Shibata et al 1996b). Several studies have been conducted to
examine changes in stability of the SOD1 protein with the various mutations it can undergo
(Furukawa & O'Halloran 2005; Hough et al 2004; Khare et al 2006; Rodriguez et al 2005; Shaw
& Valentine 2007). It has been shown that not all of the mutations that can occur within SOD1
disrupt the protein’s stability (Rodriguez et al 2005), which suggests that the different mutations
promote SOD1 aggregation by different mechanisms (Shaw & Valentine 2007). However, there
are over 100 different mutations that can occur in SOD1 and many of them have been shown to
disrupt protein stability, increase its dissociation, and increase its ability to form aggregates
(Furukawa & O'Halloran 2005; Hough et al 2004; Khare et al 2006).

Interestingly, mouse
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models of ALS show SOD1 aggregation as early as birth and these aggregates are enriched in
motor neurons (Jonsson et al 2004; Rakhit et al 2007; Zetterstrom et al 2007). Co-expression
of wild-type SOD1 with certain mutant forms of the protein in animal models actually increases
its ability to aggregate and exacerbates ALS phenotypes (Deng et al 2006; Fukada et al 2001;
Jaarsma et al 2000; Wang et al 2009).
Aggregation of mutant SOD1 protein within motor neurons has also provided support for
the hypothesis that the ubiquitin-proteosome system becomes dysfunctional during ALS
pathogenesis. It has been determined that misfolded SOD1 undergoes degradation through the
proteosome system (Di Noto et al 2005), and inhibition of the proteosome leads to increased
aggregation of mutant SOD1 and cell death (Hoffman et al 1996; Hyun et al 2003; Puttaparthi et
al 2003). Mutant forms of SOD1 have been shown to sequester proteosomal subunits, as well
as ubiquitin ligases and some chaperone proteins (Hyun et al 2003; Niwa et al 2002; Watanabe
et al 2001; Zetterstrom et al 2011b), and proteosomal dysfunction has been seen in animal and
cell culture models of the disease (Cheroni et al 2009; Sau et al 2007).

Spinal cord samples

from mouse models of FALS and ALS patients test positive for ubiquitin and ubiquitin-ligase
immunoreactive aggregates (Bendotti et al 2004; Leigh et al 1991; Mendonca et al 2006;
Watanabe et al 2001), suggesting that proteosomal dysfunction or overloading prevents
degradation of tagged proteins. These ubiquitin positive aggregates are typically found in the
anterior horn of the spinal cord (Leigh et al 1991) and have been found in astrocytes as well as
motor neurons (Mendonca et al 2006). TDP43 has also been found in these inclusions in
affected regions in ALS patients (Arai et al 2006; Neumann et al 2006), but TDP43 positive
aggregates seem to be specific to SALS patients (Tan et al 2007).
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1.2.3.4 Aberrant mRNA Processing
The discovery of ALS-associated mutations in DNA/RNA-binding proteins, TDP43 and
FUS, has lead to new ideas involving alterations in mRNA processing playing a role in the
progression of the disease. This area of ALS research is relatively new and the normal roles of
these proteins have yet to be fully characterized.

TDP43 protein aggregates were first

discovered in tissue from patients with FTD, and in 2006, TDP43 was identified as a major
constituent of protein aggregates in tissue from patients with ALS (Arai et al 2006; Neumann et
al 2006). Since then there has been an increase in research to identify mutations in the gene
encoding TDP43, understand the normal cellular functions of the protein, as well as elucidate
the mechanisms underlying its aggregation in ALS and FTD. Starting in 2008, several ALSspecific mutations in the gene encoding TDP43 were identified in both FALS and SALS patients
(Kabashi et al 2008; Lagier-Tourenne et al 2010; Sreedharan et al 2008). During this time,
mutations in the gene encoding FUS, which is functionally and structurally similar to TDP43,
were also identified and associated with ALS (Kwiatkowski et al 2009; Vance et al 2009).
Under normal conditions both TDP43 and FUS are found primarily in the nucleus, with
lower levels of both proteins detectable in the cytoplasm (Andersson et al 2008; LagierTourenne et al 2010). Both proteins are widely expressed, capable of binding DNA and RNA
and have several similarities in their sequences. TDP43 is 414 amino acids in length and
consists of two RNA recognition motifs and a glycine-rich region at the C-terminus (Ayala et al
2005; Ou et al 1995; Wang et al 2004a). The first RNA recognition motif is required for RNA
binding (Ayala et al 2005), but the second is not and is believed to play a role in the
reorganization of chromatin (Ayala et al 2008; Buratti et al 2001). The C-terminal glycine-rich
region is required for TDP43 to interact with other proteins (Ayala et al 2005; D'Ambrogio et al
2009; Wang et al 2004a) and is the primary site for ALS-associated mutations. In addition,
TDP43 also contains a predicted nuclear localization sequence closer to the N-terminus and a
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nuclear export sequence within the second RNA recognition motif (Lagier-Tourenne et al 2010).
These sequences are believed to be involved in the shuttling of the protein between the nucleus
and the cytoplasm. The FUS protein is 526 amino acids in length and consists of an N-terminal
sequence rich in glutamine, glycine, serine and tyrosine residues (called the QGSY-region), a
region of multiple arginine-glycine-glycine repeats, a zinc-finger motif at the C-terminus, and like
TDP43, a glycine-rich region and an RNA recognition motif (Crozat et al 1993; Iko et al 2004;
Morohoshi et al 1998; Prasad et al 1994). Most of the FUS mutations that are associated with
ALS are found clustered in the glycine-rich region of the protein, however the C-terminal portion
of the protein, which is believed to contain a nuclear localization sequence, can also become
mutated (Lagier-Tourenne et al 2010). Like TDP43, FUS also contains a predicted nuclear
export sequence in the RNA recognition sequence.
The exact roles of these two proteins have yet to be elucidated and there is no evidence
to suggest that TDP43 and FUS interact with each other directly despite their structural
similarities (Lagier-Tourenne et al 2010), but they may have roles in the same pathway (Kabashi
et al 2011). Under normal conditions, TDP43 is involved in the regulation of transcription,
alternative RNA splicing, RNA stabilization, and plays a role in the metabolism of micro RNA
(Buratti & Baralle 2008; Buratti et al 2010). TDP43 is capable of regulating its own mRNA levels
by binding to its own transcript (in an intron found in the 3’-untranslated region) and enhancing
splicing (Ayala et al 2011; Polymenidou et al 2011).

Variations have been found in the

sequence of the 3’-UTR in patients with FTD (Gitcho et al 2009) corresponding with increased
TDP43 protein expression (Gitcho et al 2009; Mishra et al 2007), suggesting that mutations in
this region of the protein lead to enhanced splicing and increased protein levels during disease
progression.

TDP43 has been found to be abnormally truncated in tissue collected from

patients, with C-terminal fragments found in brain and both N- and C-terminal fragments found
in spinal cord samples of FTD and ALS patients (Igaz et al 2008). In addition to truncation,
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TDP43 has found to be hyperphosphorylated and ubiquitinated (Arai et al 2006; Neumann et al
2006). Most of the TDP43 aggregates found in patients occur within the cytoplasm or neurites
of affected cells and correspond with an overall depletion of nuclear TDP43 (Arai et al 2006;
Cairns et al 2007; Neumann et al 2006). This mislocalization is a pathological hallmark of the
disease in patients with TDP43 mutations and it is unclear if it is due to mutations in the nuclear
localization sequence itself or mutations in the C-terminal glycine rich region which is involved in
interactions with other proteins.

Several models of the disease, including mouse, D.

melanogaster, and C. elegans, all show severe motor symptoms upon overexpression of wildtype and mutant forms of TDP43, with wild-type TDP43 found mainly in nuclei and mutant
TDP43 accumulating in the cytoplasm (Ash et al 2010; Hanson et al 2010; Kabashi et al 2010;
Li et al 2010b; Shan et al 2010; Swarup et al 2011a; Voigt et al 2010; Wils et al 2010; Xu et al
2010). However, mouse models of ALS that overexpress wild-type human TDP43 containing
mutations in the predicted nuclear localization sequence do not show reduced levels of human
or mouse TDP43 in the nucleus when compared to controls (Igaz et al 2011), suggesting that
TDP43 pathology in mouse models may differ from that of ALS patients.
The fused in sarcoma (FUS) protein, also called translocation in liposarcoma (TLS), was
originally identified in cancer patients where the gene encoding FUS had undergone a
chromosomal translocation leading to the production of fusion proteins (Crozat et al 1993;
Rabbitts et al 1993).

The gene encoding FUS is constitutively activated and ubiquitously

expressed in almost all human tissues and cell lines under normal conditions (Aman et al 1996;
Andersson et al 2008; Morohoshi et al 1996). Expression levels of the protein vary between
tissues, but expression seems to be downregulated in differentiated cells and upregulated in
certain cancers suggesting it may play a role in proliferation (Andersson et al 2008; Mills et al
2000). FUS is primarily nuclear, except in hepatocytes where it is found in the cytosol, and
when cells are exposed to environmental stressors it can be found in cytoplasmic aggregates
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that localize with stress granules containing translationally silenced mRNA and micro RNAs
(Andersson et al 2008).

Neurons and glial cells contain cytoplasmic aggregates that stain

positive for FUS in postmortem CNS tissue isolated from patients with mutations in the gene
(Corrado et al 2010; Kwiatkowski et al 2009; Vance et al 2009). FUS can interact with a variety
of molecules as it has two functional domains, an N-terminal domain rich in glutamine, glycine,
serine, and tyrosine residues that functions as a transcriptional activation domain and a domain
near the C-terminus for DNA/RNA binding (Yang et al 2010).
FUS

binds

to

pre-mRNA

as

a

component

of

the

heterogeneous

nuclear

ribonucleoprotein (hnRNP) H complex (Calvio et al 1995) and it takes part in pre-mRNA splicing
by forming a complex with other hnRNPs, specifically A1 and C1/C2 (Zinszner et al 1994). FUS
is also believed to form a complex with RNA that interacts with RNA polymerase II, as it
accumulates in the cytoplasm upon inhibition of RNA polymerase II (Zinszner et al 1997). It has
also been found to be part of the Drosha complex and may have a role in micro RNA processing
(Strong 2010).

In neurons FUS is believed to play a role in the reformation of actin and

maintenance of dendritic spine shape, as it has been found localized with a protein complex
involved in transporting actin-related mRNA to dendrites (Fujii et al 2005; Fujii & Takumi 2005).
In addition to its role in RNA processing, FUS is believed to play a role in maintaining the
integrity of the genome through its ability to promote annealing of DNA (Baechtold et al 1999)
and acts as a transcriptional regulator through its interactions with DNA, nuclear receptors, and
transcription factors (Amoresano et al 2010; Kaczynski et al 2003; Law et al 2006; Li et al
2010a). Exactly how ALS associated mutations in FUS disrupt its normal function and lead to
its aggregation are not entirely clear, however mutations have been found in exons that make
up the N-terminal QGSY and glycine-rich regions, as well as in the C-terminal region involved in
DNA/RNA binding (Lagier-Tourenne et al 2010). Due to the locations of these mutations, it is
not unreasonable to believe that they may disrupt protein transport (shuttling of FUS to and from
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the nucleus), DNA/RNA binding, and some of the interactions between FUS and other proteins
involved in forming the various complexes that take part in RNA processing and transcriptional
regulation.
1.2.3.5 Neurotrophic Factor Dysregulation
Neural networks are dynamic entities that are capable of changing over time in response
to molecular cues secreted by cells within the nervous system and by skeletal muscle.
Neurotrophic factors are peptides that act as these molecular cues, and when secreted,
influence the cell cycle, growth, differentiation, and survival of neurons and glia (Nestler et al
2001). They are produced in the cell body and sent to areas where they will be secreted. It has
been suggested that neurotrophic factor signaling is dysfunctional in ALS and that motor neuron
death results from withdrawal of these molecules. Studies with mouse models have supported
this idea by showing that knocking out ciliary neurotrophic factor (CNTF) resulted in motor
neuron death and loss of muscular strength (Masu et al 1993). ALS mouse models in which
CNTF had been knocked out showed earlier onset of symptoms, which correlated with early
onset seen in human FALS patients expressing mutations in the gene for CNTF, in addition to
mutations in SOD1 (Giess et al 2002). Despite these findings, neurotrophic factor deficits have
not been seen in human ALS patients. CNTF, hepatocyte growth factor (HGF), and gial-cell
derived neurotrophic factor (GDNF) were found to be upregulated in spinal cord samples of ALS
patients (Jiang et al 2005), and GDNF levels in CSF and GDNF mRNA levels in muscle
biopsies were found to be elevated in ALS patients (Grundstrom et al 1999; Grundstrom et al
2000; Yamamoto et al 1999).

The upregulation of these factors in ALS patients may be

secondary to other dysfunctional cellular processes and reflect a defense mechanism
attempting to aid in motor neuron survival.
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Vascular endothelial growth factor (VEGF) and angiogenin (ANG) are proteins involved
in vasculogenesis and angiogenesis that have been found to play roles in the CNS and have
been implicated in ALS. VEGF has been found to act as a neurotrophic factor, promoting
neurite outgrowth and increasing neuron survival in cell culture (Sondell et al 1999) and
decreased expression in mice leads to neurodegeneration (Oosthuyse et al 2001). VEGF levels
have been found to be decreased in the CSF of ALS patients (Devos et al 2004). ANG has
been found to play a role in directing the path of neurite outgrowth (Subramanian & Feng 2007),
and expression of ALS-associated ANG mutants leads to compromised neurite outgrowth and
cytotoxicity in neuron cultures (Subramanian et al 2008). The roles of VEGF and ANG in the
pathogenesis of ALS remain unclear, as their primary roles in the body are to promote de novo
blood vessel formation, as well as blood vessel formation from pre-existing vessels. In addition
to motor neuron degeneration, ALS patients exhibit decreased cerebral blood flow (Kobari et al
1996; Waldemar et al 1992) and mouse models of ALS show breakdown of the blood-spinal
cord barrier (Zhong et al 2008), suggesting that VEGF and ANG may actually play roles
vascular growth.
1.2.3.6 Neuroinflammation
Motor neurons are the primary cell target of ALS, but in many ALS models in which
mutant proteins are overexpressed, such as SOD1, these proteins are not expressed solely in
motor neurons, but in all cells of the CNS as well as other organs.

So why do motor neurons

undergo selective cell death? Several studies of ALS suggest that the disease is non-cell
autonomous, involving a variety of cell types both within and outside of the CNS.

Animal

models suggest that motor neuron-specific expression of mutatant SOD1 is not sufficient to
cause neurodegeneration (Pramatarova et al 2001), suggesting that aberrant interactions with
other cell types are necessary to cause motor neuron death. The CNS is set up in such a
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manner that even though neurons may appear to be the most important cell type (as their rapid
signaling abilities play a vital role in all life processes), they cannot function without the aid of a
variety of supporting cells.

Astrocytes, oligodendrocytes/Schwann cells, and microglia are

indispensable pieces of the nervous system, each of which play an important role in maintaining
homeostasis and proper neuronal function.
During the pathogenesis of ALS, inflammatory processes occur that involve supportive
cells within the CNS, as well as peripheral immune cells that infiltrate the CNS, resulting in a
variety of cellular interactions that lead to motor neuron death. Studies of postmortem tissue
from ALS patients suggest that neuroinflammation is an important part of the disease, however
the progression of these processes are difficult to study in human patients as most human data
comes from end stage patients. As a result, several studies have focused on animal models of
ALS where early events in neuroinflammatory processes can be monitored. Both human and
animal models of ALS show that astrocytes become activated, microglia become reactive, and
peripheral immune cells enter the CNS to take part in inflammation. Although data are not
necessarily consistent across animal and human studies of the disease, research also shows
that a variety of cytokines and chemokines are released by activated cells within the nervous
system, and can be beneficial or deleterious to the disease process.
It is not fully understood how myelinating cells (oligodendrocytes in the CNS and
Schwann cells in the PNS) contribute to the pathogenesis of ALS, but studies aimed at
characterizing other roles of these cells, suggest that they may be important players in disease
progression.

When mitochondrial cytochrome C oxidase is conditionally knocked down in

oligodendrocytes and Schwann cells of mice, animals undergo severe neuropathy that includes
defective myelination, muscle atrophy, and paralysis and a corresponding increase in brain
lactate concentrations compared to control animals (Funfschilling et al 2012). These results
suggest that there is some kind of metabolic coupling between myelinating cells and axons and
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that myelinating cells, much like astrocytes, may play multiple roles in the nervous system.
Further experimental evidence supports this idea, as it has been shown that disruption of
monocarboxylate transporter 1 (MCT1; the major lactate transporter in the brain which is
enriched in oligodendrocytes) leads to axonal damage and neuron death in cell culture and
animal models (Lee et al 2012b). Tissue from ALS patients shows a reduction in the expression
of this transporter and SOD1 mouse models support these data, showing transporter down
regulation in spinal cord tissue of early symptomatic and end stage mice (Lee et al 2012b). It is
possible that expression of the mutant SOD1 protein disrupts cell processes within myelinating
cells, as well as neurons, leading to a decline in metabolic support. Mutant misfolded SOD1
protein aggregates have been found in the nuclei of oligodendrocytes (Forsberg et al 2011) and
the complement proteins C3d and C4d have been found associated with oligodendrocytes
(Kawamata et al 1992) in CNS tissue from ALS patients. Studies focusing on Schwann cell
involvement in ALS progression have produced conflicting results.

When Schwann cell

expression of mutant SOD1 protein was reduced in transgenic mice, disease onset was not
affected but disease progression was accelerated and the average lifespan was decreased
(Lobsiger et al 2009).

However, when mutant SOD1 protein expression was targeted to

Schwann cells of mice, animals did not develop paralysis and no motor neuron degeneration
was observed.

In addition, further increasing the expression of mutant SOD1 protein in

Schwann cells of transgenic mice did not accelerate disease progression (Turner et al 2010).
Astrocytes, which also provide neurons with metabolic support and maintain an
environment suitable for synaptic signaling, become activated during the course of ALS,
increasing in size and the number of processes extending from the cell body (Boillee et al
2006).

Postmortem tissue from ALS patients shows increased glial fibrillary acidic protein

(GFAP) and phosphotungstic acid hematoxylin (PTAH) reactivity suggestive of astrocyte
activation and the number of reactive astrocytes near sites of neuron loss is inversely
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proportional to the number of motor neurons remaining (Schiffer et al 1996).

Astrocytes in

tissue from mouse models of the disease show similar characteristics upon activation
(Garbuzova-Davis et al 2007b) and those near capillaries in the brainstem show swollen endfoot processes that may contribute to the breakdown of the BBB (Garbuzova-Davis et al 2007a).
Although reactivity may be a normal response to pathogens or stress within the CNS, normal
homeostatic functions of astrocytes may become impaired upon activation and ultimately impair
neuron function.
In cell culture models, normal and mutant SOD1-expressing motor neurons plated on an
astrocyte monolayer expressing mutant SOD1 protein showed an increase in motor neuron
death, suggesting a toxic interaction between the two cell types that involves mutant protein
expression in astrocytes (Nagai et al 2007). Culturing normal and mutant SOD1-expressing
neurons in conditioned cell culture media obtained from astrocytes expressing mutant SOD1
protein also resulted in motor neuron death, suggesting that astrocytes secrete a factor that is
toxic to motor neurons (Nagai et al 2007). However, motor neurons have been found to release
factors that may contribute to activation of astrocytes and their own demise. Fibroblast growth
factor 1 (FGF-1), which is highly expressed in motor neurons, has been shown to be released
from stressed motor neurons expressing mutant SOD1 protein in culture. When these cells are
co-cultured with astrocytes, the astrocytes become activated and motor neuron survival
decreases (Cassina et al 2005). Chemically activated astrocytes isolated from ALS rats show
increased expression of mGluR5 (Vermeiren et al 2006), a metabotropic glutamate receptor
involved in regulation of astrocyte activity and proliferation (Miller et al 1995), and modulation of
excitatory synaptic transmission (Aronica et al 2003). These cells also show impaired glutamate
uptake (Vermeiren et al 2006), suggesting that reactive astrocytes may be less capable of
carrying out their normal supportive roles. It is not clear as to when astrocytes become reactive
and ALS pathogenesis cannot be explained solely by aberrant interactions between motor
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neurons and astrocytes.

In an ALS mouse model utilizing an astrocyte-specific deletable

mutant SOD1 gene, the removal of mutant SOD1 from astrocytes did not affect the onset of the
disease, but progression was slowed and microglial activation was delayed (Yamanaka et al
2008b).

These results suggest a more complex interaction of cells in the CNS and that

astrocytes may become activated first and contribute to microglial activation.
Microglia, which interact closely with both astrocytes and neurons, are considered to be
the resident macrophages of the nervous system, providing the first line of defense against
insults to the CNS. Although they are typically regarded as macrophage-like cells, they can be
activated by a variety of signals to produce an array of activated phenotypes.

These

phenotypes range from phagocytic activity characteristic of innate immunity to antigen
presentation characteristic of adaptive immunity (Town et al 2005). Once activated, microglial
morphology changes and these cells become more mobile in order to travel to sites of infection.
In addition to gaining mobility, microglia secrete a variety of pro-inflammatory molecules
including nitric oxide and superoxide to kill pathogens, and interferon  and tumor necrosis
factor  to continue stimulating an immune response (Philips & Robberecht 2011). Microglia
can also release anti-inflammatory cytokines (interleukins 4 and 10), as well as trophic factors
(insulin-like growth factor 1), to help stop inflammatory responses and initiate repair.

The

factors secreted are influenced by surrounding cells and the local environment, resulting in
either deleterious or benign effects of microglial activation.
Experimental evidence from both ALS patients and animal models of the disease
indicates that microglial activation is part of the disease process. Activated microglia have been
found in both brain and spinal cord tissue of ALS patients, specifically in areas undergoing
significant motor neuron death (Kawamata et al 1992; Moisse & Strong 2006). The exact time
point at which microglia become activated during the progression of ALS is unclear, but studies
using animal models of the disease suggest that it occurs near the end stage of the disease
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succeeding astrocyte activation (Hall et al 1998). However, some studies using animal models
of ALS have found microglial activation to occur in presymptomatic mice as early as 60 days of
age (Dibaj et al 2011), suggesting that microglial activation may have an early and a late phase
or it may be model-specific.

New techniques utilizing a specific ligand of the peripheral

benzodiazepine binding site expressed by mitochondria of activated microglia and positron
emission tomography allow for the in vivo detection of activated cerebral microglia in ALS
patients (Turner et al 2004) and may become a useful tool for studying the time course of
microglial activation in humans, provided the discovery of earlier methods of disease detection
and diagnosis.
The phenotype of activated microglia in animal models and human ALS patients appears
to be primarily pro-inflammatory in nature.

In human studies, monocyte chemoattractant

protein-1 (MCP-1), a chemokine involved in the recruitment of peripheral immune cells, was
found to be elevated in both the serum and CSF of ALS patients. However, its expression was
not limited to microglia, but was also detected in neurons and astrocytes in post-mortem spinal
cord tissue (Baron et al 2005).

Primary microglia cultures prepared from ALS mice show

increased release of MCP-1 upon stimulation with lipopolysaccharide (LPS) compared
nontransgenic primary microglia cultures (Sargsyan et al 2009), supporting human data.
Studies using animal models of ALS have also found mRNA levels of TNF, IFN, and TGF-1
and 2 are elevated in spinal cord tissue with a corresponding increase in protein levels of TNF,
IL-6, IFN, and some chemokines (Hensley et al 2003). TNF mRNA expression has been
shown to occur prior to symptom onset and increase until the end stage of the disease (Elliott
2001), suggesting that it may be the main cytokine driving neuroinflammation and possibly
motor neuron death. Microglia have been shown to express neurotransmitter receptors, such as
ionotropic and metabotropic glutamate receptors, that under normal conditions may help them
monitor their local environment. These receptors, however, may also play a role in modulating
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the release of certain cytokines from activated microglia when neurons become stressed
(Pocock & Kettenmann 2007). Animal models of the disease in which mutant SOD1 protein
expression was reduced in microglia have shown no changes in disease onset; however
disease progression was slowed (Boillee et al 2006). In mice where reactive microglia have
been significantly reduced, motor neuron degeneration continues at the same rate (Gowing et al
2008), suggesting that microglia alone are not responsible for motor neuron death.
In mouse models of ALS, it has been shown that both the blood-brain and blood-spinal
cord barriers begin to break down early in the disease (Garbuzova-Davis et al 2007a;
Garbuzova-Davis et al 2007b). Data from ALS patients corroborate these findings as albumin,
immunoglobulin G (IgG), and the complement component C3c have been detected in
cerebrospinal fluid (CSF), and IgG has been found in motor neurons of the spinal cord
(Annunziata & Volpi 1985; Engelhardt et al 2005; Leonardi et al 1984; Meucci et al 1993). In
addition, both human patients and animal models of the disease show peripheral immune cell
infiltration into the CNS, further supporting the evidence that the barriers of the CNS are
compromised during the disease (Beers et al 2008; Chiu et al 2008; Troost et al 1989).
Astrocytes and microglia work together to create an environment that allows for the
infiltration of peripheral immune cells into the CNS. Astrocytes help form the blood-brain barrier
and the blood-spinal cord barrier, which are compromised during ALS and both astrocytes and
microglia release MCP-1 to attract circulating immune cells to sites of injury. As a result, a
variety of immune cells which normally cannot enter the nervous system, have been detected in
the CNS of ALS patients and animal models. Cytotoxic (CD8+) and helper (CD4+) T cells have
been found lining the walls of capillaries and venules and extending into affected areas
(corticospinal tracts, motor nuclei of the brainstem, and the primary motor cortex) of the CNS in
postmortem tissue from ALS patients (Kawamata et al 1992). Animal models of ALS show a
similar pattern of peripheral immune cell infiltration, with CD4+ and CD8+ T cells, and natural
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killer cell populations found in spinal cord tissue prior to symptom onset (Chiu et al 2008).
Peripheral macrophages have also been shown to enter the spinal cords of ALS patients,
surrounding and possibly engulfing motor neurons (Graves et al 2004). It is unclear as to
whether or not these T cells are attracted to areas of motor neuron degeneration by chemokines
or if they are part of an antigen-driven immune response (Holmoy 2008). In animal models of
ALS in which the primary T cell receptor was knocked out disease progression was accelerated,
suggesting a potentially protective role for T cells in the disease process (Chiu et al 2008).
Specifically, helper (CD4+) T cells have been shown to have a neuroprotective effect in mouse
models of ALS (Beers et al 2008).
It has been suggested that a toxic form of SOD1 may be involved in triggering an
immune response in ALS and may possibly act as an antigen to activate immune cells
(Brotherton et al 2012). Misfolded SOD1 protein has been found in the CSF of ALS patients
suffering from both sporadic and familial ALS (Frutiger et al 2008; Zetterstrom et al 2011a) and
an antibody that can differentiate between pathologically affected cells in tissue from human and
animal models carrying SOD1 mutations has been discovered (Brotherton et al 2012) providing
evidence for the presence of a toxic form of the protein. The presence of misfolded SOD1
protein in CSF, in the absence of disease-causing SOD1 mutations, suggests that there is
probably something else going on in patients leading to motor neuron degeneration. There is a
clear immune component to ALS and more work needs to be done to characterize the immune
response and identify potential antigens that may activate immune cells and exacerbate disease
progression.
Several studies have identified a range of cellular processes that become dysfunctional
during the progression of ALS – glutamate excitotoxicity, mitochondrial dysfunction and
oxidative stress, dysfunctional protein quality control, aberrant mRNA processing, neurotrophic
factor dysregulation, and neuroinflammation – and all of these mechanisms may contribute to

44
the development of the disease. It is clear that certain mutations contribute to the disease, but
the overlap of dysfunctional cellular processes in transgenic animal models suggests that ALS
pathogenesis is much more complex than a single gene mutation can account for. Although
these studies help to identify potential therapeutic targets by dissecting out specific diseaseassociated mechanisms, treating the disease still remains a hurdle due to its difficulty to
diagnose and its rapid progression.
1.2.4 Diagnosis and Treatment of ALS
ALS is an extremely difficult disease to diagnose.

There is no individual test or

procedure that can lead to a definitive diagnosis of the disease and no diagnostic biomarkers for
the disease have been identified (Turner et al 2009). Part of the difficulty in diagnosing the
disease is due to the wide range of symptoms exhibited by ALS patients and the overlap of
these symptoms with those of other motor neuron diseases, such as spinal muscular atrophy.
Clinicians carefully monitor symptoms and typically conduct a range of diagnostic tests to rule
out other diseases in order to diagnose patients with ALS. As a result it can take a significant
amount of time, up to a year from symptom onset, to obtain a positive diagnosis of ALS (Turner
et al 2009). By the time symptoms become apparent, a significant number of the motor neurons
in the anterior horn of the spinal cord are thought to have died and these cells do not have the
ability to proliferate and replace themselves. To be able to effectively treat ALS patients and
prevent motor neuron damage, early diagnosis is critical.
The difficulty in diagnosing ALS and the need for early diagnosis lead clinicians and
scientists to convene at a workshop in 1990 where a set of diagnostic criteria were drafted. In
1994 the first set of internationally acceptable criteria for the diagnosis of ALS, resulting from
this meeting, were published in the Journal of the Neurological Sciences (Brooks 1994). The El
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Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral
Sclerosis read as follows:
The diagnosis of ALS requires the presence of
(1) signs of lower motor neuron (LMN) degeneratioin by clinical,
electrophysiological or neuropathologic examination,
(2) signs of upper motor neuron (UMN) degeneration by clinical
examination, and
(3) progressive spread of signs within a region or to other regions,
together with the absence of
(1) electrophysiological evidence of other disease processes that might
explain the signs of LMN and/or UMN degeneration, and
(2) neuroimaging evidence of other disease processes that might explain
the observed clinical and electrophysiological signs. (Brooks 1994)
In addition to basic diagnostic criteria for ALS, this guide also provided a list of steps for
clinicians to follow to diagnose the disease which read as follows:
The diagnosis of ALS is made possible by
(1) history, physical and appropriate neurological examinations to
ascertain clinical findings which may suggest suspected, possible,
probable or definite ALS,
(2) electrophysiological examinations to ascertain findings which confirm
LMN degeneration in clinically involved regions, identify LMN
degeneration in clinically uninvolved regions and exclude other
disorders,
(3) neuroimaging examinations to ascertain findings which may exclude
other disease processes,
(4) clinical laboratory examinations, determined by clinical judgment, to
ascertain possible ALS-related syndromes,
(5) neuropathologic examinations, where appropriate to ascertain findings
which may confirm or exclude sporadic ALS, coexistent sporadic
ALS, ALS-related syndromes or ALS variants,
(6) repetition of clinical and electrophysiological examinations at least six
months apart to ascertain evidence of progression. (Brooks 1994)
The El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral
Sclerosis also included a thorough description of clinical signs of the disease, a list of disorders
related to ALS, and defined the different types of ALS.

Developing a set of internationally

acceptable diagnostic criteria for ALS was a breakthrough for diagnosing the disease, and these
criteria have been built upon over the years to accommodate new technologies and to include
guidelines for clinical trials.
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Despite the continual evolution of diagnostic criteria for ALS, as well as an increased
understanding in molecular mechanisms underlying disease progression, there is still a need for
drugs that can slow progression of the disease and help increase patients’ quality of life.
Currently, the only drug approved to treat ALS in most countries is riluzole, which has a modest
effect on the lifespan of patients (Miller et al 2007). Riluzole is believed to target excitotoxicity in
ALS patients, as it has been found to prevent the release of neurotransmitters stimulated by
excitatory amino acids, like glutamate (Barbeito et al 1990; Benavides et al 1985; Hubert &
Doble 1989). Riluzole has been shown to block NMDA and kainic acid initiated currents in
Xenopus oocytes (Debono et al 1993), but radioligand binding studies failed to demonstrate its
ability to bind with glutamate receptors (Benavides et al 1985; Debono et al 1993), suggesting
that riluzole targets excitotoxicity in an indirect fashion. The drug has also been shown to inhibit
basal and synaptically stimulated glutamate release (Cheramy et al 1992; Hubert & Doble 1989;
Martin et al 1993) and appears to exhibit its indirect effects on excitotoxicity through its ability to
block tetrodotoxin-sensitive sodium channels expressed on damaged neurons, preventing
glutamate release by reducing calcium influx into the presynaptic neuron (Song et al 1997).
Riluzole has also been shown to enhance the Wnt pathway (Biechele et al 2010), which has
recently been implicated in ALS (Chen et al 2012).

Even though riluzole has been shown to

target multiple pathways involved in ALS it only extends the median survival by about two to
three months (Miller et al 2007), and by the time it is administered motor neurons have
undergone a significant amount of damage that cannot be reversed.

The issues with

diagnosing the disease combined with a lack of treatment options, makes slowing the
progression of ALS with early treatment a serious problem.
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1.3 Models of ALS
ALS is a complicated disease that is not fully understood.

A wide array of gene

mutations have been implicated as causative factors for developing the disease, and a number
of molecular mechanisms are believed to play a role in the death of motor neurons. Much has
been learned about the pathogenesis of the disease due to the development of ALS animal
models. However, it has been difficult to link all of the molecular mechanisms with gene
mutations to gain a full understanding of the initial steps leading to motor neuron death, creating
the need to continue studying ALS and developing better disease models. There are a variety of
ways in which ALS can be modeled in the laboratory, from single-cell systems to whole animal
models, each of which have a variety of advantages and disadvantages.
Single-cell models of ALS, such as Saccharomyces cerevisiae and mammalian cell
cultures of neurons, astrocytes, and microglia, are easily manipulated genetically and
pharmacologically and allow for rapid data collection.

S. cerevisiae is a simple eukaryotic

organism that shares several protein quality control mechanisms with many higher eukaryotes
and is a useful system for studying the protein misfolding that occurs as a consequence of
expressing mutations in proteins such as SOD1, TDP43, and FUS (Bastow et al 2011). In
addition, S. cerevisiae can be used to study oxidative stress associated with SOD1 mutations,
as well as a variety of different protein-protein interactions (heat shock and chaperone proteins,
and DNA/RNA binding proteins) that may occur during ALS pathogenesis (Bastow et al 2011).
Like yeast, mammalian cell culture models can also be used to gain insight into the molecular
mechanisms behind ALS, however, these cells can provide a clearer picture of exactly what is
happening in a single cell type during the disease. For example, fluorescently-tagged proteins
can be expressed in these systems and intracellular trafficking can be monitored directly using
live cell imaging, to gain a greater understanding of ER stress or aggregation of mutant proteins.
In addition, co-culturing of neurons and other cell types such as astrocytes can provide insight

48
into cell-cell interactions that may become toxic during the progression of ALS. These singlecell model systems of ALS are valuable tools for understanding the molecular mechanisms
behind the disease, but they only tell a small part of the story. S. cerevisiae may have some
similarities to human cells, but they are not human and therefore do not express all of the same
proteins, nor do they mimic the cell-cell interactions that occur within higher organisms.
Mammalian cell culture systems may model the molecular mechanisms of ALS more accurately
than yeast, but these cells do not behave in culture exactly as they do in the body. In single cell
culture systems cell-cell interactions that occur in the body (neuron-astrocyte, neuron-muscle,
and neuron-oligodendrocyte) are lost, while in co-culture systems interactions may be regained
to some extent, but again are not the same as in the human body.
Small, multicellular organisms provide a slightly better model of the disease, as these
systems maintain the cellular interactions that are lost in single-cell systems. Caenorhabditis
elegans, Drosophilia melanogaster, and zebrafish have all been used as small model systems
to study ALS (Joyce et al 2011).

C. elegans and D. melanogaster are small multicellular

organisms that are easy to manipulate genetically and grow in the lab. Both organisms have a
short life cycle and are capable of rapidly reproducing in large numbers, which allows for rapid
collection of data. C. elegans is a simple organism that has been studied extensively. It is a
transparent nematode containing less than 1000 cells, the lineage of which can be traced back
to the egg (Muller & Grossniklaus 2010). The adult nematode contains 302 neurons that can be
broken down into classes based on their function – chemosensory, mechanosensory, and
thermosensory.

C. elegans has been so thoroughly studied that the complete pattern of

synaptic connections within its nervous system has been mapped and all of the neuronal
subtypes have been identified down to the neurotransmitter secreted and the area innervated
(Gama Sosa et al 2012).

The transparent nature of C. elegans allows for proteins to be

fluorescently tagged, and specific cells and intracellular processes can then be visualized within
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living nematodes. In addition, genetic manipulations in which genes are targeted to specific
cells or turned on at specific times can be performed in C. elegans. Several proteins involved in
vesicle formation, trafficking, and release at the synapse, are highly conserved, which allows C.
elegans to be used as a model for neurodegenerative diseases (Teschendorf & Link 2009). In
ALS research C. elegans has been used to examine the effects of neuron-specific expression of
various human SOD1 and TDP43 mutations, as well as the effects of muscle-specific
expression of human SOD1 mutations, on protein aggregation, movement, and lifespan (Joyce
et al 2011).
D. melanogaster is slightly more complex than C. elegans, but the adult fly brain and the
eye have been utilized extensively to study mechanisms of neurodegeneration (Jeibmann &
Paulus 2009). D. melanogaster expresses both neurons and glial cells in the developing CNS,
that grow to produce the adult brain which contains association areas used for olfactory learning
and memory called mushroom bodies (Gama Sosa et al 2012). Neurons in the complex eye
develop in a stereotypical fashion with sequential differentiation of photoreceptors. Like C.
elegans, the fruit fly has some mammalian homologs and can be used to understand the normal
biological functions of genes, as well as dysfunctions that lead to neuronal death upon mutation
(Bonini & Fortini 2003; Gama Sosa et al 2012; Muqit & Feany 2002). D. melanogaster can be
manipulated in such a way that gene expression can be targeted to specific regions of the body
(such as the eye or mushroom bodies) or induced at specific times using hormone inducible
gene expression, or Tet-On/Tet-Off inducible systems (Gama Sosa et al 2012). The beauty of
the fruit fly as a model system is that it can be used to perform forward genetic screens in which
phenotypes are assessed and selected for through breeding to identify the genes responsible
for causing certain traits.

As a result, large-scale genetic screens can be performed in a

relatively short period of time and used to dissect out the cell-signaling pathways involved in
disease. D. melanogaster has been used to examine the effects of tissue-specific expression of
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human wild-type and mutated forms of SOD1 and TDP43 on protein aggregation, glial cell
stress, motor dysfunction, cell death, and lifespan (Joyce et al 2011).
The zebrafish (Danio rerio), an inexpensive vertebrate, has increased in popularity as a
model organism.

It is somewhat more difficult to work with in the lab than fruit flies and

nematodes, as it requires more space (for aquariums) and has a longer life cycle, but it can
reproduce rapidly and is fairly easy to breed and maintain (Gama Sosa et al 2012). Zebrafish
share a close evolutionary relationship with mammals and the overall organization of the brain is
similar to that of humans.

The zebrafish brain consists of a forebrain, a midbrain, and a

hindbrain which contains a diencephalon, telencephalon, and a cerebellum. Their peripheral
nervous system has motor and sensory components, similar to humans, and they exhibit higher
order behaviors that are not present in invertebrate systems (Gama Sosa et al 2012; Lieschke &
Currie 2007). Zebrafish are easy to manipulate genetically and there are a variety of techniques
that can be employed to generate transgenic zebrafish models of disease. Plasmid DNA can be
inserted into the cytoplasm of fertilized eggs through microinjection or electroporation, sperm
can be genetically modified, retroviral systems can be used to deliver genetic material, and
genes can be knocked down using morpholino technology (Gama Sosa et al 2012). Gene
expression can be regulated in a cell type-specific manner or temporally using similar systems
utilized in fruit fly models. During the larval stage of development, the brain and skull of the
zebrafish are transparent which allows for fluorescence imaging of cells in vivo (Cheng et al
2011).

Dyes can be injected into cells, and transgenic fish expressing genetically coded

calcium indicators in specific neurons have been developed, allowing for the imaging of neural
activity by monitoring calcium changes that occur during action potentials (Wilms & Hausser
2009). The adult zebrafish develops stripes and is no longer transparent making in vivo imaging
in the adult fish difficult, however cancer researchers recently developed a new strain of the
species (called Casper) that remains transparent as an adult (White et al 2008), which may be
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used to visualize cells involved in neurodegeneration.

In addition to the ease with which cells

can be visualized in zebrafish, this model can also be used to perform forward genetic screens,
as well as reverse genetic screens in which genes are manipulated (mutated, inserted, or
knocked down) and corresponding phenotypes assessed to identify genes with the potential to
cause neurodegeneration. Mutations in the zebrafish SOD1 gene have been used to study
motor neuron loss and muscle atrophy, and the motor defects that accompany these
phenomena during ALS.

Human wild-type and mutant TDP43 mRNA have also been

expressed in zebrafish embryos as a model for ALS (Joyce et al 2011).
C. elegans, D. melanogaster, and D. rerio, have been useful models in gaining an
understanding of the molecular mechanisms behind the pathogenesis of neurodegenerative
disorders, but they are not the best models for human diseases. Both C. elegans and D.
melanogaster lack an immune system, which is a major disadvantage when studying
neurodegeneration. These organisms also lack mylenated axons and as a result are missing an
important cell-cell interaction (that of neurons and oligodendrocytes or Schwann cells), as the
motor neurons undergoing degeneration in human ALS are myelinated (Gama Sosa et al 2012).
Microglial activation, peripheral immune cell infiltration into the CNS, and interactions between
neurons and myelinating cells play significant roles in the progression of ALS, as previously
discussed, and the inability of these organisms to mimic these processes limits the usefulness
of data collected from invertebrate models. Zebrafish are a slightly more useful model of ALS
because they have an immune system that functions similar to that of humans, and have even
been used as models for immune function during other types of infection. In addition, this model
also expresses many of the same CNS cell types seen in humans and mimics human anatomy
and physiology better than invertebrate models. The use of fish as a model system does have
its disadvantages. The gene targeting technology available for the zebrafish model is limited
and a greater range of gene targeting exists for mouse models (Gama Sosa et al 2012).
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Zebrafish also live in a very different environment than humans, which may be a disadvantage
when studying diseases like ALS that may have an environmental component.
The best organisms for models of human diseases are those that most closely resemble
humans (with respect to organ structure and function, and genetics) and can mimic human
diseases. Several mammalian models of ALS are currently being used to study the disease,
and research is ongoing to produce better mammalian models that exhibit the same hallmarks
of the disease seen in humans. Currently there are a wide variety of mouse models of ALS and
there are a few rat models of the disease. There is even a naturally occurring SOD1 mutation
that produces a neurodegenerative disorder in dogs that can be used as a model for ALS
(Awano et al 2009; Joyce et al 2011). All of these models have been invaluable tools for
studying the disease, but they do not exhibit the same symptoms and they do not always show
the same pathological hallmarks of the disease as human patients. As a result, researchers
have been working on better models of the disease and have recently produced a non-human
primate model of ALS (Uchida et al 2012).
The mouse is probably the most common and well-studied mammalian model of human
disease. The first genetically modified mouse was created in 1974 when DNA inserted into a
mouse embryo showed that the gene insert was present in all of the animal’s cells, but was
unable to be passed to offspring (Jaenisch & Mintz 1974). The first transgenic mice capable of
passing exogenous DNA to offspring were later produced in 1981. This was accomplished by
injecting purified DNA into a single-cell mouse embryo (Costantini & Lacy 1981; Gordon &
Ruddle 1981). Since then, the technology used to genetically manipulate mice has been vastly
improved and applied to other animals creating an entire industry devoted to transgenic animal
models of human disease.
The first transgenic mouse model overexpressing the human SOD1 gene was
produced in the 1980s and was used to examine the effects of increased dosage of the protein
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in Down syndrome (Epstein et al 1987).

In 1994 the first transgenic mouse model

overexpressing a mutant form of SOD1 associated with ALS, the G93A mutation, was found to
exhibit motor neuron degeneration similar to that seen in ALS patients (Gurney et al 1994).
Since this time, a variety of SOD1 mutations, both artificial and those found in ALS patients,
have been expressed in mice to discern how alterations in the protein’s structure contribute to
disease onset and progression (Joyce et al 2011). Table 1.3.1 lists the SOD1 mutations that
have been expressed in mouse models, as well as the age of disease onset and survival time
for these animals.

Interestingly, the SOD1-A4V mutation, which is the most commonly

occurring SOD1 mutation in human ALS (Deng et al 1993; Siddique & Deng 1996), does not
cause motor neuron degeneration when expressed alone in transgenic mice, but must be coexpressed with human wild-type SOD1 in order to produce a disease phenotype (Deng et al
2006). The G93A mutation, which is much less common in human ALS, is probably the most
commonly studied mutation thanks to its use in transgenic mouse models of the disease.
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Table 1.3.1 SOD1 mutations expressed in transgenic mouse models of ALS.

Table was modified from Joyce, et al. (2011)
ND indicates the survival time was not described.
a
The SOD1-A4V mutation only produces motor neuron disease when co-expressed with the
human wild-type SOD1.
b
Artificial mutations that prevent copper from binding the enzyme.
c
Mouse transgene.
d
Age of onset and survival vary depending upon the copy number of the gene, with increased
copy number leading to earlier onset and shorter survival.
e
Artificial mutation that truncates the protein.
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Since the discovery of ALS-associated mutations in TDP43, several TDP43 mouse
models of ALS have been developed. Most of these models overexpress the human wild-type
TDP43 gene, however the human A315T mutation has been successfully inserted into
transgenic mice. These models also make use of different promoters which allow the transgene
to be expressed in specific cell types or brain regions, as well as throughout the body (Joyce et
al 2011). The phenotype expressed by these models varies depending upon the promoter and
expression level of the protein. It is important to note that TDP43 aggregation seen in human
patients is not always exhibited by TDP43 transgenic mice. Since this is a relatively new area of
research, there is still work to be done to produce better TDP43 mouse models of the disease.
Many of the same human gene mutations used in mouse models have been utilized in
rat models of ALS. Both the H46R and G93A human SOD1 mutations have been successfully
inserted into rats. These SOD1 transgenic rat models exhibit an ALS-like phenotype similar to
their mouse counterparts, upon overexpression of these mutant forms of protein. Rat models
expressing both the wild type TDP43 and a mutatant form containing the M337V mutation have
also been developed (Zhou et al 2010). Expression of wild type TDP43 does not lead to a
disease phenotype in rats however the expression of the M337V mutation produces an ALS-like
phenotype exhibiting lower motor neuron loss and gliosis, but does not mimic the TDP43
aggregation seen in human patients much like the TDP43 transgenic mouse model.
The popularity of rodents as models of human disease stems from the fact that they are
evolutionarily closely related and their overall development parallels that of humans.
Genetically, mouse chromosomes are organized in a similar fashion to those of humans, with
genes displayed in similar patterns across the genome. In addition, mice and rats can be inbred
to create a homogeneous genetic background which is beneficial when studying the expression
of a transgene (Gama Sosa et al 2012). The technology used to insert genes into mice has
been translated for use in rats, but is much less available for use in rats, which is probably the
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reason for the greater variety in mouse models of disease. These genetic manipulations have
been expanded to include knocking down genes, and transgenic animals can be crossed with
other strains of animals that are missing certain genes to study the effects of the removal of a
protein on disease. Mice and rats are small, easy to care for and breed, live in an environment
similar to humans that can be tightly controlled in a lab setting, and can be easily used to study
the effects of drugs.

Unlike invertebrate and fish models of disease, rodents can be

administered drugs in the same manner as humans (i.e., orally, subcutaneously, intravenously,
etc.) which is beneficial when conducting pharmacological studies that examine the route of
administration, absorption, excretion, and things of that nature. Rats are much larger than mice
and have a greater capacity for learning in behavioral tasks, which is beneficial when drugs
need to be inserted directly into the brain or when examining the effects of a disease or
treatment on behavior. With respect to neurodegenerative disorders, the organization of the
rodent CNS is similar to that of humans, with the expression astrocytes and other cell types
involved in creating the blood-brain barrier and the blood-spinal cord barrier, which is vital when
studying treatments that need to cross these barriers in order to effectively treat diseases. Mice
and rats also exhibit immune function similar to that of humans and these disease models often
display some of the same neuroinflammatory processes that are commonly observed in
patients.
Although transgenic rodents make good models of human diseases due to their
similarities with humans, they are probably not the best models for ALS. In mouse models of
ALS that develop severe paralysis, such as the SOD1 G93A mouse, the paralysis only occurs in
the rear limbs and is primarily a lower motor neuron disease. Although humans develop lower
motor neuron symptoms, they also show significant upper motor neuron degeneration, and
mouse models do not which is a major disadvantage to studying these animals. ALS rat models
that overexpress mutant forms of SOD1 may be better models than their mouse counterparts as
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they develop symptoms that are closer to those observed in human patients.

Rats

overexpressing the G93A mutation have an aggressive disease and can exhibit symptoms in
hind limbs or forelimbs (Joyce et al 2011; Nagai et al 2001), whereas mice expressing this
mutation show only hind limb paralysis. Both mouse and rat models of ALS show some of the
pathological hallmarks that human patients exhibit, such as protein aggregation and activation
of microglia and astrocytes, but they may also show artifacts resulting from the expression of
the transgene itself which may not translate to human studies.
1.4 Purpose of the Study
ALS is a devastating neurodegenerative disease in which motor neurons are selectively
killed. The prognosis of the disease is typically poor and once a positive diagnosis is made,
patients typically only have a few years of life left. Due to the lack of treatment options for the
disease patient quality of life tends to be poor, as patients not only become paralyzed, but they
may lose the ability to speak and even breathe on their own. Since motor neurons cannot
divide to replace cells that have died, the best treatment options would be those that can
prevent motor neuron death. In order to achieve this, the disease would have to be detected
early on, prior to significant cell death. This would require patients seeking treatment at the
earliest signs of symptoms, as well as reliable biological markers of the disease and better
methods of detection.
ALS research has advanced significantly in the past few decades, with the discovery of a
wide range of molecular mechanisms providing several potential therapeutic targets of the
disease. A constantly expanding variety of animal models of the disease has aided in the
discovery of drugs that may slow ALS progression, however many drugs that have shown to be
beneficial in animal models of ALS have failed to show the same level of efficacy in human trials
(Beghi et al 2007).

This may, in part, be due to the fact that there has been incomplete
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metabolic profiling of animal models of the disease and overexpression of mutant ALSassociated proteins may actually lead to systematic metabolic defects in these models.

In

addition, many studies using animal models, as well as human patients, fail to separate male
and female data and may miss potential gender differences in the disease itself, as well as
gender differences related to treatments. Several studies have implicated a neuroprotective
effect of estrogen in spinal cord injury (Chaovipoch et al 2006; Kachadroka et al 2010) and ALS
(Choi et al 2008; Groeneveld et al 2004) and hormones have been shown to effect
inflammatory processes (Karpuzoglu & Ahmed 2006; Lang 2004; Salem 2004; Straub 2007),
which can impact disease progression.

Metabolic differences have also been observed

between men and women. Women have been shown to have lower resting metabolic rates
than men (Arciero et al 1993) and a variety of studies have suggested that there are gender
differences in energy utilization that may be modulated by hormones (Wismann & Willoughby
2006). These basic gender differences in metabolism have implications for gender differences
in xenobiotic metabolism. In rats gender-specific differences have been observed in certain
cytochrome P450s, enzymes important in drug metabolism (Kato & Yamazoe 1992), and human
studies have shown that women recover from general anesthesia faster than men (Bajaj et al
2007).

These observations suggest that gender should be considered when studying the

general progression of a disease, as well as the response to drug treatments for a disease, in
both animal and human studies in order to determine differences in underlying mechanisms and
the best therapeutic intervention for the patient.
The purpose of this study was to understand the gender-specific effects of treating
transgenic mice overexpressing the human SOD1 protein containing the G93A mutation with Lmethionine sulfoximine (MSO), an irreversible inhibitor of glutamine synthetase (GS). Initial
studies using this drug in ALS mice showed that it extends the lifespan of these animals and
targets glutamate excitotoxicity, lowering levels of glutamine and glutamate in specific brain
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regions (Ghoddoussi et al 2010). My studies have expanded on these experiments by looking
at gender differences in survival of ALS mice treated with MSO and the impact of sex hormones
on the disease progression and treatment efficacy. These experiments, discussed in Chapter 2,
show that MSO extends the lifespan of these animals in a gender-specific fashion, having a
greater effect on females than males. In addition, sex hormones play a role in MSO’s ability to
extend lifespan, as gonadectomy removes the response to MSO in both males and females.
The second portion of this study examines MSO’s effect on amino acid and nitrogen
metabolism in SOD1 G93A mice. The goal of these experiments was to characterize basic
metabolism in untreated wild-type and ALS mice, as well as in mice treated with MSO, and to
understand the effects of mutant transgene expression and MSO treatment on amino acid and
nitrogen metabolism accounting for gender.

Enzymatic assays and analysis of plasma

metabolite levels were performed to monitor metabolic changes between genders, as well as
genotypes.

These experiments, discussed in Chapter 3, show that there are a variety of

metabolic differences between males and females, some of which are specific to transgenic
animals. MSO treatment significantly lowers brain and spinal cord glutamine synthetase activity
and shows no differences in activity levels between genders or genotypes, suggesting that its
gender-specific effects on survival are probably not due to its effect on GS. MSO treatment and
SOD1 expression, however, do not have an effect on other enzymes involved in nitrogen
metabolism, specifically glutaminase and carbamoyl phosphate synthetase one (CPSI).
Interestingly, CPSI activity is higher in females than males providing evidence supporting
underlying gender differences in nitrogen metabolism. SOD1 mice show some oddities in their
metabolic profiles, such as a cysteine deficiency, suggesting that overexpression of the
transgene itself may have an impact on overall metabolic processes.
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CHAPTER 2
THE GENDER-SPECIFIC EFFECT OF MSO ON SURVIVAL
2.1 Introduction
2.1.1 Glutamine Synthetase
Glutamine synthetase (GS) is an extremely important enzyme that is expressed in a
variety of organisms, from bacteria to mammals.

It is a major enzyme involved in the

metabolism of nitrogen found in all extant organisms and the genes encoding GS have been
suggested to be some of the oldest functioning genes in existence (Kumada et al 1993). There
are three different classes of glutamine synthetases: (1) Class I glutamine synthetases (GSI)
which are expressed by prokaryotes, (2) Class II glutamine synthetases (GSII) which are
expressed by eukaryotes, plants, and certain bacteria (particularly bacteria belonging to the
Rhizobiaceae, Frakiaceae, and the Streptomycetaceae families), and (3) Class III glutamine
synthetases (GSIII) which have only been found in bacteria colonizing the gastrointestinal tracts
of animals, specifically Bacteroides fragilis and Butyrivibrio fibrisolvens (Brown et al 1994). The
structure of glutamine synthetase varies and can be an octamer, decamer, or a dodecamer,
depending upon the organism in which it is expressed (Eisenberg et al 2000; Krajewski et al
2008; Liaw & Eisenberg 1994).
Class II glutamine synthetases are the only class expressed by eukaryotes.

The

structures of Class II glutamine synthetases varies, but have been found to be octomeric in at
least one species of plant (Phaseolus vulgaris) (Llorca et al 2006) and decameric in maize
(Unno et al 2006) and some mammals (canines and humans) (Krajewski et al 2008). The
decameric form of GS is made up of two rings, each of which is composed of five monomers,
which lie back-to-back forming the barrel-shaped enzyme. At the interface of each monomer
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there is an active site and the active sites of the pentameric rings are slightly offset, producing a
decamer that contains a total of 10 active sites (Krajewski et al 2008).
GS is responsible for converting glutamate into glutamine, catalyzing the reaction
Glutamate + NH4+ + ATP

Glutamine + ADP + Pi in the presence of magnesium or

manganese. The crystal structure of human GS was determined with the enzyme bound to
magnesium, ADP, and phosphate, and with the enzyme bound to magnesium, ADP, and an
irreversible inhibitor of GS, methionine sulfoximine. The structures show that there are three
magnesium ions present in each active site and suggest that a single molecule of each reactant
– glutamate, ATP, and ammonia – can enter an active site to produce glutamine (Krajewski et al
2008).

As a result, the decamer has the potential to produce 10 molecules of glutamine, one

from each active site. The conversion of glutamate to glutamine is believed to take place in two
steps, the first of which involves the enzyme binding to glutamate and ATP, forming the
enzyme-bound intermediate, γ-glutamyl phosphate. During the second step, which requires the
presence of ADP in the active site, ammonium is covalently bound to the activated glutamate
intermediate to form glutamine and phosphate and ADP are released (Krishnaswamy et al
1962; Liaw & Eisenberg 1994; Meister 1985).
GS can be found in the cytosol or the mitochondria, depending upon the organism and
the tissue in which it is expressed. In vertebrate neural tissue GS is expressed primarily in
astrocytes where it is found in the cytosol (Kennedy et al 1974; Linser & Moscona 1983; Smith
& Campbell 1983; Smith et al 1987). However, liver GS can be found in the cytosol or the
mitochondria, depending upon the method of ammonia detoxification utilized by the organism.
In organisms such as birds, reptiles and sharks, that utilize uricotelic or ureosmotic methods to
remove excess nitrogen, liver GS is found in the mitochondria (Campbell et al 1987; Smith &
Campbell 1983; 1987; Smith et al 1987). In higher vertebrates that utilize ureotelic methods to
remove excess nitrogen, like mammals, GS is cytosolic in liver (Smith & Campbell 1988; Wu
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1963). In mammalian liver GS is primarily found in pericentral hepatocytes, a small population
of cells that surround the venules of the liver (Haussinger 1987).
Glutamine synthetase is expressed throughout the body and the concentration of GS in
a cell, as well as enzyme activity, vary depending upon the cell type (van Straaten et al 2006).
Glutamine is found in high concentrations in the body and is considered a non-essential amino
acid, as it can be produced by GS and taken up from the diet (Nelson & Cox 2008). As a result,
cells can utilize GS either to produce glutamine or to remove the potentially toxic substances,
glutamate and ammonia. Lower levels of GS are expressed in cells utilizing the enzyme for
glutamine production, while high levels of GS are found in cells that function primarily to remove
ammonia and glutamate (Lie-Venema et al 1998; van Straaten et al 2006). Organs expressing
high levels of GS, typically express it in a subset of cells (Lie-Venema et al 1998; van Straaten
et al 2006). This is seen in the brain and liver where GS is restricted to certain cell types –
astrocytes in the brain and pericentral hepatocytes in the liver. In organs that express low levels
of GS, such as adipocytes and myocytes, the enzyme appears to be expressed throughout the
organ (Lie-Venema et al 1998; van Straaten et al 2006). Mammalian GS has not been as well
characterized as bacterial forms of the enzyme, which can be regulated by a variety of posttranslational modifications. As a result, the regulation of mammalian GS is not fully understood,
but it appears to occur at the level of translation, with protein stability playing a role in regulation
(van Straaten et al 2006).

GS is susceptible to both reactive oxygen and nitrogen species and

has been found to be reversibly inhibited by nitration of tyrosine residues, however this
modification may be more important under conditions where cells are exposed to high levels of
oxidative stress (Gorg et al 2007).
GS is a central enzyme in nitrogen metabolism in a wide variety of organisms. It is the
only enzyme capable of producing glutamine, the most abundant amino acid in the body, which
acts as a carrier of ammonia in the bloodstream and as a non-toxic form of glutamate in the
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nervous system. As mentioned in Chapter 1, GS is an important enzyme in the central nervous
system, where it acts as the primary player in the recycling of the neurotransmitter glutamate.
In the liver, GS produces glutamine that donates ammonia to CPSI for the production of urea
and the excretion of excess nitrogen. Glutamine is also important for protein production and
can act as a fuel for a variety of cell types.
2.1.2 L-Methionine Sulfoximine
In the early twentieth century nitrogen trichloride (also called agene) was used to age
and bleach flour that was used for animal and human consumption. During this time it was
noticed that there was a problem with dogs developing a nervous disorder (referred to as
running fits), which was later determined to be caused by the consumption of foods containing
flour that had been treated with nitrogen trichloride (Mellanby 1946).

Despite this finding,

studies conducted on a variety of animals showed that there appeared to be species-specific
sensitivity to foods that had been treated with agene, and humans, along with monkeys and
rats, did not show any sensitivity to consumption of these substances (Newell et al 1949a;
Newell et al 1949b). Shortly after this discovery, it was determined that treating flour with agene
lead to the production of a toxic factor which could be isolated (Bentley et al 1949; Campbell et
al 1951; Reiner et al 1950). Around this same time, this toxic factor was also synthesized and
identified as methionine sulfoximine (Bentley et al 1950; Misani & Reiner 1950).
Methionine sulfoximine (MSO) is a modified form of methionine where the sulfur atom is
bound to an oxygen atom and an imine group, in addition to the methyl group. Figure 2.1.1 (A
and B) shows the structural similarities between methionine and methionine sulfoximine.
Several studies conducted in the 1950s attempted to identify targets of MSO and in 1952,
glutamine synthetase was identified as its primary target (Pace & McDermott 1952). It has also
been shown to inhibit alanine aminotransferase (De Robertis et al 1967) and stimulate ornithine
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decarboxylase activity (Di Giacomo et al 1997). MSO is also structurally similar to buthionine
sulfoximine (BSO) (Figure 2.1.1C), which acts as an inhibitor of γ-glutamylcysteine synthetase,
the first and rate-limiting step in the production of glutathione. While BSO does not inhibit GS,
MSO has been shown to inhibit γ-glutamylcysteine synthetase (Richman et al 1973).
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Figure 2.1.2.1 Chemical structure of MSO and analogous compounds.
MSO (A) is a modified form of the amino acid methionine (B) with an oxygen atom and an imine
group attached to the sulfur atom. BSO (C), an inhibitor of γ-glutamylcysteine synthetase, is
structurally similar to MSO with the sulfur atom attached to a butyl group in place of the methyl
group.
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Despite the identification of other enzymatic targets of MSO, the vast majority of
research conducted on this compound has focused on its ability to inhibit glutamine synthetase.
Initial studies conducted to determine the mechanism by which MSO inhibits GS suggested that
the compound competitively inhibited the enzyme, as the addition of glutamate seemed to
prevent inhibition by MSO (Sellinger & Weiler 1963). These studies lead to the idea that MSO
behaved as a glutamate analog, binding the enzyme in the portion of the active site normally
occupied by glutamate.

Further studies showed that inhibition of GS by MSO was more

complex, as it required ATP and once the enzyme was inhibited, glutamate was no longer
capable of reversing inhibition suggesting that MSO irreversibly inhibited GS. These studies
also showed that MSO was phosphorylated by the enzyme, producing a new compound
(methionine sulfoximine phosphate) that interacted tightly with GS but could be removed by
denaturing the enzyme (Rao & Meister 1972; Ronzio & Meister 1968; Rowe et al 1969).
Methionine sulfoximine phosphate is produced when MSO and ATP bind the enzyme and GS
phosphorylates MSO. The phosoporylated product and ADP are left behind, stuck in the active
site rendering the enzyme inactive (Krajewski et al 2008; Rao & Meister 1972; Ronzio & Meister
1968; Rowe et al 1969). It is important to note that MSO contains two chiral centers, one at the
α-carbon and a second at the sulfur atom, and therefore has four potential isomers. Only one of
these isomers, L-methionine-S-sulfoximine, has been shown to bind to GS and become
phosphorylated leading to enzymatic inhibition (Manning et al 1969) and has also been linked to
the convulsant properties of MSO (Rowe & Meister 1970).
The only way that GS can overcome inhibition by MSO is through degradation and
production of new protein.

In studies where rats were given a single i.p. injection of a

subconvulsive dose of MSO, it was shown that different tissues respond differently to the drug.
Liver GS shows maximal inhibition four hours after MSO administration, while brain GS shows
maximal inhibition 24 hours after administration. In addition, the return to normal enzymatic
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activity levels varies between tissues (Lamar 1968). Similar studies conducted on mice agree
with the results obtained from rats and show that liver GS has a higher turnover rate, as activity
levels return to normal within 30-60 days of MSO administration, while brain GS levels are only
75% of normal at 90 days after MSO administration (Rao & Meister 1972). Maximal formation
of methionine sulfoximine phosphate, the product that inhibits GS, occurs about 5 hours after
MSO injection in both the brain and the liver. However, it is more rapidly removed from the liver
than the brain and complete removal corresponds to the return to normal enzymatic activity
level (Rao & Meister 1972).
Despite its ability to cause convulsions in certain species, MSO has shown to have some
beneficial effects in certain disease models and has been a useful tool in understanding the
importance of glutamine metabolism. In diseases which elevate ammonia levels in the body,
such as acute liver failure, brain GS attempts to lower ammonia levels by incorporating it into
glutamine which builds up in astrocytes and disrupts the osmotic balance leading to astrocyte
swelling. MSO treatment of cell culture and rat models of this disease, decreases glutamine
production by inhibiting GS and reduces astrocyte swelling (Norenberg & Bender 1994; WillardMack et al 1996). In a mouse model of acute liver failure, pretreatment with MSO has been
shown to significantly increase survival and lower levels of several cytokines, including the proinflammatory cytokine TNF-α (Jambekar et al 2011). Treatment of ALS mice with MSO has also
been shown to extend lifespan and target excitotoxicity by lowering levels of glutamine and
glutamate in certain brain regions (Ghoddoussi et al 2010). It is not entirely clear if all of the
beneficial effects of MSO are due to glutamine synthetase inhibition, as there are other potential
targets of the drug that have not been well characterized. Human studies examining the effects
of consuming agenized flour, did not show that consumption of foods containing MSO had any
negative effects on people (Newell et al 1949a; Newell et al 1949b). As a result, more work

68
needs to be done to fully understand how MSO exerts its beneficial effects and if it has any
therapeutic potential.
2.1.3 Effect of Gender on Lifespan, Disease Progression, and the Response to
Methionine Sulfoximine
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder
characterized by the death of motor neurons running through ventral roots and corticospinal
tracts of the spinal cord through the brainstem and primary motor cortex. The death of these
motor neurons gives rise to symptoms such as involuntary muscle spasms, muscle weakness
and atrophy, and eventually leads to paralysis. Patients typically die within 2-5 years due to
pulmonary complications and respiratory failure (Wijesekera & Leigh 2009).
ALS has been subdivided into two categories: (1) Sporadic ALS, the most common type
of the disease, which appears to have no genetic component, and (2) Familial ALS, which is
hereditary and accounts for only 5-10% of all cases (Wijesekera & Leigh 2009). The familial
form of the disease tends to be autosomal dominant and has been linked to a variety of gene
mutations, including the genes for TAR-DNA binding protein (TDP-43), and superoxide
dismutase 1 (SOD1) (Wijesekera & Leigh 2009), the later mutation is commonly exploited in
transgenic mouse models of the disease. Despite the discovery of several inheritable mutations
involved in ALS, the underlying cause of motor neuron death remains unclear.
One mutation in particular, the SOD1 G93A mutation, has been transferred to a
transgenic mouse (Gurney et al 1994) to create the primary animal model for characterizing this
disease and for testing the effects of various drugs. This mouse lives approximately 120-130
days before the disease progresses to the point where the mouse must be euthanized. In a
previous study we showed that methionine sulfoximine (MSO), a well-characterized inhibitor of
glutamine synthetase, can extend the lifespan of the SOD1 G93A mouse by 8% when given i.p.
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injections of 20 mg/kg three times a week (Ghoddoussi et al 2010). This lifespan extension,
comparable to that seen with many other drugs tested on this mouse, was accompanied by
changes in brain metabolites which support the conclusion that there is an interruption in the
glutamine-glutamate cycle in the CNS, resulting in a decrease in both glutamine and glutamate
and supporting the idea that the therapeutic effects are a consequence of a reduction in
excitotoxicity.
We have continued these studies to test both the effect of dosage (since this
mechanism-based inhibitor has very long-lasting effects on glutamine synthetase) and the
gender-specificity of this drug, since ALS and other neurodegenerative diseases display gender
specificity – affecting one gender more than the other. We also tested the role of sex hormones
in both disease progression and the response to MSO treatment by measuring survival, disease
progression, and response to MSO of ovariectomized female mice and castrated male mice.
The results of those experiments demonstrate the involvement of sex hormones in both disease
progression and the response of these mice to MSO treatment.
2.2 Materials and Methods
Animal Handling. Breeding pairs of the SOD1 mouse – B6JL (G93A) – were purchased
from Jackson Laboratories and offspring containing the human SOD1 G93A mutation were
identified by PCR of tail DNA, using primers described for this strain by Jackson Laboratories
(jax.org). All animal experiments were approved by the Animal Investigation Committee of
Wayne State University.
Methionine sulfoximine (MSO), obtained from Sigma Chemical Company (catalogue no.
5379) was dissolved in 0.9% saline and administered intraperitoneally (i.p.) at a dose of 20
mg/kg.

70
Mice were injected with MSO or saline once per week starting at 50 (+/- 2) days of age
until they were euthanized. Mice were observed daily by the supervising veterinarians and
laboratory-animal staff and were euthanized when either 1) they lost 20% of their maximum
body weight, 2) they were unable to right themselves when put on their back or side, or 3) if, in
the opinion of the supervising veterinarians, the mice were in distress or unable to obtain
adequate food and water.
Hang-time Analysis. Mice were placed on a steel wire grid which was then inverted and
placed over a plastic bin approximately 13 inches deep, with paper towels at the bottom to
cushion the fall. The hang-time for each mouse was recorded as the time before the mouse
released the grid and fell or at 120 seconds if the mouse did not fall before then. Mice were
tested twice/week, starting at 50 days of age.
Animal Surgeries. All surgeries were performed between 30 and 40 days of age, before
the animals had reached sexual maturity. Mice were anesthetized with i.p. injections of 0.4-0.75
mg/g body weight Avertin. A stock solution of Avertin was prepared by dissolving 25g of 2-2-2tribromoethanol (Sigma) in 15.5 mL of tert-amyl alcohol (Sigma). This was then diluted to a 20
mg/mL working solution by adding 0.5 mL of the stock Avertin to 39.5 mL of PBS and filtering
through a sterile 45 µm filter. Both the stock solution and the working solution were kept in foilwrapped containers and the working solution was stored at 4°C when not in use.
Ovariectomies were performed by first shaving the lower backs of female mice and then
sterilizing the area with Betadine and isopropanol. An incision was made in the middle of the
lower back running parallel to the spinal cord. The skin was gently pulled away from the muscle
and the first ovary was located. A very small incision was then made just below the kidney and
the periovarian fat pad was gently pulled out of the body, bringing the ovary with it. Being
careful not to crush the ovary, mosquito forceps were used to crush the fallopian tube and
cranial-most portion of the uterine horn. The ovary was then removed by cutting above the
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crushed area and the uterine horn was returned to the abdominal cavity.

This was then

repeated on the other side. Once both ovaries were removed, the skin incision was closed with
wound clips.
Castrations were performed by first forcing the testicles to descend by applying light
pressure to the abdominal region and pushing towards the tail. The testicles were then shaved
and the area was sterilized with Betadine and isopropanol.

An incision was made in the

scrotum between the testicles. A second incision was then made in the tunica of the first
testicle and the testis, vas deferens, and the fat pad were gently pulled out of the body. The
blood vessels supporting the testis were cauterized and the testis was removed by cutting just
below the site of cauterization. This was repeated on the other side and the skin incision was
closed with wound clips.
Statistics and Data Analysis. The survival studies were analyzed by both parametric
(Student’s t test) and nonparametric (Kaplan-Meier) methods.

Student’s t test significance

values, p, are always two-tailed. Means are notated as x(y), where x is the mean and y is its
standard error.

Unless noted, p values are from the t test.

Kaplan-Meier analysis

supplemented the t test by allowing the comparison of the survival curves (e.g., log rank
statistic). The use of both types of analyses was possible because the certainty of death by the
disease meant that no animals needed to be censored, although two mice died very early from
causes unrelated to ALS and were removed from the study. Effect size was determined by
calculating Cohen’s d with the use of pooled standard deviations (Cohen 1988; Rosnow &
Rosenthal 1996), and Cox regression was used to obtain the hazard ratio as an additional
measure of effect size.

The interpretation of d given in the text is according to Cohen’s

explanation. The ‘hang-time’ analysis used the same statistical tools as the survival studies with
the terminal event in the ‘time to event’ Kaplan-Meier procedure being the inability to hang onto
the grid.
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2.3 Results
A weekly injection of MSO increases survival of the SOD1 G93A mouse. We previously
showed that mice injected with 20 mg/kg MSO had their survival extended by approximately 8%
(Ghoddoussi et al 2010). Since MSO is a mechanism-based inhibitor of glutamine synthetase,
a single treatment lowers GS levels for an extended period of time, as animals have to
synthesize more enzyme to overcome the inhibition – up to a week or more in rats and mice
(Lamar 1968; Rao & Meister 1972).

A single weekly injection should therefore be just as

effective as multiple injections. Figure 2.3.1 shows the Kaplan-Meier survival curves for SOD1
G93A mice treated with a weekly i.p. injection of either saline or MSO (20 mg/kg), starting at 50
(+/- 2) days of age and illustrates that this dosing-schedule improves the survival of ALS mice
(p=0.001, log rank test). A single weekly injection extends the mean lifespan from 128 (1) to
136 (2) days, where the value in parenthesis is the standard error of the mean.
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Figure 2.3.1 Kaplan-Meier survival curves for MSO’s effect on the lifespan of SOD1 G93A mice.
Animals were treated once a week with i.p. injections of either saline (diamonds) or 20 mg/kg
MSO (squares). Mice treated with MSO (136 (2) days, n=50) lived significantly longer than
saline-treated mice (128 (1) days, n=50), p<0.001, two-tailed, d=0.7.
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The increase in survival in MSO-treated SOD1 G93A mice depends on gender.

A

complete summary of the statistics for gender-dependent and treatment-dependent survival
analyses is shown in Table 2.3.1. Cox regression analysis of the entire data set showed that
gender and treatment (saline vs. MSO), were significantly affecting survival, with bootstrapped
significance values of 0.008 and 0.001 respectively. Castration or overiectomization were also
significant at 0.006 and 0.04 respectively. When we further analyzed the results by gender,
MSO significantly extended the mean lifespan of both males and females, although females
were more responsive. The mean lifespan of females is extended from 130 (2) to 140 (2) days
(p=0.001, d=1.0), while the mean lifespan of males is extended from 125(2) to 132(2) days
(p=0.02, d=0.6) (Table 2.3.1 and Figure 2.3.2). The effect sizes (d) indicate a greater effect on
females. The conclusion that the therapeutic effects of this drug on lifespan are greater on
females than on males is also supported by further analysis of survival data of MSO-treated
animals. When comparing the mean lifespan of males and females treated with MSO, we see
that females live significantly longer than males (140 (2) days and 132 (2) days respectively,
p=0.004, d=0.8). Kaplan-Meier survival analysis of saline-treated males compared to that of
saline-treated females were not significantly different (p=0.09, log rank test), but the same
analysis of the survival curves of MSO-treated males and females showed that MSO-treated
females lived significantly longer than MSO-treated males (p=0.004, log rank test).
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Table 2.3.1 Summary of survival comparisons and associated statistical values.
Category
All Intact
Mice
Intact
Females
Intact
Males
OVR
Females
CSTR
Males
Saline-treated
females
Saline-treated
males
MSO-treated
females
MSO-treated
males
Intact
Saline-treated
Intact
MSO-treated
Neutered
Saline-treated

Comparison
Saline
MSO
Saline
MSO
Saline
MSO
Saline
MSO
Saline
MSO
Intact
OVR
Intact
CSTR
Intact
OVR
Intact
CSTR
Females
Males
Females
Males
Females
Males

n
50
50
25
24
25
26
9
9
11
11
25
9
25
11
24
9
26
11
25
25
24
26
9
11

mean (SEM)
128 (1)
136 (2)
130 (2)
140 (2)
125 (2)
132 (2)
129 (2)
130 (3)
128 (3)
130 (4)
130 (2)
129 (2)
125 (2)
128 (3)
140 (2)
130 (3)
132 (2)
130 (4)
130 (2)
125 (2)
140 (2)
132 (2)
129 (2)
128 (3)

Neutered
MSO-treated

Females
Males

9
11

130 (3)
130 (4)

p (t test)

p (log rank)

0.001

0.0001

0.001

0.0004

0.02

0.02

0.8

0.4

0.6

0.4

0.7

0.6

0.4

0.4

0.01

0.004

0.5

0.9

0.06

0.09

0.004

0.004

0.8

0.9

0.9

0.6

Category = mice evaluated; Comparison = gender, treatment, or surgery group compared; n =
the number of animals/group; Mean (SEM) = average age (standard error of the mean); p (t
test) = p value determined by a bootstrapped t test with 1000 samples; p (log rank) = p value
determined using Kaplan-Meier; OVR = ovariectomized; CSTR = castrated.
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Figure 2.3.2 Kaplan-Meier survival curves of MSO’s effect on the longevity of each gender.
The data shown in Figure 2.3.1 was separated by gender and replotted. A. The mean age of
survival for females treated with MSO (140 (2) days, n=24) was significantly higher than that of
saline-treated females (130 (2) days, n=25), p=0.001, two-tailed, d=1.0. B. The mean lifespan
of male mice treated with MSO (132 (2) days, n=26) was also found to be significantly higher
than that of saline-treated males (125 (2) days, n=25), p=0.02, two-tailed, d=0.6. Diamonds
represent saline-treated animals and squares represent animals treated with MSO.
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Tests of neuromuscular function. We conducted an analysis of neuromuscular function,
a hang-time analysis (see Materials and Methods), by measuring how long mice could hang on
to an inverted wire grid before losing their grip and falling. The results of this test were analyzed
in two ways. First, we plotted the average hang-time (in seconds, 120 maximum) for each
population versus age, as shown in Figure 2.3.3 for female and male mice. For female mice,
MSO improves hang-time over the interval from 114 to 123 days of age (p<0.05 for the points
indicated in Figure 2.3.3).

For male mice, treatment makes no significant difference in

neuromuscular function. We then carried out a Kaplan-Meier analysis of these same data,
using a hang-time of zero as the terminal event. This approach allows us to analyze the effects
of gender and drug treatment on the disease progression. Additionally, a hang-time of zero is a
more objective measure of a disease endpoint than determining if a mouse has met our criteria
for euthanasia. The analysis, shown in Figure 2.3.4, demonstrates that MSO extends the time
to the complete loss of hang-time competence for females (123 (2) to 132 (2) days, p=0.0008
log rank test) and thus delays disease progression in the later stages of the disease. It also
confirms that this drug, a specific inhibitor of glutamine synthetase, exerts its effects in a
gender-specific manner. This analysis shows that the drug might benefit males – mostly in the
later stages of the disease – in addition to females, but it clearly benefits females to a greater
extent.

A complete summary of the gender-dependence and treatment-dependence of the

Kaplan-Meier hang-time competence analyses are shown in Table 2.3.2.
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Figure 2.3.3 Hang-time data for female mice and male mice treated with saline and 20 mg/kg
MSO.
Each of the four groups consisted of 17 mice except for the MSO-treated females, which
consisted of 15 mice. Each point represents the average hang-time of at least 15 mice
measured at that age +/- 2 days. In the curves for female mice (A) , we have calculated the
significance for the points where the curves diverge using a t-test, and the resultant p values are
listed above the three points on the graphs where MSO treatment produces a significant
difference. The curves for male mice (B) show no significant differences in hang-time. Curves
were truncated shortly after the mice started dying when how we treated dead mice in this
analysis began to significantly affect the statistics.
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Figure 2.3.4 Kaplan-Meier hang-time competence curves using zero hang-time (complete
inability to hang on to a wire grid) as the terminal event.
A. The average age at which hang-time competence was lost in females was improved
significantly with MSO treatment (132 (2) days, n=15) when compared to that of saline-treated
females (123 (2) days, n=17), p=0.0004, two-tailed, d=1.4. B. In male mice, the average age at
which hang-time competence was lost was not significantly improved by MSO treatment (122
(2) days, n=17) when compared to saline treatment (118 (1) day, n=17), p=0.09, two-tailed,
d=0.6. Diamonds represent saline-treated animals and squares represent animals treated with
MSO.
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Table 2.3.2 Summary of hang-time competence comparisons and associated statistical values.

Category
All Intact
Mice
Intact
Females
Intact
Males
OVR
Females
CSTR
Males
Saline-treated
females
Saline-treated
males
MSO-treated
females
MSO-treated
males
Intact
Saline-treated
Intact
MSO-treated
Neutered
Saline-treated
Neutered
MSO-treated

Comparison
Saline
MSO
Saline
MSO
Saline
MSO
Saline
MSO
Saline
MSO
Intact
OVR
Intact
CSTR
Intact
OVR
Intact
CSTR
Females
Males
Females
Males
Females
Males
Females
Males

n
34
32
17
15
17
17
9
9
11
11
17
9
17
11
15
9
17
11
17
17
15
17
9
11
9
11

mean (SEM) p (t test) p (log rank)
120 (1)
127 (2)
0.002
0.0007
123 (2)
132 (2)
0.0004
0.0008
118 (1)
122 (2)
0.09
0.06
124 (2)
124 (3)
0.9
0.9
123 (2)
126 (3)
0.4
0.3
123 (2)
124 (2)
0.7
0.6
118 (1)
123 (2)
0.03
0.02
132 (2)
124 (3)
0.009
0.01
122 (2)
126 (3)
0.2
0.07
123 (2)
118 (1)
0.02
0.02
132 (2)
122 (2)
0.0002
0.0004
124 (2)
123 (2)
0.8
0.9
124 (3)
126 (3)
0.6
0.2

Category = mice evaluated; Comparison = gender, treatment, or surgery group compared; n
the number of animals/group; Mean (SEM) = average age (standard error of the mean); p
test) = p value determined by the t test using bootstrapped samples of 1000; p (log rank) =
value determined using the log rank test for Kaplan-Meier, time to event; OVR
ovariectomized; CSTR = castrated.
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Effects of castration and ovariectomization on survival and grip strength. Given the
strong gender effect of MSO treatment, we conducted the same analyses of survival and hangtime on neutered mice – ovariectomized females and castrated males – to determine if female
sex hormones were beneficial in the response to MSO, or if male sex hormones were
detrimental to that response.

The Kaplan-Meier survival analysis shown in Figure 2.3.5A

demonstrates that MSO does not extend the lifespan of ovariectomized females (p=0.4, log rank
test), and the results of the Kaplan Meier hang-time competence analysis, shown in Figure
2.3.6A, indicate that MSO does not slow neuromuscular deterioration (p=0.9, log rank test).
Therefore, removing female sex hormones eliminates the beneficial effects of MSO on female
mice.
Castrating the male mice tested the role of male sex hormones on disease progression
in both the absence (saline) and presence of MSO. Figure 2.3.5B shows the results of the
Kaplan-Meier survival analysis and illustrates that MSO does not significantly affect castrated
mouse survival (p=0.4, log rank test). Nor does MSO treatment have a significant effect on the
time to the complete loss of hang-time competence in castrated mice (p=0.3 log rank test,
Figure 2.3.6B and Table 2.3.2). So neutering mice eliminated the beneficial effects of MSO on
survival of both male and female mice, and eliminated the beneficial effects of MSO on disease
progression, as measured by grip in females.

82
Figure 2.3.5 Kaplan-Meier survival curves of MSO’s effect on longevity in the absence of sex
hormones.
Ovariectomized female and castrated male SOD1 G93A mice were treated once a week with
i.p. injections of either saline (diamonds) or 20 mg/kg MSO (squares). A. The average lifespan
of ovariectomized female mice treated with MSO (130 (3) days, n=9) was similar to that of
saline-treated ovariectomized females (129 (2) days, n=9). In the absence of estrogens, MSO
no longer had an effect on the longevity of female mice, p=0.8. B. In castrated male mice,
MSO does not have an effect on the average lifespan (130 (4) days, n=11) compared to saline
treatment (128 (3) days, n=11), p=0.6.
A.
Saline

1
Fraction Surviving

20 mg/kg MSO
0.8

0.6
0.4
0.2
0
100

110

120

130

140

150

160

170

Age (Days)
B.

Fraction Surviving

1

Saline
20 mg/kg MSO

0.8
0.6

0.4
0.2
0
100

110

120

130

140

Age (Days)

150

160

170

83
Figure 2.3.6 Kaplan-Meier hang-time competence curves (using zero hang-time as the terminal
event) for gonadectomized mice.
A. There is no difference in the average age at which hang-time competence was lost between
ovariectomized females treated with MSO and saline (124 (3) days and 124 (2) days
respectively, n=9 for each treatment group), p=0.8. B. MSO treatment did not increase the
average age at which hang-time competence was lost in castrated males (126 (3) days and 123
(2) days respectively, n=11 for each treatment group), p=0.4. Diamonds represent salinetreated animals and squares represent animals treated with MSO.
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Interestingly, these studies showed that castration alone had a significant effect on the
hang-time competence of the male mice. Figure 2.3.7 shows a normal Kaplan-Meier analysis of
the lifespan of saline-treated gonadectomized versus non-gonadectomized males and females.
There was no significant difference in the survival curves due to gonadectomization for either
gender (p=0.4 for females and p=0.4 for males as determined by the log rank test). However,
Figure 2.3.8 and Table 2.3.2 show the Kaplan-Meier analysis of hang-time, using zero grip time
as the terminal event, and reveal that castration alone produces significant improvement in
saline-treated male mice (p=0.02, log rank test), but ovariectomization has no effect on hangtime competence of female mice (p=0.6, log rank test). These results suggest that removal of
male sex-hormones has a beneficial effect on neuromuscular function of male SOD1 G93A
mice.
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Figure 2.3.7 Kaplan-Meier survival plots comparing the longevity of saline-treated mice with
intact gonads to those that have undergone gonadectomy.
Diamonds represent saline-treated animals with intact gonads and squares represent
gonadectomized saline-treated animals. A. Saline-treated females with intact ovaries (130 (2)
days, n=25) do not live significantly longer than ovariectomized females treated with saline (129
(2) days, n=9), p=0.7, two-tailed, d=0.1. B. Saline-treated males with intact testes (125 (2)
days, n=25) do not live significantly longer than castrated males treated with saline (128 (3)
days, n=11), p=0.4, two-tailed, d=0.3.
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Figure 2.3.8 Kaplan-Meier hang-time competence plots comparing saline-treated mice with
intact gonads to those that have undergone gonadectomy.
Diamonds represent animals with intact gonads and squares represent gonadectomized
animals. A. For saline-treated female mice, there is no difference in the average age at which
hang-time competence was lost between females with intact ovaries (123 (2) days, n=17) and
ovariectomized females (124 (2) days, n=9), p=0.7, two-tailed, d=0.1. B. Castration of male
mice significantly increases the average age at which hang-time competence was lost in salinetreated males (123 (2) days, n=11 for castrated males, compared to 118 (1) day, n=17 for males
with intact gonads), p=0.03, two-tailed, d=0.9.
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2.4 Discussion
We have previously shown that MSO, a potent inhibitor of glutamine synthetase, both
extends the lifespan of SOD1 G93A mice and alters the levels of several neurochemicals notably glutamine, glutamate, and GABA - in different brain regions (Ghoddoussi et al 2010).
Those studies used the published dosage of 20 mg/kg MSO (Blin et al 2002), injected three
times per week. In this report we expanded those experiments in three ways: 1) by increasing
the total number of mice tested, 2) by using a grip assay monitoring neuromuscular function to
provide an alternative to death for measuring the effects of the drug, and 3) by examining
gender-dependence of the response to MSO and, in particular, the involvement of male and
female sex hormones in disease progression through ovariectomy and castration of SOD1
G93A mice.
Our first survival study consisted of 30 mice – half treated with saline and half treated
with MSO three times per week (Ghoddoussi et al 2010). The current study consisted of 100
mice – half treated with saline and half treated with MSO once a week. Since MSO is a
mechanism-based inhibitor of glutamine synthetase, inhibition can only be overcome by
synthesizing more of the enzyme. Hence, recovery of full brain GS activity takes a long time –
up to several weeks (Lamar 1968; Rao & Meister 1972). If the action of the drug on these mice
involves inhibition of glutamine synthetase, the reduced dosage should have the same effects
as the higher dosage. We found that in fact the reduced dosing schedule produced essentially
the same extension of lifespan in the SOD1 G93A mouse model for ALS, despite the reduction
in frequency of administration, providing additional support for MSO having a significant effect
on disease progression and again indicating that the therapeutic target is glutamine synthetase.
In order to reduce the uncertainties involved in applying criteria for euthanasia, we
conducted grip (hang-time) assays to monitor neuromuscular function and then carried out a
Kaplan-Meier analysis using the time the mice were unable to grip (hang-time of zero; i.e. total
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failure of tested muscle strength) as the terminal event, instead of death. This measurement is
more objective and provides an additional check on disease progression. While euthanasia
criteria were applied in a blinded manner the decision was made by the veterinary staff,
introducing a small measure of subjectivity to the survival analysis.
This Kaplan-Meier hang-time competence analysis also supported the conclusion that
MSO is acting in a gender-specific fashion. In the actual survival analysis, the drug appears to
be working better on females than on males, although the extension of lifespan is signif icant for
both. While the log rank test for differences in survival due to MSO treatment resulted in a
much smaller p value for females (0.0004) than for males (0.02), this does not mean that the
MSO affected females more strongly. Calculating effect sizes (d) according to Cohen (Cohen
1988), the effect size for females (1.0) is larger than that for males (0.6). This corresponds to
36% of the females improving with MSO treatment, as compared to 26% of the males.
Calculating hazard ratios by Cox regression, females reduced their risk of death on MSO by
65%; while males reduced their risk of death by 46%, again indicating that MSO has a larger
effect on female survival. In the hang-time analysis, the effect of drug treatment did not reach
significance for males (p=0.06, log rank test) while it did for females (p=0.0008).

More

importantly, the 95% confidence intervals for the hazard ratio for males, in contrast to that for
females, included a hazard ratio of 1.0, indicating that MSO does not necessarily improve
neuromuscular function.
Both ovariectomizing females and castrating males eliminated the beneficial response of
mice to MSO treatment, demonstrating that the therapeutic effects of this drug involve enzymes
or pathways whose activities are influenced by estrogen or testosterone, or some other sex
hormone. Whether the hormone-dependent effects are on glutamine synthetase itself, or on
some aspect of metabolism that is influenced by both glutamine synthetase and sex hormones,
was not tested in these studies. We have assayed brain glutamine synthetase activity in this
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mouse model, as previously described (Ghoddoussi et al 2010) and found no significant gender
differences in either treated or untreated mice. Finally, the results from castrated male mice
show that male sex hormones facilitate disease progression, since castration delayed
progression in the hang-time analysis even though it did not ultimately affect lifespan.
Testosterone or another hormone therefore acts on some process that accelerates
neurodegeneration. Ovariectomizing females, however, affected only the response to MSO but
neither lifespan nor disease progression as measured by the hang-time assay. The hormoneresponsive target affected by MSO treatment is therefore probably some pathway or protein that
can ameliorate disease progression when MSO is present, but which is not otherwise a
significant component of the disease process. In fact, comparing our various measurements on
ovariectomized females and castrated males revealed no significant differences between these
groups (Tables 1 and 2). The fact that the differences between males and females arise only in
animals with intact gonads is another indication that sex hormones play a significant role in
disease progression – male hormones exacerbate the disease, and both male and female
hormones influence some aspect of metabolism or cell biology that can respond beneficially to
treatment with MSO.
In humans, the age of onset of ALS is between 50 and 60 years of age for both the
sporadic and familial forms (Bruijn et al 2004), which are clinically indistinguishable from one
another. ALS has a slight male prevalence with a male to female ratio of 3:2 (Pasinelli & Brown
2006; Wijesekera & Leigh 2009). In large studies examining both sporadic and familial cases of
ALS, the overall incidence and prevalence of the disease are greater in mean than women
(McCombe & Henderson 2010). Although gender does not seem to have an effect on survival,
most of the ALS patients that fall within the younger age groups in these studies are men.
Interestingly, the male to female ratio decreases with increasing age and approaches 1:1 after
60 years of age (Haverkamp et al 1995), suggesting sex hormones may play a role in the
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disease. Gender differences in clinical features of the disease have also been noted, but are
difficult to explain (McCombe & Henderson 2010).

Some potential explanations for these

differences are biological differences between males and females - including gender differences
in the overall immune response and the central nervous system and its ability to repair damage,
possibly due to protective effects of certain hormones, and gender differences in exposure to
certain toxins.
Mouse models of ALS also reflect several gender differences in the disease. Survival
data from SOD1 G93A transgenic mice shows that females have a slightly longer lifespan than
males. The average lifespan of female transgenic mice is between 130 and 135 days, whereas
the average male lifespan is between 125 and 130 days (Choi et al 2008; Heiman-Patterson et
al 2005). Male mice typically show an earlier onset of the disease than females (HeimanPatterson et al 2005), which is consistent with data collected from ALS patients. Studies looking
at gender differences in the extension reflex and rotarod performance of these animals provide
evidence suggesting the disease progresses more slowly in female mice (Choi et al 2008). In
contrast to our results, those studies showed that ovariectomizing these mice leads to
accelerated disease progression (Choi et al 2008) and a decrease in the average lifespan. This
decrease in lifespan was shown to be reversed with 17β-estradiol treatment (Choi et al 2008;
Groeneveld et al 2004), further supporting the idea that estrogen plays a protective role in
female ALS mice. Our studies, however, show no protection by female sex hormones in the
absence of MSO, but suggest that male sex hormones facilitate the disease progression.
Data from both human and animal studies show that there are biological differences
between males and females that can influence the progression of diseases like ALS. If sex
hormones can alter the progression of a disease, then they should be able to influence the
effectiveness of treatment, as is seen in these studies. Using the SOD1 G93A mouse model for
ALS, Teng et al. showed that a β2-adrenoceptor agonist, clenbuterol, exhibited a gender-
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specific effect (Teng et al 2006). Clenbuterol was able to help prevent weight loss, delay motor
symptoms, and extend the median survival, and seemed to exert a protective effect on neurons
in female, but not male, mice (Teng et al 2006). It has also been shown that in the SOD1
mouse, ROS production is increased in male spinal cords but not females, and that males and
females had different responses to treatment with GCSF (Naumenko et al 2011). Genderspecific differences in both neurological parameters and electrophysiological changes have also
been observed in the SOD1 mouse (Alves et al 2011).
There has been little biochemical characterization of the overall metabolic profile of the
SOD1 G93A mouse model for ALS, much less for information on the gender-specific differences
in metabolites and metabolic enzymes. The fact that an inhibitor directed at a central enzyme of
nitrogen metabolism can delay disease progression and extend lifespan in a gender-specific
manner suggests that this disease may involve a metabolic defect that responds to sex
hormones, either directly or indirectly.

Such gender-specific differences must therefore be

identified and accounted for in the development of therapies to treat ALS. We are currently
trying to identify metabolic differences between wild-type and SOD1 G93A mice in order to
determine how treatment with MSO might influence those differences, in an effort to identify
targets for other such “metabolic” therapies.
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CHAPTER 3
BIOCHEMICAL EFFECTS OF MSO TREATMENT ON ALS MICE
3.1 Introduction
3.1.1 Amino Acid Metabolism
Amino acids are the basic building blocks of proteins within the body and can be
classified in a variety of ways – based on charge of the R-group, architecture, the body’s ability
to synthesize them, or based on their degradative end products and the metabolic cycle they
are then shuttled into. There are 20 common amino acids and a variety of uncommon amino
acids that are derived from them. Of the 20 common amino acids, humans are capable of
producing 11 of them, while the other 9 must be obtained through the diet (Nelson & Cox 2008).
Histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and
valine must be provided in the diet and are therefore considered to be essential amino acids.
The body has pathways that can produce alanine, asparagine, aspartate, glutamate, and serine
and as a result, these amino acids are considered to be nonessential.

Arginine, cysteine,

glutamine, glycine, proline, and tyrosine can also be produced by the body, but are required
during development and some disease conditions and are therefore classified as conditionally
essential amino acids (Nelson & Cox 2008).
Amino acids are ultimately broken down into seven potential end products which
converge at the citric acid cycle, where their carbon skeletons can be completely oxidized to
carbon dioxide and water or go on to produce glucose or ketone bodies.

Those amino acids

that are broken down to produce acetoacetyl-CoA (leucine, lysine, phenylalanine, tryptophan,
and tyrosine) and acetyl-CoA (isoleucine, leucine, threonine, and tryptophan) are considered to
be ketogenic because they can ultimately go on to produce ketone bodies. Those amino acids
that are converted to glutamate (glutamine, arginine, histidine, and proline) or broken down into
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succinyl-CoA (isoleucine, methionine, threonine, and valine), fumarate (phenylalanine and
tyrosine), oxaloacetate (asparagine and aspartate), or pyruvate (alanine, cysteine, glycine,
serine, threonine, and tryptophan) are considered to be glucogenic amino acids because their
carbon skeletons can be used for the production of glucose (Nelson & Cox 2008). Tryptophan,
tyrosine, isoleucine, phenylalanine, and threonine are both glucogenic and ketogenic. Figure
3.1.1.1 shows the structures of the common amino acids, organized by the charge of the Rgroup.
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Figure 3.1.1.1 The common amino acids.
The 20 common amino acids contain a variety of R-groups that can be positively or negatively
charged, polar (hydrophilic), nonpolar (hydrophobic), or aromatic. Those amino acids in red are
glucogenic, those in blue are ketogenic, and those in purple have the ability to be either
ketogenic or glucogenic. Essential amino acids are labeled with asterisks (*) and conditionally
essential amino acids are labeled with a cross (†).
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Protein obtained through the diet is denatured and broken down by the stomach and
passed to the small intestine where it is further broken down and absorbed. Absorption occurs
through enterocytes, which line the small intestine and colon.

Microvilli on the surface of

enterocytes increase the surface area available for the absorption of nutrients and the
glycocalyx coating the inside of the gastrointestinal tract contains a variety of enzymes to aid in
further protein breakdown (Purves et al 2001).

Individual amino acids and small peptide

fragments can be taken up by enterocytes (Adibi et al 1967) through a variety of amino acid
transport systems, some of which depend upon the sodium gradient within the gut for transport
(Broer 2008). The anatomy of the small intestine is such that it contains millions of projections
(called villi) extending into the lumen, each of which contains venules and arterioles lining the
center through which blood circulates (Tortora & Grabowski 1996). One mechanism believed to
be important in the uptake of amino acids by the intestine is the γ-glutamyl cycle, which utilizes
intracellular glutathione to help bring amino acids into the cell (Cornell & Meister 1976; Meister
et al 1979; Orlowski & Meister 1970). Figure 3.1.1.2 shows the γ-glutamyl cycle, which brings
amino acids into the cell by first attaching them to glutathione via γ-glytamyl transpeptidase and
then releasing them inside the cell and replenishing glutathione.

Peptides taken up by

enterocytes lining the villi in the lumen are broken down within the cell and transported into the
blood stream through the basolateral membrane (Broer 2008). Once in the bloodstream, amino
acids are circulated to organs and taken up through transport systems similar to those utilized in
the small intestine (Broer 2008). The brain, which contains barriers preventing the entry of
many substances, also expresses a variety of amino acid transport systems (Smith 2000) to
bring in precursors of neurotransmitters and neuropeptides.
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Figure 3.1.1.2 The γ-glutamyl cycle of amino acid uptake.
1) γ-glutamyl transpeptidase (γ-GT) within the membrane transfers the γ-glutamyl moiety of
glutathione to the amino acid, bringing it into the cell as γ-glutamyl amino acid (γ-Gaa). 2a) γglytamyl cyclotransferase (γ-GCT) cleaves the amino acid, releasing it in the cytosol, and
producing 5-oxoproline (5-OP). 2b) The cysteinyl-glycine (Cys-Gly) produced by γ-GT in the
first step of the cycle is cleaved by peptidase into glycine and cysteine. 3) 5-oxoprolinase
converts 5-OP into glutamate. 4) γ-glutamylcysteine ligase (γ-GCL) begins to replenish
glutathione by attaching cysteine to the carboxylate group of glutamate to produce γ-glutamyl
cysteine (γ-GC). 5) Glutathione synthetase replenishes glutathione (GSH) by attaching glycine
to γ-GC.
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3.1.2 L-Glutamine and Nitrogen Metabolism
L-Glutamine is the most abundant amino acid in the body, with plasma levels ranging
from 500 to 700 µM in humans (Rennie et al 1981).

Glutamine obtained from the diet is

absorbed by enterocytes in the intestine, which utilize glutamine as a source of energy and
probably use most of what they absorb, resulting in very small amounts of dietary glutamine
released into the bloodstream (Windmueller & Spaeth 1974). Glutamine is in high demand in
the body since most tissues utilize glutamine for a variety of cellular processes. However, this is
not a problem for most mammalian tissues, since they express glutamine synthetase (Krebs
1935) and can therefore produce glutamine from glutamate. In addition, skeletal muscle has the
largest glutamine store in the body and has the ability to release it into circulation to maintain
plasma glutamine levels (Newsholme 1994; Newsholme & Parry-Billings 1990), ensuring its
availability for all tissues.
Glutamine is probably the most important amino acid in the body due to the wide variety
of roles it can play. One of its most important roles is to detoxify ammonia and transport it
through the bloodstream (Bulus et al 1989) to the liver for urea production. Glutamine can act
as an ammonia donor for carbamoyl phosphate synthetase I (CPSI) (Nelson & Cox 2008), the
first enzyme in the urea cycle, and it can be converted to glutamate by mitochondrial
glutaminase, which can also donate ammonia to CPSI.

Figure 3.1.2.1 shows the role of

glutamine and glutamate in the urea cycle. CPSI acts as the first and rate limiting enzyme in the
urea cycle, catalyzing the reaction between bicarbonate, ammonia and two molecules of ATP to
produce carbamoyl phosphate. This carbamoyl phosphate is then used in the second step in
the cycle, catalyzed by ornithine transcarbamoylase, where the phosphate group is released
and it is combined with ornithine producing citrulline. The citrulline is then transported to the
cytosol where it undergoes a reaction with ATP, catalyzed by arginosuccinate synthetase,
forming an intermediate that then reacts with aspartate (produced within the mitochondria)
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yielding arginosuccinate. Arginosuccinate lyase then removes fumarate from arginosuccinate to
produce arginine, which is converted to urea and ornithine through the ureohydrolase arginase.
The ornithine produced in this last step is then taken back up by the mitochondria for another
round of the cycle (Berg et al 2007; Nelson & Cox 2008).
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Figure 3.1.2.1 The urea cycle.
The urea cycle starts in the mitochondrial matrix. Amino acids enter the urea cycle as
glutamate which can be taken up by mitochondria, or produced within the mitochondrial matrix
from glutamine via glutaminase. The carbon atom in urea comes from bicarbonate that is
incorporated into carbamoyl phosphate, while one of the amino groups is donated by external
amino acids and the other is donated by aspartate produced within the mitochondria via
aspartate aminotransferase.
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Glutamine has many other roles within the body, besides acting as a source of
ammonia. The kidneys utilize glutamine to maintain acid-base homeostasis (Newsholme et al
2003) and in the brain glutamine acts as a nontoxic form of glutamate and ammonia (Nestler et
al 2001). Glutamine also acts as a source of metabolic intermediates for a variety of cells
(Newsholme et al 2003). Enterocytes consume glutamine as a source of energy, but other
cells, such as colonocytes, fibroblasts, tumor cells, and proliferating immune cells, also utilize
glutamine at high rates (Askanazi et al 1980; Kovacevic & McGivan 1983; Koyama et al 1998).
Glutamine acts as a nitrogen donor for the production of nucleotides and can be incorporated
into proteins (Nelson & Cox 2008), which makes it especially important for proliferating cells.
Mononuclear cells lack the ability to synthesize glutamine (Ardawi & Newsholme 1983; Rohde
et al 1996) and must rely on glutamine circulating in the bloodstream. Lymphocyte proliferation
upon stimulation is dependent upon the presence of glutamine in cell culture systems and the
ability of stimulated lymphocytes to produce cytokines is dependent upon the extracellular
concentration of glutamine (Ardawi & Newsholme 1982; 1983; Crawford & Cohen 1985; Rohde
et al 1996; Wallace & Keast 1992).

In addition, the phagocytotic ability of peritoneal

macrophages isolated from mice has been shown to be dependent upon glutamine (ParryBillings et al 1990; Wallace & Keast 1992).
3.1.3 The Effects of Gender and MSO Treatment on Nitrogen Metabolism in SOD1 G93A
Mice
The first disease-associated mutations in the gene encoding superoxide dismutase 1
(SOD1) were discovered in 1993 and linked with the familial form of the ALS (Rosen et al 1993),
which accounts for only 5-10% of all cases of the disease. Mutations in SOD1 account for
approximately 20% of familial cases, and a much smaller percentage of overall cases of ALS.
Over 100 mutations in SOD1 have been characterized and associated with the disease, but the
exact mechanism by which these mutations lead to disease is unknown. Mutations in SOD1

101
have also been implicated in sporadic ALS and recent research suggests that the normal wildtype form of SOD1 may play a role in the disease, through transcriptional and posttranslational
modifications of the protein (Milani et al 2011).
Superoxide dismutases are a group of enzymes that scavenge superoxide free radical
anions, converting them to hydrogen peroxide and molecular oxygen (McCord & Fridovich
1969).

There are three isoforms of superoxide dismutase ubiquitously expressed by

mammalian cells: 1) SOD1, a homodimeric copper/zinc-binding form of the enzyme found in the
cytosol (Fridovich 1974); 2) SOD2, a tetromeric manganese-binding form of the enzyme found
within the mitochondria (Abe & Okazaki 1987); and 3) SOD3, a tetromeric copper/zinc-binding
form of the enzyme found outside of cells (Zelko et al 2002). These three isoforms of the
enzyme help to protect cells against oxidative damage that can occur as a result of oxidative
phosphorylation (Zelko et al 2002). All of the ALS-related SOD mutations have been isolated to
the SOD1 isoform and most of these mutations allow the enzyme to retain its normal superoxide
scavenging activity.

Disease associated mutations in SOD1 are believed to exert their

deleterious effects through a toxic gain of function, however most of these mutations have not
been well characterized and the exact functions gained through the various mutations are
unknown.
These toxic functions gained by mutant SOD1 proteins can vary, depending upon the
mutation, and can have a tremendous impact on metabolic processes within the cell.

Mutant

SOD1 protein can undergo conformational changes which can result in new, potentially
detrimental, protein-protein interactions.

Several studies have shown that mutant SOD1

proteins have novel binding partners and can disrupt normal cellular functions. Motor neuron
cultures expressing mutant SOD1 protein have been used in immunoprecipitation studies that
showed that SOD1 with the G93A mutation interacts with cytosolic malate dehydrogenase, part
of the malate-aspartate shuttle involved in maintaining the NADH/NAD+ balance in brain
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mitochondria (Mali & Zisapels 2008). Mutant SOD1 protein has also been shown to interact
with the anti-apoptotic protein Bcl-2 (Pasinelli et al 2004). When bound to Bcl-2, mutant SOD1
induces a conformational change in the protein, resulting in the exposure of a toxic domain that
has been found to be deleterious to cells in the spinal cords of mice and humans (Pedrini et al
2010). Mutant SOD1 protein with the G93A mutation has been shown to interact with TDP-43 in
cell culture and animal models (Higashi et al 2010) and with cytosolic and mitochondrial lysyltRNA synthetase, an enzyme required for the translation of protein, resulting in decreased
mitochondrial protein synthesis and overall morphological changes in mitochondria (Kawamata
et al 2008). In addition, mutant SOD1 protein can form detergent insoluble aggregates with the
heat shock proteins HSP70, HSP40, and αB-cyrstallin in cells isolated from transgenic mice
(Shinder et al 2001).
Interactions between mutant SOD1 proteins and mitochondrial proteins, such as lysyltRNA synthetase, indicate that the normally cytosolic protein ends up in the mitochondria where
it can encounter different proteins. Since mitochondria are vital to producing energy within the
cell, mutant SOD1 entering the organelle where it could potentially come into contact with
integral energy producing proteins might have a major impact on energy production.

In

transgenic mouse models of ALS, expression of the mutant SOD1 protein has been shown to
lead to morphological abnormalities, such as vacuolization occurring within the intermembrane
space, in spinal cord mitochondria (Higgins et al 2003). It has also been shown to be selectively
recruited to mitochondria in cells of the spinal cord in areas affected by the disease (Liu et al
2004).

Although most of these studies have focused on spinal cord tissue, studies of

mitochondrial function have shown that mitochondrial respiration is decreased not only in
mitochondria isolated from brain and spinal cord, but liver as well (Mattiazzi et al 2002). Liver
tissue from ALS patients shows morphological changes in mitochondria and rough ER, and
records from these patients suggest that they also suffered from mild liver dysfunction (Nakano
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et al 1987). Transgenic mouse models of ALS also show global metabolic deficits and a high
energy diet has been shown to extend the average lifespan (Dupuis et al 2004). These data
combined with data from human patients suggests that dysfunctional liver metabolism may play
a role in ALS.
Since ALS is classified as a neurodegenerative disorder most research conducted on
ALS patients and animal models focuses on the central nervous system. Motor neurons are the
primary target of degeneration and several cellular processes undergo alterations during the
disease, all of which can lead to cell death. However, in human and animal models where
mutated genes are considered to be the cause of the disease, these mutated proteins are
typically expressed throughout the body. ALS is almost always age-related so the effects of
expressing mutant proteins builds up over time and leads to cell death in motor neurons, but
can affect other cell types which often go ignored because problems in these cells do not cause
paralysis. The following experiments were designed to test the hypothesis that transgenic mice
overexpressing the human form of SOD1 containing the G93A mutation have defective nitrogen
metabolism, specifically alterations in the urea cycle. To test this hypothesis, we examined the
activity of nitrogen-metabolizing enzymes in the brain (glutamine synthetase and glutaminase,
which are also important to the glutamate-glutamine cycle) and examined the levels of several
plasma metabolites, including ammonia.

Preliminary analysis of plasma metabolite levels

suggested that nitrogen metabolism may be affected in these animals, so we followed up the
plasma metabolite studies with assays of carbamoyl phosphate synthetase I and glutamine
synthetase in the liver. These assays were carried out in both wild-type and SOD1 G93Aexpressing mice.
Since our previous studies showed that treating SOD1 G93A mice with an irreversible
inhibitor of glutamine synthetase, MSO, significantly extends the lifespan and improves
neuromuscular function in these mice in a gender-specific fashion (with females benefiting more
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than males), we treated a group of mice with MSO and examined both the effects of MSO and
gender on nitrogen metabolism. The results of our experiments show that expression of the
transgene does not affect glutamine synthetase activity, but MSO treatment significantly lowers
GS activity in both genders and genotypes, suggesting that MSO’s gender-specific effects are
not through its action on GS. We found that there are gender-specific differences in plasma
metabolite profiles in nontransgenice mice and metabolic profiles of these mice change with
age, providing evidence for gender-specific and age-related changes in general metabolism.
We also found that presymptomatic mice have several deficits in plasma metabolites indicative
of underlying metabolic defects. These plasma metabolite deficits are gender-specific, with
males and females showing different metabolic profiles, and change with age suggesting that, at
least early in the disease, compensatory mechanisms can “normalize” metabolism to some
extent. MSO treatment significantly alters the metabolic profile of SOD1 mice, while doing little
to that of wild-type mice, and has the ability to alter metabolites in a gender-specific manner.
Taken together, these data suggest that global metabolic defects play a role in the pathogenesis
of ALS in this mouse model and that gender is also a significant factor in the disease.
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3.2 Materials and Methods
Animal Breeding and Care. All animal experiments were approved by Wayne State
University’s Animal Investigation Committee. SOD1 breeding mice were obtained from Jackson
Laboratories. Female C57BL/6*SJL mice were crossed with B6SJL males overexpressing the
human SOD1 transgene containing the G93A mutation (SOD1 G93A).

Offspring were

genotyped by performing PCR on DNA isolated from tail clippings using primers recommended
by Jackson Laboratories for this strain of transgenic mice (jax.org). Animals were assigned to
one of five groups – a 50, 70, or 110 day time point, or a surgery group which consisted of
SOD1 females.
Experimental Groups. The 50 day group consisted of untreated wild-type and SOD1
mice from which liver, central nervous system tissue and plasma were collected at 50 ± 2 days
of age. The 70 day group consisted of wild-type and SOD1 mice that were given weekly i.p.
injections of saline or 20 mg/kg body weight MSO (prepared in 0.9% saline; Sigma Chemical
Company, no. 5379) starting at 50 ± 2 days of age and were euthanized at 70 ± 2 days of age.
The 110 day group consisted of wild-type and SOD1 mice that were given weekly i.p. injections
of saline or 20 mg/kg body weight MSO starting at 50 ± 2 days of age and were euthanized at
110 ± 2 days of age. The 70 and 110 day mice were given their final injection within three days
of euthanasia. Central nervous system tissue, liver, and plasma were collected from 50 and 70
day animals while only CNS tissue and plasma were collected from 110 day animals.
Plasma and Tissue Collection. A stock solution of Avertin was prepared by dissolving 25
g of 2-2-2-tribromoethanol (Sigma Chemical Company) in 15.5 mL of tert-amyl alcohol (Sigma
Chemical Company). This solution was then used to prepare a working solution of 20 mg/mL by
dissolving 0.5 mL of the stock solution in 39.5 mL of PBS.
Mice were anesthetized with an i.p. injection of Avertin (0.4-0.75 mg/g body weight) and
blood was collected via cardiac puncture. Blood was placed in BD Microtainer tubes containing
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lithium heparin and centrifuged at 13,000 rpm for 3 minutes in a Sorvall Biofuge pico desktop
centrifuge to obtain plasma. For the 50 and 70 day groups, 100 µL aliquots of plasma were
taken for plasma ammonia analysis and the remaining plasma was immediately frozen on dry
ice for later use. For the 110 day group, plasma was frozen on dry ice immediately. All tissue
samples were placed in centrifuge tubes and immediately frozen on dry ice and thawed prior to
homogenization.
Plasma Ammonia Determination. Plasma ammonia levels were determined using an
ion-exchange resin and the Berthelot indophenol reaction as described by Brusilow (Brusilow
1991). A 100 µL aliquot was taken immediately after obtaining the plasma and added to a
microfuge tube containing 200 µL of deionized water and 50 µL of prepared ion-exchange resin
(BioRad AG 50W-X4 Resin, 100-200 Mesh hydrogen form). The procedure was carried out
according to Brusilow (1991) and absorbance values were read at 630 nm. Ammonia levels
were determined by comparing sample absorbances to those of an ammonium sulfate standard
curve and values were expressed as µmoles of ammonia per liter of plasma.
Plasma Metabolite Analysis.

Plasma samples that were not used for ammonia

determination were immediately frozen on dry ice and transported to the Biochemical Genetics
Laboratory in the Detroit Medical Center where Dr. Robert Grier processed and analyzed them
for a variety of metabolites using HPLC.
Glutamine Synthetase Activity Assays. Brain and spinal cord preparation for GS activity
were carried out according to Alton Meister’s Methods in Enzymology protocol (Meister 1985).
Liver sample preparation was carried out using a modified version of Pierson’s protocol for
preparation of samples for CPSI activity assays (Pierson 1980). GS activity was determined
using a modified version of Meister’s protocol.
Whole mouse brains and spinal cords were thawed and homogenized by hand using a
glass and Teflon Dounce homogenizer in 1-2mL of homogenizing buffer (150 mM KCl, 5 mM 2-
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mercaptoethanol, 1 mM EDTA, 1 mM PMSF, and protease inhibitor cocktail (Sigma, P8340), pH
7.2). Brain and spinal cord homogenates were centrifuged for five minutes at 5000 rpm in a
Sorvall RC 5B Plus centrifuge (SS-34 rotor) cooled to 4°C. Liver samples were prepared by
homogenizing 100 mg of liver in 2mL of buffer containing 50 mM triethanolamine, 10 mM ATP,
15 mM magnesium acetate, and 1 mM dithiothreitol, pH 8, using 4-5 strokes in a motorized
glass and Teflon Dounce homogenizer set to a speed of six.

Liver homogenates were

centrifuged in a Sorvall Ultracentrifuge (OTD65B; Beckman TY 65 rotor) cooled to 4°C at 37,000
x g for 15 minutes. After centrifugation, 1 mL of the supernatant was added to 10 µL protease
inhibitor cocktail (Sigma, P8340) and 10 µL of 100 mM PMSF. Protein concentrations for brain,
spinal cord, and liver samples were determined using the Coomassie Plus Protein Assay
(Thermoscientific).
Enzyme activity was determined by following the reaction in which GS catalyzes the
conversion of L-glutamine to L-γ-glutamyl hydroxamate in the presence of hydroxylamine, ADP,
arsenate, and Mn2+:
ADP, Mn2+, Asi

L-Glutamine + NH2OH

L-γ-Glutamyl Hydroxamate + NH3.

This reaction was carried out by adding 100 µg of protein from sample homogenates to 0.5 mL
of GS reaction buffer (100 mM imidazole, 0.2 mM MnCl 2, 62.5 mM hydroxylamine, 10 mM
sodium arsenate, 0.4 mM ATP, and 100 mM L-glutamine, pH 7.4) and incubating in a 37°C
water bath. After 10 minutes the reaction was quenched with 0.5 mL stop solution consisting of
370 mM FeCl3, 670 mM HCl, and 200 mM trichloroacetic acid. Samples were centrifuged for
three minutes at 15,000rpm in a Sorvall Microspin 24S desktop centrifuge and absorbances
were read at 535 nm.
GS activity assays were performed on 5-9 animals per treatment group for each gender
at every time point. Absorbance values were converted to micromoles of product formed by
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comparing them to an L-γ-glutamyl hydroxamate standard curve and specific activities were
determined accordingly.
Glutaminase Activity Assays. Glutaminase activity assays were carried out on the same
brain homogenates used for GS activity assays. Brain glutaminase activity was determined by
monitoring the production of ammonia using a modified version of Sigma’s protocol for the
enzymatic assay of glutaminase from E. coli. Test tubes containing 0.9 mL of glutaminase
reaction buffer (100 mM sodium phosphate, and 20 mM L-glutamine, pH 8.0) were equilibrated
to 37°C in a water bath and 100 µL of brain homogenate was added. The reaction was allowed
to proceed for 15 minutes at 37°C before being quenched with 9 mL of cold deionized water on
ice. A 100 µL aliquot from the quenched reaction mixture was added to a tube containing 200
µL of deionized water and 50 µL of the prepared ion-exchange resin used for determining
ammonia levels. The ammonia assay was then carried out from this point to determine the
amount of ammonia produced during the reaction.
Several controls were run to eliminate any color development due to ammonia
contamination of water, glutamine hydrolysis, and protein breakdown within samples. Controls
in which the reaction was immediately quenched on ice following the addition of homogenate
were run for each sample to determine any background from protein breakdown within the
sample itself. A hot blank (containing reaction buffer and no protein) was assayed to determine
any background due to glutamine hydrolysis. A corresponding cold blank (containing reaction
buffer and no protein), which was quenched immediately on ice, was also assayed to determine
any background from ammonia contamination of the deionized water.
Ammonia produced during the reaction was quantified by reading absorbances of
samples at 630 nm and comparing them to absorbance values from an ammonium sulfate
standard curve.

Glutaminase activity assays were performed on 5-8 brain samples per

treatment group for each gender at every time point.
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Carbamoyl Phosphate Synthase I Activity Assays. Sample preparation and carbamoyl
phosphate synthetase I enzymatic activity assays were carried out according to a modified
version of a protocol by Pierson (Pierson 1980).

A 100 mg sample of mouse liver was

homogenized in 2 mL of buffer containing 50 mM triethanolamine, 10 mM ATP, 15 mM
magnesium acetate, and 1 mM dithiothreitol with a final pH of 8.0. Four to five strokes of a
motor-driven glass and Teflon Dounce homogenizer were used to homogenize samples, which
were then centrifuged at 37,000 x g for 15 minutes in a 4°C Sorvall Ultracentrifuge (OTD65B,
TY65 rotor). A 0.5 mL aliquot of the resulting supernatant was desalted by running it over a
Sephadex G-25 spin column (GE Healthcare PD MiniTrap G-25; 28-9180-07), according to the
manufacturer’s specifications. Protein concentrations were determined by using the Coomassie
Plus Protein Assay (Thermoscientific).
Enzyme activity was determined by adding 5 µL of desalted liver homogenate to 200 µL
of CPSI reaction buffer (50 mM NH4HCO3, 50 mM triethanolamine, 10 mM magnesium acetate,
5 mM ATP, 5 mM N-acetyl-L-glutamic acid, and 1 mM dithiothreitol, pH 8.0) and incubating at
37°C for 10 minutes.

The carbamoyl phosphate produced during the reaction was then

chemically converted to hydroxyurea by adding 10 µL of 2 M hydroxylamine, pH 7.0, and
incubating for 10 minutes at 95°C. To quantify the hydroxyurea, 800 µL of chromogenic reagent
was added and samples were incubated for another 15 minutes at 95°C. Samples were cooled
to room temperature and absorbances were measured at 458 nm.
The chromogenic reagent was prepared fresh just prior to use (during the last 5 minutes
of the first 95°C incubation) and consisted of equal volumes of Solutions A and B. Solution A
was made by dissolving 0.85 g antipyrine in 40% (v/v) H2SO4. Solution B was prepared by
dissolving 0.625 g of 2, 3-butanedione monoxime in 100 mL of 5% (v/v) acetic acid in a brown
bottle.

110
The concentration of hydroxyurea was determined by use of a carbamoyl phosphate
standard curve. The standard curve was prepared by adding known amounts of carbamoyl
phosphate to 200 µL of CPSI reaction buffer (without ATP, N-acetyl-L-glutamic acid, and
dithiothreitol), converting the carbamoyl phosphate to hydroxyurea by the addition of 10 µL of 2
M hydroxylamine, and measuring the absorbance at 458 nm.

The carbamoyl phosphate

standard curve was linear up to 100 nmoles and the equation of the line of regression was used
to calculate the amount of carbamoyl phosphate produced. Specific activities were calculated
accordingly. CPSI activity assays were performed on 10 animals per treatment group for each
gender at the 70 day time point.
Statistical Analysis of Data. Data were organized by gender and genotype and each
data

set

was

subjected

to

a

Grubb’s

test

using

an

online

calculator

(http://www.graphpad.com/quickcalcs/Grubbs1.cfm). Data points which failed Grubb’s test with
an α value of 0.01, extreme outliers, were dropped from the analysis. Two male wild-type mice
were dropped from the spinal cord GS analysis (one from the 50 day group and one from the 70
day saline-treated group), two 110 day old saline-treated wild-type mice were dropped from both
the brain and spinal cord GS analysis (one female and one male), one 110 day old MSO-treated
female wild-type mouse was dropped from the brain glutaminase analysis, two male wild-type
mice were dropped from the plasma ammonia analysis (one 50 day old and one saline-treated
70 day old mouse), and one 70 day old MSO-treated female wild-type mouse was dropped from
the liver GS analysis. Animals that were suspected of having received the wrong treatment
were also dropped from the analysis. Once outliers were detected and removed, data files were
analyzed using SPSS. An analysis of variance (ANOVA) was used to analyze data from all
enzyme activity assays and plasma ammonia data.

A multivariate analysis of variance

(MANOVA) was used to analyze plasma metabolite data. Plasma metabolites that were below
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the detection limit were entered as zero and the MANOVA was carried out. Student’s t test was
used to double check ANOVA and MANOVA p values.
3.3 Results
3.3.1 Glutamine Synthetase Activity in the CNS
Glutamine synthetase is a cytosolic enzyme expressed primarily in astrocytes in the
central nervous system. MSO is an irreversible inhibitor of glutamine synthetase and a single
subconvulsive dose has been shown to inhibit brain glutamine synthetase activity in mice for
several weeks, with the enzyme regaining 75% of control activity after 90 days (Rao & Meister
1972). Survival studies in which SOD1 G93A mice were given a single i.p. injection of 20 mg/kg
MSO once per week showed that this dosing schedule had a positive impact on survival,
extending lifespan by about 10% (see Chapter 2). As a result we measured the specific activity
of the enzyme in central nervous system tissue (brain and spinal cord) to monitor changes that
may occur with age as the disease progresses.

Brain and spinal cord samples were

homogenized and assayed for glutamine synthetase activity (see Materials and Methods) at
three time points. Treatment was started at 50 ± 2 days of age and treated animals were
euthanized at 70 ± 2 and 110 ± 2 days of age. Animals in the 50 day group were not exposed to
i.p. injections and were euthanized at 50 ± 2 days of age. The 50 day time point provided a
baseline level of glutamine synthetase activity at the time treatment was started, while the 70
day time point provided presymptomatic GS activity after four i.p. injections of saline. The 110
day time-point provided end-stage GS activity levels after long-term treatment.
End-stage mice expressing the SOD1 G93A transgene have lower glutamine synthetase
activity. Figure 3.3.1.1 shows the specific activity of brain glutamine synthetase in untreated 50
day old animals (A) and saline-treated 70 and 110 day old animals (B and C respectively).
There is no difference in GS activity between wild-type and SOD1 untreated presymptomatic
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mice (Figure 3.3.1.1A). At 70 days of age, GS activity remains the same and continues to show
no difference between wild-type and SOD1 saline-treated mice (Figure 3.3.1.1B). However, at
110 days of age, GS activity is significantly reduced in both wild-type and SOD1 mice treated
with saline when compared to 70 day old saline-treated animals, with p<0.001 for both groups.
Figure 3.3.1.1C shows that in the 110 day age group, saline-treated SOD1 mice have
significantly lower GS activity (890 ± 70 nmoles/min/mg protein) than their wild-type
counterparts (1130 ± 20 nmoles/min/mg protein), p<0.001.
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Figure 3.3.1.1 Brain glutamine synthetase activity in wild-type and SOD1 mice.
The specific activity of GS was measured in brain homogenates from 50, 70, and 110 day old
wild-type (WT) and SOD1 mice. Data are presented as the average specific activity with error
bars representing the S.E.M. Green bars indicate the enzyme activity of wild-type mice while
purple bars indicate the activity of SOD1 mice. A. Average specific activity of brain GS in 50
day old untreated wild-type and SOD1 mice (n=16 mice/group). B. Average specific activity of
brain GS in 70 day old saline-treated wild-type and SOD1 mice (n=18 wild-type and n=16 SOD1
mice). (C) Average specific activity of brain GS in 110 day old saline-treated wild-type and
SOD1 mice (n=15 wild-type and n=13 SOD1 mice; ** indicates p<0.01).
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Since the majority of neurodegeneration occurs within the spinal cord of SOD1 G93A
mice, we also looked at GS activity in whole spinal cord homogenates to examine changes with
age and disease progression. Spinal cord samples were extracted from the same animals that
brain samples were taken from; however one wild-type spinal cord sample from the 50 day
group was determined to be an outlier and subsequently dropped from the analysis.

The

specific activity of spinal cord GS is significantly lower (approximately 40-50% lower) than that
of brain GS in both wild-type and SOD1 mice, with p<0.001. Figure 3.3.1.2 shows the specific
activity of GS from spinal cord homogenates of 50 day old untreated mice, as well as 70 and
110 day old saline-treated mice. At 50 days of age, the specific activity of spinal cord GS is
similar in wild-type and SOD1 mice (Figure 3.3.1.2A). There is no change in GS activity in 70
day old saline-treated mice and the specific activity of GS of SOD1 mice remains the same as
that of wild-type mice (Figure 3.3.1.2B). Overall, the spinal cord GS activity follows the same
trend as that of brain GS activity and by 110 days of age, the average specific activity
significantly decreases in both SOD1 and wild-type mice when compared to their 70 day old
counterparts, with p<0.001 for SOD1 mice and p<0.01 for wild-type mice. As with brain GS
activity, saline-treated SOD1 mice show significantly lower spinal cord GS activity (450 ± 50
nmoles/min/mg protein) than wild-type mice (630 ± 30 nmoles/min/mg protein) at 110 days of
age, p<0.01 (Figure 3.3.1.2C).
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Figure 3.3.1.2 Spinal cord glutamine synthetase activity in wild-type and SOD1 mice.
The specific activity of GS was measured in spinal cord homogenates from 50, 70, and 110 day
old wild-type (WT) and SOD1 mice. Data are presented as the average specific activity with
error bars representing the S.E.M. Green bars indicate the enzyme activity of wild-type mice
while purple bars indicate the activity of SOD1 mice. A. Average specific activity of spinal cord
GS in 50 day old untreated wild-type and SOD1 mice (n=15 WT and n=16 SOD1 mice). B.
Average specific activity of spinal cord GS in 70 day old saline-treated wild-type and SOD1 mice
(n=18 wild-type and n=16 SOD1 mice). C. Average specific activity of spinal cord GS in 110
day old saline-treated wild-type and SOD1 mice (n=15 wild-type and n=13 SOD1 mice; **
indicates p<0.01).
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End-stage male and female SOD1 mice show lower levels of brain and spinal cord GS
activity. Glutamine synthetase activity data were further broken down by gender and genotype
to examine the effects of gender on enzyme activity. Figure 3.3.1.3 shows the average specific
activity of brain glutamine synthetase broken down by gender and genotype. Untreated male
and female wild-type and SOD1 mice all have similar levels of brain GS activity (Figure
3.3.1.3A). Saline-treated animals in the 70 day age group show levels of brain GS activity
similar to that of untreated 50 day mice, with no gender or genotype differences (Figure
3.3.1.3B). In saline-treated male and female mice of both genders, the specific activity of brain
GS significantly decreases between 70 and 110 days of age, p<0.01. Male and female SOD1
mice experience a greater decrease in GS activity than their wild-type counterparts. This age
group shows that saline-treated wild-type males and females have similar levels of brain GS
activity (Figure 3.3.1.3C). Both 110 day old male and female SOD1 mice, have lower levels of
GS activity than their wild-type counterparts, with SOD1 males showing significantly lower brain
GS (760 ± 80 nmoles/min/mg protein) activity than wild-type males (1110 ± 30 nmoles/min/mg
protein), p<0.001.
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Figure 3.3.1.3 Brain glutamine synthetase activity broken down by gender and genotype.
Data are presented as the average specific activity with error bars representing the S.E.M.
Green bars indicate the enzyme activity of wild-type mice while purple bars indicate the activity
of SOD1 mice. A. Average specific activity of brain GS in 50 day old untreated male and
female wild-type and SOD1 mice (n=8 mice/group). B. Average specific activity of brain GS in
70 day old saline-treated male and female wild-type and SOD1 mice (n=9 wild-type mice/group
and n=8 SOD1 mice/group). C. Average specific activity of brain GS in 110 day old salinetreated male and female wild-type and SOD1 mice (n(F,WT)=7, n(M, WT)=8, n(F, SOD1)=8,
n(M, SOD1)=5; ** indicates p<0.01).
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When spinal cord GS activity data are broken down by gender and genotype, enzyme
activity in spinal cord homogenates is significantly lower than that of brain homogenates. Figure
3.3.1.4 shows the specific activity of spinal cord GS broken down by gender and genotype. In
50 day old untreated mice, enzyme activity is approximately the same across all groups (Figure
3.3.1.4A). Saline-treated male and female wild-type and SOD1 mice in the 70 day group, have
spinal cord GS activity similar to that of untreated 50 day old animals, with no gender or
genotype differences in enzyme activity (Figure 3.3.1.4B). Between 70 and 110 days of age,
the specific activity of GS in spinal cord significantly decreases, with female SOD1 mice
showing the greatest decrease in activity. Like with brain GS activity, spinal cord GS activity is
lower in both male and female saline-treated SOD1 mice than wild-type mice (Figure 3.3.1.4C).
Saline-treated female SOD1 mice show significantly lower GS activity (410 ± 50 nmoles/min/mg
protein) than their wild-type counterparts (650 ± 60 nmoles/min/mg protein), p<0.01.
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Figure 3.3.1.4 Spinal cord glutamine synthetase activity broken down by gender and genotype.
Data are presented as the average specific activity with error bars representing the S.E.M.
Green bars indicate the enzyme activity of wild-type mice while purple bars indicate the activity
of SOD1 mice. A. Average specific activity of spinal cord GS in 50 day old untreated male and
female wild-type and SOD1 mice (n=8 mice/group, except for male, wild-type where n=7). B.
Average specific activity of spinal cord GS in 70 day old saline-treated male and female wildtype and SOD1 mice (n=9 wild-type mice/group and n=8 SOD1 mice/group). C. Average
specific activity of spinal cord GS in 110 day old saline-treated male and female wild-type and
SOD1 mice (n(F,WT)=7, n(M, WT)=8, n(F, SOD1)=8, n(M, SOD1)=5; ** indicates p<0.01).
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A weekly i.p. injection of 20 mg/kg MSO lowers brain and spinal cord glutamine
synthetase activity.

To examine the effects of MSO treatment on brain and spinal cord

glutamine synthetase activity, we first grouped the data by genotype to determine if MSO
treatment affected SOD1 animals differently than wild-type animals. Figure 3.3.1.5 shows the
effects of MSO treatment on brain GS activity in 70 and 110 day old mice. In 70 day old wildtype and SOD1 mice, a single weekly injection significantly inhibits brain GS activity by
approximately 90% (Figure 3.3.1.5A).

Glutamine synthetase activity in wild-type mice is

significantly reduced from 1380 ± 30 nmoles/min/mg protein (saline-treated mice) to 170 ± 20
nmoles/min/mg protein with MSO treatment (p<0.001), while brain GS activity of SOD1 mice is
reduced from 1340 ± 60 nmoles/min/mg protein (saline-treated mice) to 150 ± 10
nmoles/min/mg protein with MSO treatment (p<0.001).

As previously mentioned, brain

glutamine synthetase activity in saline-treated mice is significantly lower in 110 day old mice
than in 70 day old mice in both genotypes. This trend, however, is not reflected in MSO-treated
mice.

MSO treatment inhibits brain GS to the same extent in 110 day old mice, by

approximately 90% (Figure 3.3.1.5B). Glutamine synthetase activity in 110 day old wild-type
mice is significantly reduced from 1130 ± 20 nmoles/min/mg protein (saline treatment) to 140 ±
10 nmoles/min/mg protein with MSO treatment (p<0.001), while enzyme activity of SOD1 mice
is reduced from 890 ± 70 nmoles/min/mg protein (saline treatment) to 120 ± 10 nmoles/min/mg
protein with MSO treatment (p<0.001).
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Figure 3.3.1.5 Brain glutamine synthetase activity in saline and MSO-treated mice.
Wild-type and SOD1 mice were treated with a single weekly i.p. injection of MSO and brain GS
activity was measured at different time points. Data are presented as the average specific
activity with error bars representing the S.E.M. Blue bars indicate the enzyme activity of wildtype and SOD1 mice treated with saline, while red bars indicate the activity of wild-type and
SOD1 mice treated with MSO. A. MSO treatment significantly lowers the specific activity of
brain GS in both wild-type and SOD1 mice at 70 days of age (n=18 wild-type mice/treatment, n
(SOD, Saline) =16, and n (SOD, MSO) =17). B. MSO treatment lowers the specific activity of
brain GS in 110 day old mice (n (WT, Saline) =15, n (WT, MSO) =18, n (SOD, Saline) =13, and
n (SOD, MSO) =15). *** indicates that values are significant with p<0.001.

122
Figure 3.3.1.6 compares the specific activity of spinal cord glutamine synthetase of mice
treated with saline to that of MSO-treated mice. Like brain GS activity, spinal cord GS activity is
inhibited by 90% with a single weekly injection of MSO in wild-type and SOD1 70 day old mice
(Figure 3.3.1.6A). Enzyme activity in the spinal cord of 70 day old saline-treated SOD1 mice
(770 ± 30 nmoles/min/mg of protein) is significantly lower than that of brain GS (1340 ± 60
nmoles/min/mg protein), and MSO further decreases spinal cord GS activity (50 ± 5
nmoles/min/mg protein).

Saline-treated wild-type mice from this age group show a similar

pattern of enzyme activity, with significantly higher GS activity in brain than spinal cord and a
corresponding decrease in activity with MSO treatment, which does not differ significantly from
SOD1 mice. There is no difference in the enzyme activity of MSO-treated mice between 70 and
110 days of age, unlike what was seen in saline-treated animals. Like with 70 day wild-type and
SOD1 mice, we see a 90% reduction in the average specific activity of GS isolated from spinal
cord with MSO treatment (Figure 3.3.1.6B). MSO treatment reduces spinal cord GS activity in
110 day old SOD1 mice from 450 ± 50 nmoles/min/mg protein (saline treatment) to 40 ± 5
nmoles/min/mg protein (p<0.001), while spinal cord GS activity in wild-type mice is reduced from
630 ± 30 nmoles/min/mg protein to 50 ± 5 nmoles/min/mg protein (p<0.001).

As seen with

saline-treated mice, brain GS activity is significantly higher than spinal cord GS activity with
MSO treatment for both age groups, with p<0.001.
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Figure 3.3.1.6 Spinal cord glutamine synthetase activity in saline and MSO-treated mice.
Wild-type and SOD1 mice were treated with a single weekly i.p. injection of MSO and brain GS
activity was measured at different time points. Data are presented as the average specific
activity with error bars representing the S.E.M. Blue bars indicate the enzyme activity of wildtype and SOD1 mice treated with saline, while red bars indicate the activity of wild-type and
SOD1 mice treated with MSO. A. MSO treatment significantly lowers the specific activity of
spinal cord GS in both wild-type and SOD1 mice at 70 days of age (n (WT, Saline) =18, n (WT,
MSO) =17, n (SOD, Saline) =16, and n (SOD, MSO) =17). B. MSO treatment lowers the
specific activity of spinal cord GS in 110 day old mice (n (WT, Saline) =15, n (WT, MSO) =18, n
(SOD, Saline) =13, and n (SOD, MSO) =15). *** indicates that values are significant with
p<0.001.
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MSO treatment does not inhibit brain and spinal cord glutamine synthetase activity in a
gender-specific fashion. To examine whether or not MSO inhibits the activity of GS in the
central nervous system in a gender-specific manner, both brain and spinal cord GS activity data
were broken down by gender and genotype. Figure 3.3.1.7 shows brain GS activity broken
down by gender and genotype and compares the activity of saline and MSO-treated mice. The
specific activity of brain glutamine synthetase is inhibited by approximately 90% in male and
female wild-type and SOD1 mice at 70 days of age, with no significant gender or genotype
differences in enzyme activity (Figure 3.3.1.7A). Although we see a slight decrease in the
specific activity of brain GS in MSO-treated male and female wild-type and SOD1 mice between
70 and 110 days, this difference is not considered significant like that of saline-treated animals.
Overall, MSO significantly reduces brain GS activity in 110 day old male and female wild-type
and SOD1 mice to the same extent as 70 day old mice with no significant gender or genotype
differences (Figure 3.3.1.7B).
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Figure 3.3.1.7 Brain glutamine synthetase specific activity broken down by gender and
genotype.
Data are presented as the average specific activity with error bars representing the S.E.M. Blue
bars indicate the enzyme activity of male and female wild-type and SOD1 mice treated with
saline, while red bars indicate the activity of male and female wild-type and SOD1 mice treated
with MSO. A. The specific activity of brain glutamine synthetase is significantly decreased by
MSO treatment in 70 day old male and female wild-type and SOD1 mice (n=8 male and 8
female WT mice/group, n=8 female SOD1 mice/group, n(M, SOD1, Saline)=8, and n(M, SOD1,
MSO)=9). B. The specific activity of brain glutamine synthetase is significantly decreased by
MSO treatment in 110-day old male and female wild-type and SOD1 mice (n=5-9 mice/group).
*** indicates that values are significant with p<0.001.

126
Figure 3.3.1.8 shows spinal cord glutamine synthetase activity broken down by gender
and genotype and compares that of saline to MSO-treated mice. In MSO-treated animals the
specific activity of brain GS is significantly higher than that of spinal cord GS in male and female
wild-type and SOD1 mice, with p<0.001 for all groups. Like with brain GS activity, spinal cord
enzyme activity is significantly reduced by approximately 90% in male and female wild-type and
SOD1 mice at 70 (Figure 3.3.1.8A) and 110 (Figure 3.3.1.8B) days of age. While there are no
gender or genotype differences in enzyme activity of 70 day old mice, there is a decrease in GS
activity in saline-treated male and female SOD1 mice compared to their wild-type counterparts
at 110 days of age, but this difference is not reflected in MSO-treated animals in this age group.
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Figure 3.3.1.8 Spinal cord glutamine synthetase activity broken down by gender and genotype.
Data are presented as the average specific activity with error bars representing the S.E.M. Blue
bars indicate the enzyme activity of male and female wild-type and SOD1 mice treated with
saline, while red bars indicate the activity of male and female wild-type and SOD1 mice treated
with MSO. A. The specific activity of spinal cord glutamine synthetase is significantly
decreased by MSO treatment in 70 day old male and female wild-type and SOD1 mice (n=8-9
mice/group). B. The specific activity of spinal cord glutamine synthetase is significantly
decreased by MSO treatment in 110-day old male and female wild-type and SOD1 mice (n=5-9
mice/group). *** indicates that values are significant with p<0.001.
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In general, we see that brain and spinal cord glutamine synthetase activity is about the
same in presymptomatic wild-type and SOD1 mice - 50 day old untreated and 70 day old salinetreated mice. Changes in GS activity occur between 70 and 110 days of age, when both brain
and spinal cord GS activity of saline-treated wild-type and SOD1 mice decrease significantly.
This decrease in activity is greater in SOD1 mice and probably begins around the time of
symptom onset, approximately 90 days of age. The specific activity of brain glutamine
synthetase in untreated and saline-treated control mice is approximately 40-50% higher than
that of spinal cord GS for all age groups. When the data are broken down by gender and
genotype, there are no significant differences in either brain or spinal cord GS activity observed
in presymptomatic mice. We continue to see a decrease in activity between 70 and 110 day old
saline-treated mice, but it is independent of gender and genotype. In the 110 day age group,
both male and female saline-treated SOD1 mice show lower levels of brain and spinal cord GS
activity. Male SOD1 mice show significantly lower brain GS activity when compared to wild-type
male mice, while female SOD1 mice show significantly lower spinal cord GS activity when
compared to their wild-type counterparts. A single weekly injection of MSO (20 mg/kg body
weight) significantly reduces both brain and spinal cord activity by about 90%.

Prolonged

treatment (110 days – about 10 injections) inhibits enzyme activity to the same extent as shortterm treatment (70 days – about 4 injections), and results in no gender or genotype differences
in brain or spinal cord GS activity.
3.3.2 Glutaminase Activity in the Brain
We have shown that treating ALS mice with MSO at a dose of 20 mg/kg three times a
week, not only increases the lifespan of these animals, but also lowers levels of some
neurochemicals (glutamine, glutamate, and GABA) and increases levels of the antioxidant
tripeptide glutathione in specific regions of the brain (Ghoddoussi et al 2010). Survival studies,
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explained in Chapter 2, show that reducing the dosing schedule of MSO to 20 mg/kg
administered once a week has the same effect on the survival of SOD1 G93A mice. The results
of the brain and spinal cord glutamine synthetase assays show that MSO treatment reduces
enzyme activity by 90% in all animals.

One would expect that this inhibition of glutamine

synthetase would lower levels glutamine while simultaneously increasing levels of glutamate,
because this excitotoxic amino acid would no longer be able to be converted to glutamine. The
aforementioned results indicate that this is not the case and that MSO somehow lowers levels of
glutamate, along with glutamine. In an effort to better understand how MSO lowers glutamate
levels in the brain, we examined the activity of brain glutaminase, the neuronal enzyme
responsible for converting glutamine back into glutamate. Using a modified version of Sigma’s
protocol for assaying the enzymatic activity of glutaminase purified from E. coli, we were able to
monitor the specific activity of glutaminase from mouse brain homogenates by measuring the
production of ammonia.
The specific activity of brain glutaminase is not affected by the overexpression of mutant
SOD1 protein. The specific activity of brain glutaminase was measured using the same mouse
brain homogenates that were assayed for glutamine synthetase activity. Enzyme activity was
measured in untreated 50 day old animals, as well as saline and MSO-treated 70 and 110 day
old animals. Figure 3.3.2.1 shows the average specific activity of brain glutaminase from wildtype and SOD1 mice. At 50 days of age, untreated wild-type and SOD1 mice have similar
levels of glutaminase activity in the brain (Figure 3.3.2.1A). At 70 days of age, saline-treated
wild-type mice show a slight decrease in glutaminase activity while SOD1 mice show no change
(Figure 3.3.2.1B). Glutaminase activity increases slightly by 110 days of age in both wild-type
and SOD1 saline-treated mice, but this change is not significant (Figure 3.3.2.1C).
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Figure 3.3.2.1 Specific activity of brain glutaminase in wild-type and SOD1 mice.
Data are presented as the average specific activity bars with error bars representing the S.E.M.
Green bars represent data from wild-type mice while purple bars represent data from SOD1
mice. A. In untreated 50 day old mice there is no difference in specific activity of brain
glutaminase in wild-type and SOD1 mice (n=15 SOD1 and n=16 WT mice). B. The activity of
brain glutaminase does not change in 70 day old wild-type and SOD1 mice (n=16 mice/group).
C. By 110 days of age, the average specific activity of glutaminase seems to increase in both
wild-type and SOD1 mice, however this change is not significant (n=13 SOD1 and n=15 WT
mice).
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There are no gender differences in the specific activity of brain glutaminase.

To

examine gender differences in brain glutaminase activity, the data were broken down by gender
and genotype.

Figure 3.3.2.2 shows the average specific activity of brain glutaminase of

untreated 50 day old animals and saline-treated 70 and 110 day old animals broken down by
gender and genotype. There are no significant gender differences in the enzyme activity of
untreated 50 day old animals (Figure 3.3.2.2A). In 70 day old saline-treated mice, it appears as
though there may be a gender difference in brain glutaminase activity, with females showing
lower activity than males (Figure 3.3.2.2B). Saline-treated male SOD1 mice in this age group
have significantly higher brain glutaminase activity (88 ± 12 nmoles/min/mg protein) than female
SOD1 mice (56 ± 7 nmoles/min/mg protein), with p<0.05, however the difference between male
and female wild-type mice is not considered significant. Between 70 and 110 days of age, the
average specific activity of glutaminase appears to increase in female mice and decrease in
male mice of both genotypes. However, this difference is only significant for wild-type females
where glutaminase activity increases from 52 ± 8 nmoles/min/mg protein at 70 days of age to 87
± 11 nmoles/min/mg protein at 110 days of age (p<0.05). In 110 day old saline-treated mice
(Figure 3.3.2.2C), there again appears to be a gender difference in enzyme activity with females
now having higher glutaminase activity than males, however this was not found to be significant.
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Figure 3.3.2.2 Brain glutaminase activity broken down by gender and genotype.
Data are presented as the average specific activity bars with error bars representing the S.E.M.
Green bars represent data from wild-type mice while purple bars represent data from SOD1
mice. A. When glutaminase activity data are broken down by gender and genotype, there are
no clear gender differences in 50 day old untreated mice (n=8 mice/group except for the female
SOD1 group which contains 7 mice). B. In 70 day old saline-treated mice, females appear to
have lower brain glutaminase than males (n=8 mice/group; * indicates values are significant
with p<0.05). C. Female saline-treated mice appear to have higher glutaminase activity than
male saline-treated mice at 110 days of age (n=5-8 mice/group).
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MSO treatment does not impact glutaminase activity in the brain.

Figure 3.3.2.3

compares the average specific activity of brain glutaminase in saline-treated wild-type and
SOD1 mice to that of MSO-treated wild-type and SOD1 mice. MSO treatment does not have an
effect on glutaminase activity in the brains of 70 day old mice (Figure 3.3.2.3A). The average
specific activities of glutaminase from MSO-treated wild-type and SOD1 mice are similar to that
of saline-treated mice. In 110 day old mice, brain glutaminase activity is elevated in saline and
MSO-treated wild-type and SOD1 mice compared to 70 day old mice, but this increase in
activity is not significant. In the 110 day age group brain homogenates of both genotypes show
higher glutaminase activity with MSO treatment (Figure 3.3.2.3B), however this increase is not
significant.
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Figure 3.3.2.3 The effects of MSO treatment on glutaminase activity.
Data are presented as the average specific activity with error bars representing the S.E.M. Blue
bars represent data from saline-treated wild-type and SOD1 mice and red bars represent data
from mice treated once a week with 20 mg/kg MSO. A. The average specific activity of
glutaminase from 70 day old saline-treated wild-type and SOD1 mice compared to that of MSOtreated mice (n=16 mice/group). B. The average specific activity of glutaminase from 110 day
old saline-treated wild-type and SOD1 mice compared to that of MSO-treated mice (n=13-19
animals/group).
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There are no significant gender differences in glutaminase activity with MSO treatment.
Glutaminase activity data were further broken down by gender and genotype to determine if
MSO treatment affects glutaminase activity in a gender-specific fashion.

Figure 3.3.2.4

compares saline and MSO-treated mice by gender and genotype. Based on these data, the
effects of MSO on glutaminase activity of male and female wild-type and SOD1 mice are
unclear. In Figure 3.3.2.4A, it appears as though MSO may be elevating enzyme activity in
females while reducing it in males in 70 day old mice, however none of these changes were
considered statistically significant. The results of glutaminase activity assays performed on 110
day old mice treated with saline and MSO are equally confusing. In this age group, it appears
as though MSO may be elevating glutaminase activity in male SOD1 and female wild-type mice,
lowering activity in male wild-type mice, and having no effect on female SOD1 mice (Figure
3.3.2.4B).

Like with the 70 day age group, these changes in enzyme activity with MSO

treatment were not found to be significant.
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Figure 3.3.2.4 Brain glutaminase activity of saline and MSO-treated mice broken down by
gender and genotype.
Data are presented as the average specific activity with error bars representing the S.E.M. Blue
bars represent data from saline-treated wild-type and SOD1 mice and red bars represent data
from mice treated once a week with 20 mg/kg MSO. A. The average specific activity of
glutaminase from 70 day old saline-treated wild-type and SOD1 mice compared to that of MSOtreated mice broken down by gender and genotype (n=8 mice/group). B. The average specific
activity of glutaminase from 110 day old saline-treated wild-type and SOD1 mice compared to
that of MSO-treated mice broken down by gender and genotype (n=5-9 animals/group).
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Overall, the results of the glutaminase activity assays show no differences in enzyme
activity. We see no differences in activity levels of wild-type and SOD1 mice at all time points,
and enzyme activity doesn’t appear to change with age. When the data are broken down by
gender and genotype, there are no significant gender differences in glutaminase activity in
untreated 50 day old mice. It appears as though gender differences in activity begin to emerge
at 70 days of age, with females exhibiting lower levels of brain glutaminase activity than males,
but only SOD1 mice show a significant gender difference in enzyme activity. By 110 days of
age, there seems to be a reversal in activity levels, with males now exhibiting lower glutaminase
activity than females, but these differences were not significant. MSO treatment does not have
a clear effect on glutaminase activity and it has not been determined to interact directly with the
enzyme. If MSO has an effect on glutaminase it may be region-specific or indirect, possibly
through altering levels of reactants, such as glutamate.
3.3.3 Plasma Metabolite Analysis
Glutamine synthetase is the only enzyme capable of producing glutamine and is
expressed in varying concentrations throughout the body (van Straaten et al 2006). Glutamine
is the most abundant free amino acid in the body (Brosnan 2003) and acts as an ammonia
carrier in the bloodstream. It is considered to be a nonessential amino acid and can be taken
up from the diet, and as a result the primary role of GS in certain organs is not to produce
glutamine but to detoxify glutamate and ammonia.

We have previously shown that MSO

lowers levels of glutamate, glutamine, and GABA in certain brain regions (Ghoddoussi et al
2010), but GS is expressed throughout the body and widespread inhibition of the enzyme by
MSO could potentially alter these chemicals in other areas.
Glutamine plays several roles in the body. It donates nitrogen for the production of
purines and ammonia to CPSI for the production of carbamoyl phosphate, leading to the
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production of arginine which then continues on to form urea (in the liver) and nitric oxide
(through nitric oxide synthases in a variety of tissues) (Newsholme et al 2003). Glutamine is
also involved in protein synthesis and acts as a precursor in the production of glutamate (Nelson
& Cox 2008; Newsholme et al 2003). Glutamate, which in most cells is the immediate product
of glutamine metabolism, can act as a precursor for GABA and n-acetyl glutamate (an allosteric
activator of CPSI), and indirectly acts as a precursor for glucose through α-ketoglutarate and its
flow into the Citric Acid Cycle (Newsholme et al 2003). Glutamate is also involved in protein
synthesis and is one of three amino acids that make up the antioxidant glutathione. Altering
glutamine levels through the use of MSO has the potential to affect several aspects of
metabolism throughout the body. We decided to examine a variety of amino acids, and other
metabolites including ammonia, in the plasma of presymptomatic mice to 1) understand the
effects that the overexpression of the mutant SOD1 protein has on nitrogen metabolism and 2)
monitor the effects of MSO treatment on nitrogen metabolism.
Young untreated SOD1 mice have elevated levels of plasma ammonia.

Plasma

ammonia levels were examined in 50 day old untreated wild-type and SOD1 mice, as well as
saline-treated 70 day old animals. Figure 3.3.3.1 shows the results of the plasma ammonia
analysis. In 50 day old untreated mice, plasma ammonia levels are significantly higher in SOD1
animals (78 ± 7 µmoles/L plasma) when compared to wild-type mice of the same age (52 ± 5
µmoles/L plasma), with p<0.01 (Figure 3.3.3.1A). Between 50 and 70 days of age, plasma
ammonia levels drop and both 70 day old wild-type and SOD1 mice treated with saline have
significantly lower levels of ammonia detected in their plasma when compared to untreated 50
day old animals (p<0.001). By 70 days of age, plasma ammonia levels have evened out and no
longer differ between wild-type and SOD1 mice (Figure 3.3.3.1B).
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Figure 3.3.3.1 Plasma ammonia concentrations in wild-type and SOD1 mice.
Plasma ammonia levels are expressed as the average concentration of ammonia in µmoles/L of
plasma with error bars representing the S.E.M. Green bars indicate plasma ammonia levels in
wild-type mice, while purple bars indicate that of SOD1 mice. A. The average concentration of
ammonia in 50 day old, untreated wild-type and SOD1 mice (n=31 mice/group; ** indicates that
values differ significantly with p<0.01). B. The average concentration of ammonia in 70 day old
wild-type and SOD1 mice treated with saline (n=24 mice/group).
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Plasma ammonia levels in SOD1 mice show no gender-specific differences.

Figure

3.3.3.2 shows the plasma ammonia data broken down by gender and genotype. In 50 day old
untreated mice, both female and male SOD1 mice have higher levels of ammonia in their
plasma. Female SOD1 mice were found to have significantly higher levels of ammonia (83 ± 11
µmoles/L plasma) than wild-type females (56 ± 5 µmoles/L plasma), with p<0.05, while males
were not found to differ significantly (Figure 3.3.3.2A). There are no significant differences in
the levels of plasma ammonia between males and females of the same genotype. Between 50
and 70 days of age, plasma ammonia levels drop in all groups analyzed. There is a much
larger decrease in plasma ammonia levels of SOD1 males and females than in wild-type males
and females, but the overall decrease is significant for all groups (p<0.01). Interestingly, by 70
days of age, plasma ammonia in saline-treated SOD1 male and female mice resemble that of
male and female wild-type mice, with no significant differences between genders (Figure
3.3.3.2B).
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Figure 3.3.3.2 Plasma ammonia concentrations broken down by gender and genotype.
Plasma ammonia levels are expressed as the average concentration of ammonia in µmoles/L of
plasma with error bars representing the S.E.M. Green bars indicate plasma ammonia levels in
wild-type male and female mice, while purple bars indicate that of SOD1 male and female mice.
A. Plasma ammonia levels are higher in both male and female SOD1 mice in 50 day old
untreated mice (n=16 female mice/group and n=15 male mice/group; * indicates that values
differ significantly with p<0.05). B. Plasma ammonia levels in 70 day old saline-treated mice
broken down by gender and genotype (n=12 mice/group).
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A single weekly injection of MSO elevates plasma ammonia levels in wild-type and
SOD1 mice. Animals were given an i.p. injection of saline or 20 mg/kg MSO starting at 50 ± 2
days of age and continued to receive a weekly injection until euthanized at 70 ± 2 days of age.
Plasma was taken and immediately assayed for ammonia content and the results are presented
in Figure 3.3.3.3. In both wild-type and SOD1 mice, treatment with MSO significantly increases
plasma ammonia levels with p<0.01 (Figure 3.3.3.3A). These data were further broken down by
gender and genotype to determine if MSO has a gender-specific effect on plasma ammonia
levels. MSO treatment significantly increases plasma ammonia levels in all groups with p<0.05,
except male SOD1 mice where the elevation in plasma ammonia was not found to be significant
(Figure 3.3.3.3B). Male wild-type mice have the lowest levels of plasma ammonia of all groups
examined, when treated with both saline and MSO. Male wild-type mice treated with MSO have
significantly lower levels of plasma ammonia (34 ± 2 µmoles/L plasma) when compared with
both female wild-type mice treated with MSO (48 ± 4 µmoles/L plasma; p<0.01) and male SOD1
mice treated with MSO (50 ± 7 µmoles/L plasma; p<0.05).
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Figure 3.3.3.3 The effects of MSO treatment on plasma ammonia levels.
Plasma ammonia levels are expressed as the average concentration of ammonia in µmoles/L of
plasma with error bars representing the S.E.M. Blue bars indicate plasma ammonia levels in
wild-type and SOD1 mice treated with saline, while red bars indicate that of wild-type and SOD1
mice treated with MSO. A. The effects of MSO treatment on plasma ammonia levels in 70 day
old wild-type and SOD1 mice (n=24 mice/group; ** indicates that values differ significantly with
p<0.01). B. The effects of MSO treatment on plasma ammonia levels in 70 day old male and
female wild-type and SOD1 mice (n=12 mice/group; * indicates that values differ significantly
with p<0.05).
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Several glucogenic amino acids are significantly lower in presymptomatic SOD1 mice
when compared to wild-type mice. Mouse plasma samples were obtained by anesthetizing
mice and drawing blood directly from the heart, which was immediately centrifuged in plasma
separator tubes. If needed, a portion of the plasma was used for ammonia determination and
the rest was immediately frozen on dry ice and then placed at -80°C until analyzed for
metabolite content. Plasma samples were taken from 50 day old untreated mice as well as 70
day old saline and MSO-treated mice of both genotypes. In 50 day old, untreated animals
several plasma metabolites were found to differ significantly between wild-type and SOD1 G93A
mice.

The top of Table 3.3.3.1 compares the concentrations (expressed in µmoles/L with the

standard error of the mean in parentheses) of several plasma metabolites analyzed in SOD1
mice (n=13) and compares them to those of wild-type control animals (n=19) of the same age.
A multivariate analysis of variance (MANOVA) was used to compare plasma metabolite
concentrations and the p values obtained are listed in the right-most column of the table.
Phosphoserine, phosphoethanolamine, urea, and citrulline are all significantly lower in SOD1
plasma compared to wild-type plasma. Lysine, a ketogenic amino acid that can be converted
into acetoacetyl-CoA and eventually ketone bodies, is significantly lower in SOD1 plasma. In
addition, aspartate, cystine, methionine, and arginine, all of which are glucogenic amino acids
and can be converted to glucose and glycogen, are also significantly lower in the plasma of
SOD1 animals at 50 days of age. Asparagine and glutamine, which are also glucogenic amino
acids, are elevated in SOD1 plasma when compared to that of wild-type animals.

Of the

metabolites that differ between SOD1 and wild-type mice, glutamine, methionine and lysine are
essential, while cystine and arginine are considered to be conditionally essential amino acids.
Interestingly, cystine was detectable in all wild-type plasma samples but could only be detected
in one SOD1 sample.
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Table 3.3.3.1 Plasma metabolite differences between 50 day old untreated and 70 day old
saline-treated SOD1 and wild-type mice.

Age

50 Days

70 Days
(Saline)

Metabolite

WT

SOD1

p (MANOVA)

Phser

14.43 (0.84)

6.76 (1.24)

0.000009

Pea

11.55 (1.27)

5.57 (2.00)

0.01

Urea

9866.08 (358.87)

8088.85 (696.89)

0.02

Asp

18.03 (1.51)

11.32 (0.87)

0.002

Asn

38.98 (2.09)

47.83 (4.03)

0.04

Gln

560.08 (13.21)

676.66 (37.19)

0.002

Citr

109.36 (4.91)

87.14 (5.46)

0.006

Cys

27.91 (2.40)

0.36 (0.36)

0.000000

Met*

87.38 (5.84)

65.47 (7.01)

0.02

Lys*

319.96 (12.69)

273.63 (16.00)

0.03

Arg

122.45 (8.41)

86.84 (7.51)

0.006

Pea

6.11 (1.74)

1.12 (0.61)

0.008

Asp

13.06 (1.38)

9.15 (0.35)

0.007

Sarc

9.33 (5.38)

32.38 (5.12)

0.005

Ala

720.05 (52.53)

593.61 (32.61)

0.045

Cys

13.34 (5.45)

0.00 (0.00)

0.02

116.87 (10.32)

75.54 (11.55)

0.01

†

Pro

†

†

†

†

Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L.
Amino acids highlighted in red are glucogenic and can be converted to glucose and glycogen.
Amino acids highlighted in blue are ketogenic and can be converted to acetoacetyl-CoA and/or
acetyl-CoA.
* indicates essential amino acids.
†
indicates conditionally essential amino acids.
n (WT, 50 days) = 19
n (SOD1, 50 days) = 13
n (WT, 70 days) = 12
n (SOD1, 70 days) = 14
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When we examine plasma metabolite changes in 70 day old SOD1 and wild-type mice
treated with saline we see a strikingly different profile. There are fewer metabolite differences
between saline-treated SOD1 and wild-type mice at 70 days of age and the metabolites that
differ significantly between the two groups are different from what we see in 50 day old
untreated mice. The bottom of Table 3.3.3.1 shows the amino acids that differ significantly
between 70 day old saline-treated SOD1 and wild-type mice, as well as the p values obtained
from the MANOVA. As with 50 day old untreated mice, phosphoethanolamine, aspartate, and
cystine levels were all found to be significantly lower in saline-treated SOD1 mice when
compared to saline-treated wild-type mice. Cystine levels were found to follow a similar pattern
in 70 day old animals, with levels being undetectable in all SOD1 plasma analyzed. Alanine and
proline levels were also found to be significantly lower in saline-treated SOD1 animals, while
sarcosine (N-methylglycine) levels were found to be elevated in SOD1 plasma.

Of these

metabolites, aspartate, alanine, cystine, and proline are all glucogenic and both cystine and
proline are considered to be conditionally essential amino acids.

We also no longer see

significant differences in plasma urea or glutamine levels in SOD1 mice at 70 days of age.
Many metabolites vary between genotypes within the same gender. When we break the
data from Table 3.3.3.1 down and look at genotype differences in plasma metabolites within
each gender, we see that male and female SOD1 mice, when compared to their wild-type
counterparts, have different plasma metabolite profiles. Table 3.3.3.2 shows the data broken
down by gender, comparing wild-type mice to SOD1 mice. Female SOD1 mice in the 50 day
age group show a variety of differences in plasma metabolites, some of these differences are
the same seen in Table 3.3.3.1, while other differences are specific to females and are not
detected when gender is not accounted for.

For example, lower levels of plasma

phosphoserine, citrulline, cystine, methionine, lysine, and arginine, and higher levels of
glutamine, seen in female SOD1 mice agree with plasma metabolite differences seen between
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wild-type and SOD1 mice when gender is not accounted for.

However, when we examine

genotype differences in plasma metabolites of female mice, we now detect significant
differences in threonine and ornithine, both of which are significantly lower in plasma from
SOD1 females (Table 3.3.3.2). When we look at 50 day old male mice a similar pattern is
observed, where several of the plasma metabolite differences agree with those seen in Table
3.3.3.1 and new male-specific differences become apparent.

Lower levels of plasma

phosphoserine, phosphoethanolamine, urea, aspartate, and cystine, and higher levels of
asparagine and glutamine, detected in male SOD1 mice when compared to male wild-type mice
agree with differences seen when gender is not accounted for. However, focusing on genotype
differences in plasma metabolites from male mice shows that there are several metabolite
differences that are specific to males. Male SOD1 mice show significantly higher plasma levels
of alanine, tyrosine, phenylalanine, and proline, which are not seen in females.
Several of the plasma metabolite differences between 50 day old wild-type and SOD1
mice are not considered to be gender-specific. Decreased levels of phosphoserine and cystine,
and elevated levels of glutamine are seen in both male and female SOD1 mice when the data
are broken down by gender. It is also interesting to point out that several of the differences
seen in 50 day old SOD1 mice in Table 3.3.3.1 are accounted for by only one gender. Lower
levels of methionine, lysine, and arginine are specific to females, while male specific changes
include alterations in levels of phosphoethanolamine, urea, aspartate, and asparagine.
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Table 3.3.3.2 Plasma metabolite profiles of 50 and 70 day old mice broken down by gender.
Age & Gender

Metabolite

WT

SOD1

p (MANOVA)

Phser
Thr*

14.45 (1.47)
203.07 (10.99)

8.66 (1.54)
131.50 (16.26)

0.02
0.002

568.60 (16.63)
119.86 (8.34)

709.78 (74.95)
72.97 (7.40)

0.04
0.002

23.32 (3.73)
97.44 (10.56)
99.00 (8.66)
356.96 (17.17)

0.77 (0.77)
47.63 (6.17)
53.06 (8.53)
255.59 (24.42)

0.0003
0.003
0.003
0.004

138.40 (13.63)
14.40 (0.96)
11.02 (2.28)
10907.49 (366.39)
20.73 (1.76)
35.65 (2.21)

76.58 (11.60)
5.13 (1.75)
2.37 (1.82)
8117.83 (1287.87)
11.20 (1.15)
53.62 (4.98)

0.007
0.0002
0.01
0.03
0.001
0.002

552.41 (20.69)
532.65 (19.38)

648.27 (28.90)
754.24 (26.03)

0.01
0.000004

Cys

32.04 (2.58)

0.00 (0.00)

0.000000

Tyr
Phe*

65.22 (3.55)
58.07 (2.25)

81.65 (5.26)
68.15 (3.43)

0.02
0.02

84.78 (4.10)
11.21 (1.40)
8.90 (5.65)

129.72 (11.49)
1.61 (1.06)
37.80 (4.86)

0.0008
0.0002
0.002

†

50 day

Gln
Citr

†

Females

Cys
Met*
Orn
Lys*
†

50 day
Males

Arg
Phser
Pea
Urea
Asp
Asn
†

Gln
Ala

†

†

†

70 day Females
70 day Males

Pro
Pea
Sarc
†

Gly
325.48 (13.66)
281.24 (5.40)
0.009
Ala
673.60 (28.49)
521.33 (43.07)
0.02
Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L.
Amino acids highlighted in red are glucogenic, those in blue are ketogenic, and purple indicates
amino acids that can be both ketogenic and glucogenic.
* indicates essential amino acids and † indicates conditionally essential amino acids.
n (WT, F, 50 days) = 9
n (WT, M, 50 days) = 10
n (SOD1, F, 50 days) = 6
n (SOD1, M, 50 days) = 7
n (WT, F, 70 days) = 6
n (WT, M, 70 days) = 6
n (SOD1, F, 70 days) = 7
n (SOD1, M, 70 days) = 7
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When we look at genotype differences between 70 day old female and male mice, we
see that there are far fewer metabolite differences than with 50 day old mice. The bottom of
Table 3.3.3.2 shows the differences between 70 day old saline-treated wild-type and SOD1
female and male mice. Some of the genotype differences seen in Table 3.3.3.1, when the data
were examined by genotype only, disappear when gender is accounted for, while the other
differences appear to be gender-specific. When we look at 70 day old females treated with
saline, we see that SOD1 females have significantly lower levels of phosphoethanolamine, with
elevated sarcosine, which agrees with the genotype differences seen in Table 3.3.3.1. These
alterations in phosphoethanolamine and sarcosine are specific to females, as males show no
significant changes in levels of these metabolites. When we look at 70 day old males treated
with saline, we see that SOD1 males show decreased plasma levels of glycine and alanine,
which are not shared with females but are seen when gender is not accounted for (Table
3.3.3.1).

Significant differences in aspartate and proline, observed between wild-type and

SOD1 mice (Table 3.3.3.1) are no longer seen when gender is accounted for.

Differences in

cystine levels do not reach significance when gender is accounted for, but continue to be
undetectable in 70 day old saline-treated SOD1 male and female mice.
Several plasma metabolites differ between males and females of the same genotype.
When the plasma metabolite data are broken down by genotype and analyzed for gender
differences, 50 day old wild-type mice show more gender differences than SOD1 mice. Table
3.3.3.3 shows the plasma metabolites that differ significantly between 50 day old female and
male wild-type and SOD1 mice, as well as differences between saline-treated 70 day old
females and males. Nine plasma metabolites differ between 50 day old female and male mice –
urea, threonine, serine, alanine, citrulline, tyrosine, lysine, histidine, and tryptophan. Of these
metabolites, only urea is significantly higher in male wild-type mice. Male wild-type mice show
significantly lower levels of the other eight plasma metabolites. This is much different than what
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is observed in SOD1 mice. First, there are fewer plasma metabolites that differ between male
and female SOD1 mice. The overall plasma metabolite profile of these animals is different than
that of wild-type mice.

Only two of the significantly different metabolites in SOD1 mice –

threonine and citrulline – overlap with the metabolites that differ in wild-type mice. All of the
differences seen between SOD1 females and males occur because males have significantly
higher levels than females, whereas the differences in wild-type animals are due to males
having significantly lower levels than females. SOD1 males have significantly higher levels of
threonine than SOD1 females, but their levels of threonine are closer to those of wild-type
females, which have higher threonine levels than wild-type males. We also see that levels of
citrulline in SOD1 male mice, which are significantly higher than those of SOD1 females, are
similar to citrulline levels in wild-type male mice.

151
Table 3.3.3.3 Gender differences in plasma metabolites of wild-type and SOD1 mice.
Age & Genotype

50 day
WT

Metabolite

Female

Male

p (MANOVA)

Urea

8708.96 (354.88)

10907.49 (366.39)

0.0005

Thr*

203.07 (11.00)

163.34 (9.19)

0.01

Ser

163.93 (7.19)

138.98 (4.92)

0.01

Ala

627.88 (40.72)

532.65 (19.39)

0.04

Citr

119.86 (8.34)

99.90 (3.88)

0.04

79.45 (5.61)

65.22 (3.55)

0.04

Lys*

356.96 (17.17)

286.65 (10.76)

0.02

His*

73.38 (2.87)

66.08 (2.76)

0.03

Trp*

76.56 (3.39)

43.50 (7.64)

0.001

Thr*

131.50 (16.26)

187.67 (12.48)

0.02

Citr

72.97 (7.40)

99.29 (4.30)

0.009

Met*

47.63 (6.17)

80.77 (8.41)

0.01

Orn

53.06 (8.53)

88.90 (11.71)

0.04

77.27 (10.86)

129.72 (11.49)

0.007

Taur

374.83 (20.66)

281.63 (21.25)

0.01

Pea

11.21 (1.40)

1.02 (1.02)

0.0002

Gln*

638.99 (34.74)

531.61 (29.86)

0.04

1-Mhis

15.07 (1.41)

10.09 (1.22)

0.02

His*

81.79 (3.31)

67.63 (2.41)

0.006

Trp*

76.07 (7.38)

50.16 (4.57)

0.01

Urea

9447.01 (548.05)

11606.02 (354.13)

0.006

Gln

646.85 (25.91)

540.98 (29.63)

0.02

Ala

665.88 (31.81)

521.33 (43.07)

0.02

Phe*

71.48 (2.11)

61.65 (2.94)

0.02

Lys*

318.41 (17.80)

242.03 (26.80)

0.04

His*

81.73 (6.61)

64.16 (2.34)

0.03

Tyr

50 day
SOD1

†

Pro

70 day
WT

†

†

70 day
SOD1

Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L and n values are the same
as those of Table 3.3.3.2. * indicates essential amino acids and † indicates conditionally
essential amino acids. Amino acids highlighted in red are glucogenic, those in blue are
ketogenic, and purple indicates amino acids that can be both ketogenic and glucogenic.
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When the data from 70 day old saline-treated mice are broken down by genotype and
examined for gender differences, we see a different plasma metabolite profile than what was
observed in 50 day old mice, with new metabolite differences appearing. The bottom portion of
Table 3.3.3.3 lists the plasma metabolites found to differ significantly between male and female
70 day old mice treated with saline. When we compare male and female wild-type mice treated
with saline, significant gender differences in six plasma metabolites are observed. Male wildtype

mice

in

this

age

group

have

significantly

lower

plasma

levels

phosphoethanolamine, glutamine, 1-methylhistidine, histidine, and tryptophan.

of

taurine,
Of these

differences, only two are shared with 50 day old wild-type mice – histidine and tryptophan –
which are also lower in male wild-type mice compared to females.

When we compare

metabolite levels in plasma from male and female SOD1 mice treated with saline there is very
little overlap with the profile of wild-type males and females. In both wild-type and SOD1 mice
glutamine and histidine levels are found to be significantly higher in females when compared to
males. The other plasma metabolites that show gender differences in SOD1 mice at this age –
urea, alanine, phenylalanine, and lysine – are lower in males than females, with the exception of
urea which is elevated in male SOD1 mice. The 50 and 70 day age groups show no similarities
with respect to gender differences in plasma metabolite levels.
MSO treatment significantly lowers plasma glutamine levels, increases plasma cystine
levels, and alters the profile of several other plasma metabolites in SOD1 mice. The plasma
metabolite profile of SOD1 mice treated with MSO shows several changes in the levels of a
variety of chemicals. We examined plasma metabolite levels in 14 mice treated with saline and
16 mice treated with MSO and Figure 3.3.3.4 shows the plasma metabolites that are altered
with MSO treatment in these SOD1 mice. Phosphoethanolamine, AAAA (α-aminoadipic acid,
an intermediate in lysine metabolism), and ornithine levels increase, while sarcosine levels
decrease in MSO-treated SOD1 mice compared to their saline-treated counterparts. The levels
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of several glucogenic amino acids are altered with MSO treatment.

Asparagine, alanine,

arginine, and cystine levels increase significantly with MSO treatment, while glutamine levels
decrease significantly with treatment. Interestingly, cystine, which is undetectable in salinetreated SOD1 mice, becomes detectable with MSO treatment.

Lysine, an essential ketogenic

amino acid, also increases significantly in SOD1 mice with MSO treatment. We also compared
the plasma metabolite profile of wild-type mice treated with saline to that of MSO-treated wildtype mice and only found one amino acid to change with treatment. Lysine levels in wild-type
mice increase significantly from 290.03 ± 18.13 to 352.86 ± 17.99 µmoles/L, with p=0.02. This is
similar to the increase in plasma lysine levels seen in SOD1 mice with MSO treatment.
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Table 3.3.3.4 The effects of MSO treatment on plasma metabolite levels of SOD1 mice.

Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L.
Amino acids highlighted in red are glucogenic and can be converted to glucose and glycogen.
Amino acids highlighted in blue are ketogenic and can be converted to acetoacetyl-CoA and/or
acetyl-CoA.
* indicates essential amino acids.
†
indicates conditionally essential amino acids.
n (Saline) = 14
n (MSO) = 16
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There are several gender-specific changes in plasma metabolites of 70 day old mice
with MSO treatment. When the plasma metabolite data are further broken down by gender and
genotype and examined for changes with MSO treatment, the plasma concentrations of several
metabolites are altered in a gender-specific fashion. Table 3.3.3.5 lists the metabolites that
change significantly with MSO treatment, as well as their concentrations in saline and MSOtreated animals. When we compare the concentrations of plasma metabolites of saline-treated
wild-type female mice to those of MSO-treated wild-type female mice, there are no significant
changes with MSO treatment. However, when we look at treatment-related changes in plasma
metabolites of female SOD1 mice we see that glutamine and sarcosine levels are significantly
lower, while arginine levels are significantly higher, in MSO-treated mice. This corresponds to
the overall changes that were seen when in plasma metabolite levels were examined only by
genotype (Table 3.3.3.4). We see a greater number of plasma metabolites change with MSO
treatment in male wild-type mice. Male wild-type mice treated with MSO have significantly
higher levels of phosphoserine, phosphoethanolamine, glutamate, ornithine, and lysine in their
plasma than their saline-treated counterparts. Fewer plasma metabolite changes are seen in
male SOD1 mice that have been treated with MSO. As with wild-type males, plasma levels of
phosphoethanolamine increase with MSO treatment in SOD1 males. This is the only similarity
between wild-type and SOD1 male mice. SOD1 males also show significantly increased levels
of AAAA, alanine, and tryptophan in their plasma with MSO treatment, which are not seen in
wild-type males.
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Table 3.3.3.5 Gender-specific changes in plasma metabolites with MSO treatment.

Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L.
Amino acids highlighted in red are glucogenic and can be converted to glucose and glycogen.
Amino acids highlighted in blue are ketogenic and can be converted to acetoacetyl-CoA and/or
acetyl-CoA.
Amino acids highlighted in purple can be ketogenic or glucogenic.
* indicates essential amino acids.
†
indicates conditionally essential amino acids.
n (F, WT, Saline) = 6
n (F, WT, MSO) = 6
n (F, SOD1, Saline) = 7
n (F, SOD1, MSO) = 8
n (M, WT, Saline) = 6
n (M, WT, MSO) = 5
n (M, SOD1, Saline) = 7
n (M, SOD1, MSO) = 8
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To summarize the results of the plasma metabolite analysis, we see that there are a
variety of differences in SOD1 mice when compared to wild-type mice, some of which are
gender-specific. We see that 50 day old untreated SOD1 mice have significantly higher levels
of plasma ammonia than wild-type mice, but the overall level of ammonia in both groups
declines with age and these genotype differences disappear in 70 day old saline-treated mice.
We also see that when plasma ammonia data are broken down by gender and genotype, both
female and male SOD1 mice have higher plasma ammonia levels, but the differences between
wild-type and SOD1 females reached significance, while those between males did not. The
same trend is seen in 70 day data broken down by gender and genotype, where overall plasma
ammonia levels decrease in all groups and show no significant gender or genotype differences.
MSO treatment significantly increases plasma ammonia levels in both wild-type and SOD1
mice, and no gender differences are seen with treatment.
With respect to plasma metabolites, 50 day old untreated animals show many more
genotype differences in metabolites than 70 day old saline-treated mice and several of these
differences in plasma metabolite levels between wild-type and SOD1 mice show genderspecificity when data are broken down by both genotype and gender. For example, significantly
lower levels of methionine, lysine, and arginine are only seen in 50 day old female SOD1 (when
compared

to

female

wild-type)

mice

and

significant

differences

in

levels

of

phosphoethanolamine, urea, aspartate, and asparagine are only seen when 50 day old male
SOD1 and wild-type mice are compared.

When gender is taken into account, genotype

differences in metabolites from 50 day old mice that are not seen when gender is ignored
become apparent.

For example, when 50 day old wild-type and SOD1 mice are grouped

according to gender and examined for genotype differences females show differences in
ornithine and threonine, while males show differences in alanine, tyrosine, phenylalanine, and
proline, which are not observed when animals are simply grouped by genotype.

Gender
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specific differences in plasma metabolites continue to be seen in 70 day old saline-treated mice,
but there are fewer than what was observed in 50 day old mice. MSO treatment alters a variety
of metabolite levels in SOD1 mice, however only lysine levels are altered in wild-type mice.
When treatment data are broken down by gender and genotype, there are a variety of
metabolite changes observed but no changes occur in female wild-type mice.
3.3.4 Nitrogen Metabolism in the Liver
Preliminary analysis of plasma metabolite data suggested that several amino acids,
particularly those involved in urea production, were significantly different in SOD1 mice when
compared to wild-type animals. In mammals urea production occurs primarily in the liver (and to
some extent in the kidney) through the urea cycle, which consists of five reactions that function
to remove ammonia from the body. The first two reactions occur in the mitochondria, the first of
which is catalyzed by carbamoyl phosphate synthetase one (CPSI) and is the rate limiting step
of the urea cycle. The mutant SOD1 protein is ubiquitously expressed in the SOD1 G93A
mouse model of ALS and the protein has been shown to associate with mitochondria isolated
from spinal cord (Liu et al 2004) and aggregate in brain mitochondria (Vijayvergiya et al 2005) of
these animals. In addition, mice expressing mutant SOD1 protein have been found to have
overall defects energy homeostasis (Dupuis et al 2004) and liver samples collected from ALS
patients exhibit hepatic ultrastructural changes and abnormal mitochondria, suggestive of liver
dysfunction (Nakano et al 1987). As a result, it seems reasonable to believe that the SOD1
mutation could potentially interact with liver mitochondria in such a way as to impair the urea
cycle. We decided to assay CPSI activity to see if SOD1 mice exhibit changes in enzyme
activity prior to symptom onset. We also examined the impact of gender and MSO treatment on
CPSI activity.
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The specific activity of CPSI does not differ between wild-type and SOD1 mice. Figure
3.3.4.1 compares the specific activity of CPSI in wild-type mice to that of SOD1 mice. In 50 day
old untreated mice, both wild-type and SOD1 animals have about the same level of CPSI
activity, approximately 150 nmoles/min/mg protein (Figure 3.3.4.1A). At 70 days of age, CPSI
activity increases significantly in both wild-type (p<0.001) and SOD1 (p<0.05) mice treated with
saline (Figure 3.3.4.1B). It also appears as though SOD1 mice may have lower CPSI activity
than wild-type mice at this age; however this difference did not reach significance.
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Figure 3.3.4.1 Specific activity of liver CPSI in wild-type and SOD1 mice.
The data are presented as the average specific activity of CPSI with error bars representing the
S.E.M. Green bars indicate data from wild-type mice, while purple bars indicate data from
SOD1 mice. A. The specific activity of CPSI in 50 day old wild-type and SOD1 mice (n=20
mice/group). B. The specific activity of CPSI in saline-treated 70 day old wild-type and SOD1
mice (n=20 mice/group).
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Female mice have higher CPSI activity levels than males, regardless of genotype.
When the CPSI activity data are broken down by gender and genotype there is a clear
difference between males and females. Figure 3.3.4.2 shows the results of the CPSI activity
assays broken down by gender and genotype. In 50 day old untreated wild-type and SOD1
female mice, the average CPSI activity is around 200 nmoles/min/mg protein, almost twice the
activity of CPSI in wild-type and SOD1 males (Figure 3.3.4.2A). In 70 day old saline-treated
mice, CPSI activity is elevated across all groups when compared to 50 day old untreated
animals (p<0.05). The gender difference in the specific activity of CPSI remains apparent in 70
day old mice (Figure 3.3.4.2B). Saline-treated female wild-type mice show significantly higher
CPSI activity (280 ± 20 nmoles/min/mg protein) than their male counterparts (210 ± 10
nmoles/min/mg protein), with p<0.05. Saline-treated SOD1 female mice also show significantly
higher CPSI activity (250 ± 10 nmoles/min/mg protein) than their male counterparts (160 ± 10
nmoles/min/mg protein), with p<0.001. It is also interesting to point out that in the 70 day age
group, saline-treated SOD1 males have significantly lower CPSI activity levels than salinetreated wild-type males (p<0.01), but this difference is not observed when female SOD1 and
wild-type mice are compared.
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Figure 3.3.4.2 Specific activity of liver CPSI broken down by gender and genotype.
The data are presented as the average specific activity of CPSI with error bars representing the
S.E.M. Green bars indicate data from male and female wild-type mice, while purple bars
indicate data from male and female SOD1 mice. A. Specific activity of CPSI from 50 day old
untreated mice (n=10 mice/group; *** indicate values are significant with p<0.001). B. Specific
activity of CPSI from 70 day old mice treated with saline (n=10 mice/group; *, **, and *** indicate
values are significant with p<0.05, 0.01, and 0.001 respectively).
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MSO treatment does not affect CPSI activity levels in wild-type or SOD1 mice. Figure
3.3.4.3 shows the effect of MSO treatment on CPSI activity. When the data are grouped by
genotype, 70 day old wild-type animals treated with saline have CPSI activity levels similar to
those of wild-type animals treated with MSO and the same holds true for SOD1 mice (Figure
3.3.4.3A). SOD1 mice in this age group have slightly lower, but not significant, CPSI activity
levels than wild-type mice for both treatment groups. When the data are broken down by
gender and genotype (Figure 3.3.4.3B), we see that MSO-treated wild-type females have
slightly higher, but not significant, CPSI activity than saline-treated wild-type females. However,
female SOD1 mice and male wild-type and SOD1 mice all show slightly lower, but not
significant, levels of CPSI activity when treated with MSO.

164
Figure 3.3.4.3 The effects of MSO treatment on CPSI activity in presymptomatic wild-type and
SOD1 mice.
The data are presented as the average specific activity of CPSI with error bars representing the
S.E.M. Blue bars indicate data from both wild-type and SOD1 mice treated with saline while red
bars indicate data from wild-type and SOD1 mice treated with MSO. A. In 70 day old mice,
MSO treatment has no effect on CPSI activity in wild-type or SOD1 mice (n=20 mice/group). B.
When the data depicted in A are broken down by gender and genotype, MSO treatment still has
no effect on CPSI activity in 70 day old animals (n=10 mice/group).
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In summary, we see no significant differences in CPSI activity between wild-type and
SOD1 mice at 50 or 70 days of age. However, we do see that CPSI activity is significantly
elevated in 70 day old saline-treated mice of both genotypes when compared to 50 day old
animals. When CPSI activity data are further broken down by gender and genotype, we see
that there is a clear gender difference in 50 day old mice, in which female mice of both
genotypes have significantly higher CPSI activity levels than their male counterparts.

We

continue to see significantly elevated CPSI activity in all groups of mice at 70 days of age.
While we still see a gender difference in this age group (females continue to having significantly
higher CPSI activity than males), we also start to see changes in CPSI activity in male SOD1
mice, which have the lowest activity level of all the groups examined. MSO treatment shows no
effect on CPSI activity in wild-type and SOD1 mice of both genders.
After analyzing CPSI activity levels in the liver of wild-type and SOD1 mice, we assayed
glutamine synthetase activity levels in the same mice. In mammals, CPSI and GS protein
expression are compartmentalized within different cell types. In the mammalian liver CPSI is
broadly expressed in most hepatocytes, while glutamine synthetase expression is restricted to
only a small number of cells which do not express CPSI, specifically those surrounding the
terminal hepatic venules where GS is found in the cytosol (Smith & Campbell 1988). Glutamine
synthetase is also cytosolic in the brain, however it is much more widely expressed within
astrocytes which can make up about 50% of the volume in certain regions (Squire et al 2008).
As previously mentioned, a single dose of MSO has been shown to inhibit glutamine synthetase
activity in the brain for an extended period of time, with brain GS regaining 75% of control
activity after 90 days. This same study also showed that a single subconvulsive dose of MSO
had slightly different effects on the liver. Maximal inhibition of glutamine synthetase in mouse
liver was obtained within one hour of injection with MSO and the enzyme regained 70% of
control activity within 4 days of injection (Rao & Meister 1972). In an effort to continue the
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characterization of glutamine metabolism in ALS mice, as well as to examine potential metabolic
effects of the overexpression of mutant SOD1 protein in liver, we assayed the specific activity of
liver glutamine synthetase in both wild-type and SOD1 mice and looked at the effects of MSO
treatment on enzyme activity.
The SOD1 G93A mutation does not affect the specific activity of glutamine synthetase in
liver homogenates of presymptomatic mice. All animals assigned to these experiments were
given a final injection of MSO within 24 hours prior to euthanasia. When liver samples were
processed, a portion of the supernatant from each liver homogenate was desalted for CPSI
enzyme activity assays, while the remainder was set aside for liver GS activity assays. The
activity assays were performed in the same manner as those conducted on brain and spinal
cord GS, differing only in sample preparation. The results of liver GS activity assays can be
seen in Figure 3.3.4.4. In 50 day old untreated mice, there is no difference in the specific
activity of GS between wild-type and SOD1 mice (Figure 3.3.4.4A). The specific activity of liver
GS in wild-type mice appears to increase slightly by 70 days of age, while that of SOD1 mice
remains the same as that of 50 day old mice. In 70 day old saline-treated mice, liver GS activity
appears to be slightly lower in SOD1 mice than wild-type mice (Figure 3.3.4.4B), but this
difference was not found to be significant.
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Figure 3.3.4.4 Specific activity of liver glutamine synthetase in wild-type and SOD1 mice.
The data are presented as the average specific activity of GS with error bars representing the
S.E.M. Green bars indicate data from wild-type mice, while purple bars indicate data from
SOD1 mice. A. The specific activity of liver GS in untreated, 50 day old wild-type and SOD1
mice (n=20 mice/group). B. The specific activity of liver GS in saline-treated, 70 day old wildtype and SOD1 mice (n=20 mice/group).
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Male SOD1 mice treated with saline have significantly lower liver GS activity than female
SOD1 and male wild-type mice. Figure 3.3.4.5 shows the specific activity of liver GS broken
down by gender and genotype. Untreated 50 day old mice have about the same level of GS
activity across genders and genotypes (Figure 3.3.4.5A). In 70 day old mice treated with saline,
we see that the specific activity of liver GS is higher in female mice when compared to male
mice of both genotypes (Figure 3.3.4.5B). However, this difference is only significant when
comparing female SOD1 mice to male SOD1 mice treated with saline. Saline-treated female
SOD1 mice have significantly higher liver GS activity (810 ± 30 nmoles/min/mg protein) than
male SOD1 mice (580 ± 30 nmoles/min/mg protein), with p<0.001. Saline-treated male SOD1
mice also have significantly lower GS activity than their wild-type counterparts (580 ± 30
nmoles/min/mg protein compared to 740 ± 50 nmoles/min/mg protein), with p<0.05.
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Figure 3.3.4.5 Specific activity of liver GS broken down by gender and genotype.
The data are presented as the average specific activity of GS with error bars representing the
S.E.M. Green bars indicate data from male and female wild-type mice, while purple bars
indicate data from male and female SOD1 mice. A. Specific activity of liver GS from 50 day old
untreated mice (n=10 mice/group). B. Specific activity of liver GS from 70 day old mice treated
with saline (n=10 mice/group; * and *** indicate values are significant with p<0.05 and 0.001
respectively).
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MSO treatment significantly lowers liver glutamine synthetase activity. Figure 3.3.4.6
shows the effects of MSO treatment on the specific activity of liver glutamine synthetase. Much
like with brain and spinal cord GS activity, a single weekly injection of 20 mg/kg MSO lowers
liver glutamine synthetase activity; however the extent of inhibition varies slightly. Whereas with
brain and spinal cord, in which MSO treatment lowered GS activity by about 90% in both
genotypes, we see that liver GS activity at 70 days of age is inhibited by almost 90% in wild-type
mice, but in SOD1 mice GS activity is only inhibited by approximately 70% (Figure 3.3.4.6A).
SOD1 mice treated with MSO have significantly higher liver GS activity (200 ± 35
nmoles/min/mg protein) than wild-type mice treated with MSO (110 ±

10 nmoles/min/mg

protein), p<0.05. When these data are broken down by gender and genotype, we see that liver
GS activity is significantly lowered in all groups (p<0.001). However, GS activity is clearly
altered in SOD1 male mice compared to wild-type male and SOD1 female mice (Figure
3.3.4.6B). While MSO treatment lowers GS activity by approximately 85% in male and female
wild-type mice, as well as female SOD1 mice, it only lowers GS activity in male SOD1 mice by
approximately 55%.

When compared to wild-type male mice treated with MSO (95 ± 10

nmoles/min/mg protein), male MSO-treated SOD1 mice have significantly higher liver GS
activity (260 ± 50 nmoles/min/mg protein), with p<0.05. While female SOD1 mice treated with
MSO have lower GS activity than their male counterparts, this difference was not found to be
significant.

Interestingly,

female wild-type mice treated with MSO were found to have

significantly higher GS activity (120 ± 30 nmoles/min/mg protein) than their male counterparts
(95 ± 10 nmoles/min/mg protein), with p<0.05.
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Figure 3.3.4.6 The effects of MSO treatment on liver GS activity in presymptomatic wild-type
and SOD1 mice.
The data are presented as the average specific activity of GS with error bars representing the
S.E.M. Blue bars indicate data from both wild-type and SOD1 mice treated with saline while red
bars indicate data from wild-type and SOD1 mice treated with MSO. A. MSO treatment
significantly lowers liver GS activity in 70 day old wild-type and SOD1 mice (n=20 mice/group,
except for WT mice treated with MSO where n=19 mice/group). B. When the data are further
broken down by gender and genotype, MSO inhibits GS activity by approximately 90% in all
groups, except male SOD mice where GS activity is only inhibited by 55% (n=10 mice/group,
except for female WT mice treated with MSO where n=9 mice/group; *** indicates that values
differ significantly with p<0.001).
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In summary, we see that there are no significant differences in liver glutamine
synthetase activity between wild-type and SOD1 mice at 50 days of age. The specific activity of
liver GS is slightly, but not significantly, lower in SOD1 mice treated with saline at 70 days of
age when compared to saline-treated wild-type mice. When the data are further broken down
by gender and genotype, we see no significant gender differences at 50 days of age. However,
much like with CPSI activity, we begin to see differences emerging in male SOD1 mice at 70
days of age. Liver GS activity in saline-treated male SOD1 mice decreases at 70 days of age
and is significantly lower than that of female SOD1 mice, as well as wild-type male mice, treated
with saline. A similar pattern is seen with the CPSI activity in these animals, but is not reflected
in the activities of brain or spinal cord GS in animals of the same age.

MSO treatment

significantly lowers liver glutamine synthetase activity in both wild-type and SOD1 mice, but has
a much greater impact on GS activity in wild-type mice where activity is decreased by almost
90%. MSO treatment impacts liver GS activity in male and female wild-type mice and female
SOD1 mice similarly, but it does not inhibit liver GS activity in male SOD1 mice to the same
extent. Whereas females of both genotypes and male wild-type mice show between 83 and
85% liver GS inhibition with MSO treatment, male SOD1 mice show only 55% inhibition.
3.3.5 The Effects of Ovariectomization on Enzyme Activity and Plasma Metabolites
In an effort to understand how the removal of sex hormones impacts ammonia and
amino acid metabolism, we performed glutamine synthetase assays on liver and brain extracts,
glutaminase assays on brain extracts, ammonia and metabolite analyses on plasma, and CPSI
activity assays on liver extracts isolated from 70 day old female SOD1 mice that had treated
with weekly i.p. injections of saline starting at 50 days of age. We focused on female mice
because survival experiments and grip assays showed that females benefit more from MSO
treatment than males. Obtaining a metabolic profile from these SOD1 female mice might help in
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understanding how ammonia and amino acid metabolism change when female sex hormones
are removed, and possibly pinpoint a metabolic pathway that may be responsive to these
hormones as well as MSO treatment.

For these experiments, female SOD1 mice were

ovariectomized between 30 and 40 days of age, prior to reaching sexual maturity and
subsequent exposure to sex hormones. Intraperitoneal injections of saline were administered
once a week starting at 50 ± 2 days of age and mice were euthanized at 70 ± 2 days of age.
Metabolic profiles of these mice were compared to those obtained from SOD1 females treated
with saline that had not undergone ovariectomy to understand how metabolism was affected by
removal of sex hormones.
Ovariectomized SOD1 females have altered glutamine metabolism when compared to
SOD1 females with intact ovaries.

Table 3.3.5.1 compares the activity levels of enzymes

involved in glutamine and ammonia metabolism from 70 day old female SOD1 mice that had
their ovaries removed to those from female SOD1 mice with intact ovaries.

As shown in

Chapter 2, SOD1 females that have undergone ovariectomy no longer respond to MSO
treatment and those treated with saline show no change in lifespan. When compared to normal
SOD1 females treated with saline, 70 day old ovariectomized SOD1 females have significantly
lower levels of brain glutamine synthetase activity and elevated brain glutaminase activity.
These mice also exhibit significantly lower levels of liver glutamine synthetase activity. The
average specific activity of CPSI from ovariectomized female SOD1 mice is lower than that of
females with intact ovaries, but this difference did not reach significance.
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Table 3.3.5.1 The effects of ovariectomization on enzyme activity in SOD1 females.

Enzyme activities are expressed as average specific activity (S.E.M.) in nmoles/minute/mg
protein. OVR indicates ovariectomized females.
n (OVR, SOD1) = 7-10
n (SOD1) = 8-12
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Ovariectomized female SOD1 mice treated with saline exhibit a different plasma
metabolite profile than non-ovariectomized female SOD1 mice. Table 3.3.5.2 lists the plasma
metabolites that differ significantly between 70 day old ovariectomized and non-ovariectomized
female SOD1 mice treated with saline. Ovariectomized female mice have slightly higher levels
of plasma ammonia than non-ovariectomized female mice however this difference did not reach
significance.

We do see that there are significant differences in several other plasma

metabolites in SOD1 females that have had their ovaries removed. Aspartate, proline, and
AAAA levels are elevated in plasma from ovariectomized SOD1 females, while threonine,
serine, sarcosine, lysine, and histidine are all significantly lower in ovariectomized SOD1
females. It is interesting to note that SOD1 females treated with saline show elevated levels of
plasma sarcosine when compared to their wild-type counterparts (Table 3.3.3.2) and that MSO
treatment lowers plasma sarcosine levels in these mice (Table 3.3.3.5), but ovariectomized
female SOD1 mice have undetectable levels of sarcosine in their plasma.
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Table 3.3.5.2 The effects of ovariectomization on plasma metabolite levels in SOD1 female
mice.

Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L with OVR indicating
ovariectomized female mice.
Amino acids highlighted in red are glucogenic and can be converted to glucose and glycogen.
Amino acids highlighted in blue are ketogenic and can be converted to acetoacetyl-CoA and/or
acetyl-CoA, while those in purple can be glucogenic or ketogenic.
* indicates essential amino acids.
†
indicates conditionally essential amino acids.
n (OVR SOD1) = 11
n (SOD1) = 7
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In general, we see a variety of changes take place in SOD1 females upon ovariectomy.
The specific activity of glutamine synthetase from both brain and liver is significantly lower, while
the specific activity of brain glutaminase is significantly higher, in ovariectomized female SOD1
mice treated with saline. In addition, the specific activity of liver CPSI is slightly lower in these
mice. Plasma ammonia levels are not significantly different from those of female SOD1 mice
with intact ovaries; however we do see several plasma metabolite differences in ovariectomized
female mice. Threonine, serine, sarcosine, lysine, and histidine levels in the plasma are all
significantly lower in ovariectomized female SOD1 mice compared to non-ovariectomized
female SOD1 mice, while aspartate, proline, and AAAA levels are significantly elevated.
Sarcosine is particularly interesting because it is elevated in SOD1 female mice with intact
ovaries and MSO treatment significantly lowers plasma levels of this metabolite.

In

ovariectomized females, sarcosine is undetectable in all of the mice tested.
3.4 Discussion
3.4.1 Glutamine Synthetase Activity in the CNS
The results obtained from glutamine synthetase activity assays performed on wild-type
and SOD1 brain and spinal cord homogenates show that there are no genotype-specific
differences in GS activity in presymptomatic mice. Untreated, 50 day old mice have brain and
spinal cord GS activity levels similar to those of saline-treated 70 day old mice, and all age
groups show that brain homogenates have higher levels of GS activity than spinal cord
homogenates.

This is probably due to a greater density of astrocytes, the primary GS-

expressing cell type, in the brain than spinal cord.

However, GS activity levels begin to

decrease after symptom onset in 110 day old saline-treated mice and SOD1 mice show
significantly lower GS activity levels in brain and spinal cord extracts. Studies conducted on
ALS mice show that GS expression does not change over the course of the disease and that
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enzyme activity is elevated in the lumbar spinal cords of end stage mice (120-150 days of age)
(Fray et al 2001). The results obtained from the current study show that GS activity in the whole
spinal cord of SOD1 mice is lower than that of wild-type mice. Studies performed on rat primary
astrocyte cultures have shown that the cytokine, TNFα, (which has been implicated in ALS
(Hensley et al 2003)) can reduce GS expression and inhibit glutamate-induced activation of the
enzyme (Zou et al 2010). In mouse models of ALS, TNFα mRNA expression has been shown
to increase until the terminal stages of the disease (Elliott 2001) and it is possible that the
decrease in GS activity seen in 110 day old saline-treated SOD1 mice may be due to gradually
increasing levels of TNFα production over the course of the disease. However, cytokine levels
would have to be measured at the same time intervals at which GS activity levels were
examined in order to correlate the decrease in GS activity levels to TNFα production.
When gender differences in GS activity levels were examined, presymptomatic mice (50
day untreated and 70 day old saline-treated animals) showed similar levels of GS activity in
males and females. However, symptomatic 110 day old saline-treated mice, which showed an
overall decrease in GS activity, also showed some gender-specific changes in GS activity. Male
SOD1 mice show significantly lower levels of brain GS activity, while female SOD1 mice show
significantly lower levels of spinal cord GS activity.

Since studies conducted in other

laboratories suggested that GS protein levels do not change over the course of the disease in
ALS mice (Fray et al 2001), GS expression was not examined. Microarray analysis of estradiol
treated mice showed that astrocyte-specific genes, including GS, are increased compared to
vehicle-treated controls (Mong & Blutstein 2006). Studies conducted on female rats and mice
show that female hormones increase GS expression in specific brain regions (arcuate nucleus,
ventromedial nucleus, amygdala, and hippocampus), but these studies did not examine enzyme
activity levels (Blutstein et al 2009; Blutstein et al 2006). These results suggest that there could
be region-specific differences in GS activity in female ALS mice, but since whole tissue
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homogenates (brain and spinal cord) were used to assay enzyme activity, these potential
differences were not observed. It is possible that female hormones that lead to increased levels
of GS protein expression in certain brain regions, may also lead to a corresponding increases in
enzyme activity, leading to the normalized levels of whole brain GS activity observed in SOD1
females. Low serum levels of free testosterone have been implicated in human ALS (Militello et
al 2002) and dihydrotestosterone treatment of ALS mice has been shown to increase lifespan
and ameliorate motor neuron and muscle degeneration that occurs during the disease (Yoo &
Ko 2012). However, studies on the developing rat brain showed that testosterone did not have
an impact on GS activity (Patel et al 1983). These studies also showed that female hormones
did not affect GS activity in the developing rat brain, suggesting that hormones may play a
greater role in the fully developed brain, but no studies examining the effects of testosterone on
GS activity could be found. Since ALS targets a subset of neurons, whole brain and spinal cord
homogenates may not be the best samples to use in order to examine enzyme activity. In order
to better understand potential gender-specific alterations in GS activity levels, enzyme activity
and expression levels should be examined in a region-specific manner.
Treatment with a single weekly i.p. injection of 20 mg/kg MSO showed that enzyme
activity was significantly decreased by approximately 90% in both brain and spinal cord
homogenates from SOD1 mice and their wild-type counterparts.

This observation was

consistent across age groups and 110 day old mice treated with MSO show the same levels of
inhibition as 70 day old mice treated with MSO. When examined for gender-specific changes in
GS activity with MSO treatment, male and female (wild-type and SOD1) mice show consistent
levels of GS activity. These results suggest that the gender-specific effects of MSO treatment
on survival of these mice observed in Chapter 2 are probably not entirely due to MSO’s ability to
inhibit glutamine synthetase, but may be due to some other effect of the drug.
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3.4.2 Glutaminase Activity in the Brain
The results obtained from the brain glutaminase activity assays show that there are no
significant differences in enzyme activity between wild-type and SOD1 mice. There are also no
clear gender-specific differences in glutaminase activity. Saline-treated male SOD1 mice at 70
days of age show significantly increased glutaminase activity levels when compared to female
SOD1 mice of the same age, but these differences are not observed in 50 day old mice or
postsymptomatic 110 day old mice. By 110 days of age, glutaminase activity in male SOD1
mice has decreased to levels similar to that of female SOD1 mice. In addition, MSO treatment
does not have an impact on glutaminase activity in wild-type or SOD1 mice and there are no
gender-specific differences in enzyme activity with treatment. Studies showing that estradiol
increases levels of GS protein levels in the female rat arcuate nucleus also show that
glutaminase protein levels increase with estradiol treatment (Blutstein et al 2009), but did not
examine enzyme activity levels. The results of these experiments do not show any increase in
activity in female mice. The lack of an effect of transgene expression as well as a treatment
effect on glutaminase activity suggests that glutaminase activity is not affected by mutant SOD1
protein and glutaminase does not play a role in MSO’s ability to prolong lifespan in this mouse
model.
3.4.3 Plasma Metabolite Analysis
3.4.3.1 Plasma Ammonia Levels
The assays measuring plasma ammonia levels show that untreated 50 day old SOD1
mice have elevated levels of plasma ammonia, suggesting that expression of the mutant
transgene alters ammonia metabolism in this mouse model. When gender differences were
examined, both male and female 50 day old untreated SOD1 mice show elevated average
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plasma ammonia levels but only female ammonia levels reached significance. This elevation in
plasma ammonia disappears in 70 day old mice, as saline-treated SOD1 mice have levels of
ammonia similar to those of wild-type mice at this age. Plasma ammonia levels in 70 day old
saline-treated wild-type and SOD1 mice are also significantly lower than the levels seen in 50
day untreated mice, suggesting that elevations in ammonia in young animals may have
something to do with development as mice are just reaching sexual maturity at the 50 day time
point. Gender differences in plasma ammonia levels at 50 days of age also disappear in salinetreated 70 day old animals and all genders show similar levels of plasma ammonia.
MSO treatment significantly increases plasma ammonia levels in both wild-type and
SOD1 animals.

When broken down by gender the same trend is observed in all groups

examined, including male wild-type mice which have lower levels of plasma ammonia than any
other group, with and without MSO treatment.

Elevations in plasma ammonia with MSO

treatment were expected since the drug irreversibly inhibits the incorporation of ammonia into
glutamine, and therefore prevents it from being transported to the liver as glutamine for proper
removal.
3.4.1.2 Plasma Metabolites in 50 Day Untreated Mice
The plasma metabolite profile of 50 day old untreated animals shows that several
metabolites differ between wild-type and SOD1 mice. Most of these metabolite differences are
due to SOD1 animals having significantly lower levels of various metabolites than wild-type
mice. Several of the metabolites that are significantly lower in SOD1 mice are associated with
the urea cycle, specifically urea, aspartate, citrulline, and arginine.

The fact that urea is

significantly lower in plasma collected from 50 day untreated SOD1 mice corresponds to the
observation that ammonia levels in these animals are elevated and suggests that ammonia is
not being incorporated into urea, implying an underlying defect in the urea cycle.

Plasma
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glutamine, a precursor of both ammonia and glutamate, is elevated in these mice and could
indicate an increase in glutamine uptake from the diet, as glutamine synthetase activity was not
elevated in these animals. It is interesting to note that the average plasma levels of glutamate
and ornithine, which are also involved in the urea cycle, are also slightly lower in SOD1 mice,
but these levels do not reach significance (see Appendix A).
In addition to urea cycle intermediates, several other plasma metabolites are altered in
SOD1 mice.

Phosphoserine, phosphoethanolamine, cystine, methionine, and lysine are all

significantly lower in plasma from SOD1 mice when compared to their wild-type counterparts,
while asparagine levels are elevated.

Six of the metabolites that are significantly altered

(aspartate, asparagine, cystine, methionine, and arginine) are glucogenic amino acids that can
be used as a carbon source to produce glucose.

Since most of these metabolites are

significantly lower in the plasma of SOD1 mice, this could suggest changes in the rate of
gluconeogenesis in this model. Hindlimb suspension loading is a common technique used in
rats to simulate the weightlessness experienced during space flights (Morey-Holton & Globus
2002). This method induces muscular atrophy, as rats are positioned in such a way that their
hindlimbs no longer support their body weight, and recent research has shown that the rate of
gluconeogenesis in these rats is elevated in a time-dependent manner (Bederman et al 2012).
It is possible that SOD1 mice experience an increase in gluconeogenesis associated with
muscle atrophy, leading to an overall reduction in the levels of certain glucogenic amino acids in
the plasma. These animals may experience insulin resistance or some other problem utilizing
glucose obtained from the diet and may resort to using amino acids as fuel.

Both insulin

resistance and biomarkers suggestive of insulin resistance have been observed in ALS patients
(Gonzalez de Aguilar et al 2005; Pradat et al 2010). ALS mice have been shown to have a
significantly lower body mass than their wild-type littermates, decreased plasma levels of leptin
and insulin, and increased plasma levels of corticosterone suggestive of global metabolic
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defects (Dupuis et al 2004).

Data obtained from human ALS studies suggests that

hypermetabolism may occur in patients, as a low body-mass is typically observed in patients
suffering from the disease (Desport et al 1999; Vaisman et al 2009) and worsens with
progression (Desport et al 2000; Kasarskis et al 1996; Wijesekera & Leigh 2009). In addition to
low body-mass, ALS patients also show increased levels of energy expenditure (Desport et al
2001; Desport et al 2005; Funalot et al 2009) further supporting the idea of impaired metabolism
as a factor in ALS.
One interesting finding from these studies is that SOD1 mice appear to have a cysteine
deficiency, as cystine levels were undetectable in all but one 50 day old SOD1 plasma sample.
These results have serious implications for oxidative damage during the disease due to
impaired glutathione synthesis, as cysteine is one of the three amino acids that make up the
antioxidant tripeptide. Oxidative damage has been implicated in the progression of ALS and
mutant SOD1 mice deficient in a subunit of γ-glutamylcysteine ligase (the first enzyme in
glutathione synthesis catalyzing the condensation of cysteine and glutamate) show a 55%
reduction in average lifespan (Vargas et al 2011). Cell culture models of the disease show that
motor neurons expressing mutant SOD1 protein under standard culture conditions have
significantly lower glutathione levels than those expressing wild-type SOD1 protein
(D'Alessandro et al 2011). It is possible that SOD1 mice have decreased glutathione levels due
to a lack of cysteine, which could exacerbate oxidative damage in sensitive neuronal cells.
Decreased levels of glutathione in SOD1 mice could further exacerbate amino acid uptake by
inhibiting the γ-glutamyl cycle, which has been shown to play a role in amino acid uptake in cells
of the intestine (Cornell & Meister 1976).

Follow up experiments to determine if the

undetectable levels of cystine in the plasma of SOD1 mice correlate with decreased levels of
glutathione and altered amino acid uptake must be performed.
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When plasma metabolite data from 50 day old untreated mice is further broken down
and analyzed based on gender, a different plasma metabolite profile emerges.

Plasma

glutamine levels remain elevated in both male and female SOD1 mice when compared to their
wild-type counterparts, but only female SOD1 mice show significantly lower citrulline, arginine,
and ornithine levels. Male SOD1 mice, however, show significantly lower plasma levels of
aspartate and urea. These gender-specific differences in plasma levels of urea cycle
intermediates suggest that the expression of the transgene alters the urea cycle differently
depending upon gender.

Cysteine levels, which are decreased in SOD1 mice, continue to be

significantly lower in these animals when gender is accounted for.
When plasma metabolite data from 50 day old mice are grouped by genotype and
gender differences are examined, there are several significant differences between males and
females of both genotypes. Wild-type animals show a wider range of gender differences in
plasma metabolites, with males showing significantly lower levels of several metabolites when
compared to females.

These data suggests that there are basic gender differences in

metabolism in nontransgenic mice. SOD1 mice, however, show fewer gender differences in
plasma metabolites and males show significantly higher levels of the metabolites that differ. It is
interesting to note that those metabolites that show gender differences in both wild-type and
SOD1 mice tend to be increased in wild-type females but decreased in SOD1 females. For
example, threonine levels are significantly higher in female wild-type mice compared to male
wild-type mice but are significantly lower in SOD1 female mice. The levels of threonine in male
mice of both genotypes are similar, suggesting that the changes observed are due to an overall
decrease in female SOD1 mice. A similar pattern is seen in citrulline levels, which are similar in
male mice of both genotypes, but lower in female SOD1 mice. Women have been shown to
have a lower resting metabolic rate than men (Arciero et al 1993), and as a result one might
expect to see slightly higher levels of metabolites in the plasma of female animals compared to
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males. However, in this SOD1 mouse model of ALS female mice show lower levels of certain
metabolites, that do not differ between male wild-type and SOD1 mice, suggesting higher rates
of utilization or impaired uptake of these substances. A list of all average plasma metabolite
levels and p values and all of the comparisons made of 50 day old untreated mice can be found
in Appendix A.
3.4.1.3 Plasma Metabolites in 70 Day Saline-treated Mice
Plasma metabolite levels from 70 day old saline-treated mice were examined to see how
metabolite profiles from older mice compared to those obtained from young, untreated mice and
to understand how wild-type and SOD1 mice differ. When comparing 70 day old saline-treated
wild-type and SOD1 mice, there are fewer differences in plasma metabolites than what was
observed in 50 day old mice. Phosphoethanolamine, aspartate, and cystine levels, which are
significantly lower in 50 day old SOD1 mice, continue to be low in 70 day old saline-treated
SOD1 mice. Cystine is completely undetectable in the plasma of 70 day old SOD1 mice and
may indicate that cysteine is not being properly absorbed from the diet, or that it is being utilized
faster than it can be absorbed by these mice.
Plasma levels of alanine and proline, which were not significantly different in 50 day old
SOD1 mice, are significantly lower and sarcosine (n-methylglycine) levels are significantly
higher in SOD1 plasma.

High levels of plasma glutamine and alterations in urea cycle

intermediates observed in 50 day old untreated mice are no longer seen in 70 day old salinetreated mice and may indicate the existence of compensatory mechanisms that normalize
metabolism in these animals. Alanine, however, can act as a carrier of the carbon skeleton of
pyruvate and of ammonia from muscle to the liver (Nelson & Cox 2008) and lower levels of
alanine in the plasma of SOD1 mice may be an early sign of alterations in muscle metabolism
prior to significant atrophy.

Sarcosine, which is an intermediate in glycine metabolism, is
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significantly higher in SOD1 plasma, with levels exceeding three times that found in wild-type
mice.

Sarcosine dehydrogenase is a tetrahydrofolate-binding enzyme responsible for the

production of glycine from sarcosine found in the matrix of liver mitochondria (Eschenbrenner &
Jorns 1999). Defects in this enzyme cause sarcosinemia and are associated with elevated
levels of sarcosine in the blood (Eschenbrenner & Jorns 1999). In the CNS sarcosine acts as a
natural agonist of glycine transporter 1 which increases the effect of glycine on NMDA receptors
and has been shown to have beneficial effects in patients suffering from schizophrenia when
added to antipsychotic treatments for the disorder (Tsai et al 2004). There are a variety of
factors that may play a role in elevating sarcosine levels in SOD1 mouse plasma. These mice
may have a defect in sarcosine dehydrogenase activity due to the expression of mutant SOD1
protein expression or due to a deficiency in folate. Folate deficiencies have been shown to lead
to increased levels of sarcosine in humans (Allen et al 1993) and treatment of SOD1 mice with
folate has been shown to delay the onset and progression of the disease (Zhang et al 2008).
When plasma metabolites were grouped by gender and compared based on genotype, a
different profile is seen in male and female mice, much like with 50 day old mice. Alterations in
phosphoethanolamine and sarcosine are specific to female SOD1 mice, while decreases in
glycine and alanine levels are specific to male SOD1 mice. Phosphoethanolamine is used to
make sphingomyelins, glycolipids involved in the production of membranes (Nelson & Cox
2008). Low levels of phosphoethanolamine in plasma may lead to problems in producing cell
membrane material in female SOD1 mice. Male SOD1 mice show low levels of glycine, which
acts as a coagonist of NMDA receptors during glutamatergic signaling, and may impair
excitatory synaptic signaling. Although it was not determined to be statistically significant by the
MANOVA, cystine levels continue to be undetectable in plasma from both male and female
SOD1 mice and may contribute to reduced glutathione levels and oxidative damage in ALS
mice.
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When plasma metabolite data are broken down by genotype and males and females are
compared, several gender differences in plasma metabolites can be observed in both wild-type
and SOD1 mice. Glutamine and histidine levels are similar in wild-type and SOD1 mice, with
females showing significantly higher plasma levels of glutamine. In SOD1 mice, urea levels are
significantly higher in male mice, while females show significantly higher levels of all other
plasma metabolites. Much like with 50 day old untreated mice, 70 day old saline-treated mice
show gender differences in metabolism. However, the alterations in urea cycle intermediates
are completely absent, with the exception of urea itself which is elevated in male SOD1 mice.
Plasma levels of ammonia in these mice show no gender differences and are actually much
lower than what is observed in 50 day old animals. These results suggest that between 50 and
70 days of age, compensatory mechanisms normalize nitrogen metabolism in SOD1 mice. A
list of all average plasma metabolite levels and p values and all of the comparisons made of 70
day old saline-treated mice can be found in Appendix A.
3.4.1.4 Plasma Metabolites in 70 Day MSO-treated Mice
Wild-type and SOD1 mice began a weekly treatment with either saline or MSO at
approximately 50 days of age and plasma was taken at approximately 70 ± 2 days of age,
resulting in animals receiving a total of 4 injections. Plasma metabolite levels were grouped by
genotype and treatment effects were examined.

Wild-type mice show only one significant

metabolite alteration with MSO treatment and that is in lysine levels, which increase
significantly.

This effect is also observed in SOD1 mice treated with MSO.

SOD1 mice,

however, have similar plasma lysine levels to wild-type mice with and without treatment and this
effect of MSO is probably not significant to the disease.

SOD1 mice show several other

changes in plasma metabolite levels with MSO treatment, despite this one similarity. MSO
treatment

significantly

increases

the

levels

of

a

variety

of

metabolites

including
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phosphoethanolamine, alanine, cystine, ornithine, and arginine.

Increased levels of

phosphoethanolamine and cystine in the plasma may allow these substances to be more
available for use in making membranes and glutathione respectively. It is important to note that
previous studies have shown that MSO increases glutathione levels in certain brain regions
(Ghoddoussi et al 2010), and this may be due to its ability to increase cysteine levels in the
plasma. Although the plasma metabolite profile of saline-treated mice did not suggest urea
cycle defects, MSO treatment increases levels of ornithine and arginine, two urea cycle
intermediates, and also significantly elevates plasma ammonia levels. Glutamine levels, which
were not found to differ in saline-treated SOD1 and wild-type mice, are significantly decreased
by MSO treatment in SOD1 mice.

Since MSO inhibits the enzyme responsible for the

production of glutamine, GS, it is not surprising to see a significant decrease in glutamine levels
in mice treated with MSO. Lower levels of glutamine may impair the immune response and
reduce neuroinflammation in ALS mice by starving immune cells of glutamine. Alanine levels,
which were found to be significantly lower in saline-treated SOD1 mice, are increased with MSO
treatment and may indicate a normalization of the alanine-glucose cycle.
When 70 day plasma metabolite data are broken down by gender and analyzed by
treatment, a variety of metabolite changes appear to be gender-specific. Female wild-type mice
show no significant alterations in plasma metabolite levels with MSO treatment, while female
SOD1 mice show decreases in plasma glutamine and sarcosine and increases in plasma
arginine levels. All plasma metabolites that are altered with MSO treatment in male wild-type
mice increase upon treatment.

A similar pattern is observed in male SOD1 mice, but the

metabolites that increase differ from those that increase in wild-type males. Although it is not
clear how all of these treatment-related changes in plasma metabolites impact the disease, it is
a start to understanding how MSO treatment extends the lifespan of ALS mice. Since many of
these metabolites show gender-specific alterations and MSO treatment alters plasma
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metabolites in a gender-specific fashion, it is possible that sex hormones may modulate
metabolic pathways affected by the drug therefore producing gender-specific effects in survival
and neuromuscular function.
Human and animal studies of circulating metabolite levels associated with ALS have
been conducted however these studies have not been done in a consistent manner and have
produced widely conflicting data. Cerebrospinal fluid (CSF), which circulates through the CNS,
may provide more information about metabolite changes due to neuroinflammation and
neurodegeneration in diseases of the CNS. CSF is difficult to obtain from animals and studies
of CSF from ALS patients have not provided the best data, as often times controls used in these
studies are patients with neurological disorders due to the difficulty of obtaining CSF from
healthy controls (Blin et al 1994; Iijima et al 1978; Patten et al 1978). As a result, better
information can be obtained from blood samples, which are easier to obtain from healthy
controls. However, many of the studies analyzing plasma or serum also use samples from
controls with other diseases. In a study which detected elevated levels of ornithine in the serum
of ALS patients, some of the controls used suffered from neuropathy and multiple sclerosis
(Patten et al 1978), diseases which are believed to have underlying mechanisms similar to
those thought to play a role in ALS. In another study in which plasma samples were examined,
patients were not clearly classified as having ALS (Iijima et al 1978) and may have had other
motor neuron diseases.

In addition to issues with experimental design many studies of ALS

patients include both genders, which are matched in control groups, but fail to examine gender
differences in the disease. As a result, most biochemical data collected on ALS patients comes
from ambiguous groups composed of both males and females and underlying gender
differences remain unclear.
The data presented here show that there are clear differences in plasma metabolites in
presymptomatic SOD1 mice when compared to their wild-type counterparts, suggesting that
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early metabolic defects (in 50 day old mice) play a role in, or are related to neurodegeneration in
this mouse model.

Some of the differences seen in plasma metabolites are gender-specific

and only appear when comparing wild-type and SOD1 mice by gender, suggesting that
expression of the transgene alters metabolism differently in male and female mice. In addition,
there are several metabolites that differ between male and female SOD1 mice, providing further
evidence of gender-specific metabolic effects of mutant SOD1 expression. There are also agerelated changes in plasma metabolites that indicate there may be some ability to compensate
for metabolic defects, at least in presymptomatic mice. In order to fully understand metabolic
abnormalities associated with the disease, these experiments should also be performed in mice
at the time of symptom onset, as well as in postsymptomatic animals. MSO’s ability to reverse
some of the changes in plasma metabolites in a gender-specific manner further supports the
idea that metabolic defects are involved in the disease progression and that gender is also an
important factor in the disease.
Several studies conducted with ALS patients provide evidence of metabolic defects in
the human disease, but it is unknown as to whether these defects are a direct result of the
disease itself or are present prior to development of the disease. Most studies conducted on
animal models of ALS focus on the central nervous system and there are only a few studies
available in which metabolism has been the primary focus. However, those studies that have
focused on metabolism in mouse models of ALS support the idea of metabolic defects playing a
role in the disease. It is important to note that gender is typically not discussed in studies of
ALS patients and mice, even though both genders have been studied. Most articles published
make note that patients and mice have been age and gender-matched, but data are not broken
down by gender resulting in a missing piece in the puzzle.
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3.4.1.5 Nitrogen Metabolism in the Liver
Carbamoyl phosphate synthetase I (CPSI) activity was measured in desalted liver
homogenates from both wild-type and SOD1 mice. At 50 days of age, CPSI activity in SOD1
mice does not differ significantly from that of wild-type mice, even though plasma metabolite
analysis shows that SOD1 mice have slightly lower levels of plasma urea and significantly
higher levels of plasma ammonia. CPSI is the rate-limiting enzyme in the urea cycle, but the
decrease in plasma levels of urea cycle intermediates and the finding that CPSI activity is not
affected by the SOD1 transgene suggests that there may be a problem with one of the other
enzymes in the cycle.

Decreased citrulline levels could indicate a problem with ornithine

transcarbamoylase, while decreased levels of arginine could indicate a decrease in activity of
arginosuccinate synthetase or arginosuccinate lyase. Although it was not determined to be
significant, ornithine levels are also slightly lower in these mice and could be an indicator of
decreased arginase activity.
When liver CPSI activity data are broken down by gender, 50 day old untreated females
of both genotypes have significantly higher activity levels than males. These results suggest
that in 50 day old mice, gender is a more important factor in determining CPSI activity than
transgene expression. Since CPSI is the rate-determining enzyme in the urea cycle, low activity
is expected to correlate with low levels of urea and elevated levels of other intermediates that
are not being consumed in the cycle but this trend is not observed in these mice. Only wild-type
mice show a gender difference in plasma urea levels, with males having higher urea levels than
females. In addition, wild-type females show elevated levels of citrulline compared to males
which would not be expected if the overall rate of the cycle is comparable to that of CPSI which
is high in females. SOD1 females, however, show decreased levels of ornithine and citrulline
compared to their male counterparts which would correlate with a higher rate of the urea cycle.
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More work needs to be done to fully characterize potential urea cycle defects and the role of
gender in neurodegeneration in this mouse model.
CPSI activity levels are significantly increased in 70 day old saline-treated mice
compared to 50 day old untreated mice of both genotypes, suggesting age-related changes in
activity occur. This corresponds to an overall decrease in plasma ammonia levels that are seen
in both wild-type and SOD1 mice treated with saline at 70 days of age. Mice in this age group
also no longer show significant alterations in plasma metabolites associated with the urea cycle.
Males of both genotypes continue to show significantly lower levels of CPSI activity in 70 day
old saline-treated mice; however it is at this point that SOD1 males start to show alterations in
CPSI activity. Saline-treated 70 day old male SOD1 mice not only have lower activity than
female SOD1 mice, but also show significantly lower CPSI activity than their wild-type
counterparts. The changes in plasma metabolite levels in 70 day old saline-treated male SOD1
mice do not correlate well with the changes in CPSI activity. In order to better understand if
these changes are disease-related, CPSI activity levels at later time points in postsymptomatic
or end stage animals should be examined.
It is possible that CPSI activity differences result from gender differences in allosteric
regulation of the enzyme. N-acetyl-L glutamate is an allosteric activator of the enzyme (Nelson
& Cox 2008) but a consistent amount of this activator was added to the reaction mixture and
should not cause gender-specific differences in activity levels, suggesting the presence of
another regulator of the enzyme.

Purine nucleotides, ornithine, and increased levels of

ammonia have been found to activate CPSI, while pyrimidine nucleotides and decreased ATP
levels have been found to inhibit the enzyme (Meister 1989). It could be that other genderspecific cycles that feed into the urea cycle are affected. MSO treatment has no effect on CPSI
activity levels, despite its ability to significantly increase plasma ammonia, ornithine, and
arginine levels. In addition, CPSI activity in the presence of MSO is unaffected by gender and
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expression of the transgene. MSO’s ability to extend the lifespan may be through its effects on
plasma metabolite levels, but it does not affect the urea cycle.
Liver glutamine synthetase activity levels were examined using the same samples that
were used to assay CPSI activity. The results of these assays in 50 day old untreated mice are
similar to those of brain GS activity, showing no differences between wild-type and SOD1 mice.
When broken down by gender, GS activity remains at about the same level across gender and
genotype. In 70 day old saline-treated mice, there are still no differences in GS activity between
wild-type and SOD1 mice, however there appear to be changes in GS activity in SOD1 male
mice. When the data are broken down by gender, male SOD1 mice show significantly lower
activity than female SOD1 mice and male wild-type mice, similar to the results of CPSI activity
assays in these mice. This suggests that nitrogen metabolism in the liver of male SOD1 mice
may start to decline prior to symptom onset. MSO treatment significantly decreases GS activity
in both wild-type and SOD1 mice and continues to significantly decrease GS activity when these
groups are further broken down by gender. However, MSO does not inhibit GS in male SOD1
mice to the same extent as the rest of the groups. MSO inhibits liver GS activity by about 85%
in all groups, except male SOD1 mice where it only inhibits GS activity by about 55%. This
further supports the idea that liver metabolism undergoes changes in presymptomatic male
SOD1 mice and may partially explain why male SOD1 mice have a shorter lifespan than female
SOD1 mice, as well as MSO’s reduced effect on increasing lifespan and neuromuscular function
in these mice.
Since ALS is a neurodegenerative disease and motor neurons are the primary target,
most research conducted in animal and human studies revolves around the central nervous
system. As a result, there are few studies that actually focus on global metabolism in animal
models of the disease. In studying transgenic animal models of disease, especially those that
ubiquitously express (or overexpress) a transgene throughout the body, it is important to not
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only study the major organ(s) affected but to also study organs outside of the target system.
This allows researchers to better understand the disease model and potential effects that can
occur in other organs upon expression of a transgene. It also provides researchers with the
ability to understand shortcomings of the model that may confound the results of studies
conducted on therapeutic interventions, as expression of transgenes that alter metabolism may
also impact the pharmacology of a drug. This being said, it is also important to consider gender
in these studies as sex hormones have the ability to alter the expression of a wide range of
genes and may also impact drug metabolism.
3.4.1.6 The Effects of Ovariectomization on Enzyme Activity and Plasma Metabolites
As shown in Chapter 2, removal of sex hormones in female mice through ovariectomy,
removes the MSO effect on survival. Ovariectomized SOD1 female mice treated with saline
have significantly lower levels of brain GS activity with a corresponding increase in brain
glutaminase activity. In addition to these changes in the CNS, ovariectomized SOD1 females
also exhibit significantly lower levels of liver glutamine synthetase activity and lower CPSI
activity levels.

These results suggest that estrogen has the ability to influence nitrogen

metabolism and that removing the ovaries, and subsequently estrogen, lowers activities of
several enzymes involved in nitrogen metabolism.
In addition to showing altered activity levels of enzymes involved in nitrogen metabolism,
ovariectomized female mice treated with saline have a different metabolic profile than their
normal female counterparts. Although the results are not considered to be significant, plasma
ammonia levels in ovariectomized SOD1 females are lower than those in SOD1 females with
intact ovaries.

There are also no significant alterations in urea cycle intermediates in

ovariectomized females in this age, which agrees with results obtained from other 70 day old
SOD1 mice. It is interesting to note that sarcosine levels, which are significantly increased in
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SOD1 females with intact ovaries and are lowered with MSO treatment, are completely
undetectable in ovariectomized mice. This suggests that changes in sarcosine levels in female
SOD1 mice may be part of the disease process and enzymes involved in sarcosine production
and breakdown should be examined in order to better understand its role in disease.
3.5 Future Experiments
The results of these biochemical studies show that the expression of the SOD1
transgene impacts plasma metabolite levels in this mouse model, but does not have much of an
impact on the nitrogen handling enzymes examined.

Young presymptomatic SOD1 mice

appear to have defects in nitrogen metabolism that are no longer observed in 70 day old mice,
suggesting that there are age related changes in metabolism of these mice. Gender also plays
a role in altering plasma metabolites and estrogen impacts nitrogen metabolizing enzymes as
well as plasma metabolites. It is not clear how MSO’s impact on plasma metabolites and
glutamine synthetase activity lead to an increase in lifespan in SOD1 mice, but estrogen
appears to facilitate its ability to extend the lifespan and suggests that MSO impacts estrogensensitive pathways.
GS and glutaminase data from older postsymptomatic mice aid in our understanding of
defective glutamine metabolism and treatment effects in this disease model, showing that brain
and spinal cord GS activity levels begin to decline later in the disease. While glutaminase
activity does not seem to be important, gender-specific age-related decreases in GS activity
may be important. Males show decreased activity in brain, while females show decreased
activity in spinal cord and these results may be important in explaining why females are able to
maintain grip strength with MSO treatment. Presymptomatic male SOD1 mice also show slight
alterations in liver GS (and CPSI) activity that may indicate the beginning of disease associated
metabolic perturbations. MSO is able to decrease the glutamine-glutamate cycle, leading to
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decreased glutamine and glutamate levels in specific brain regions (Ghoddoussi et al 2010),
and may further decrease levels of these chemicals in the spinal cords of female mice and allow
them to maintain neuromuscular connections. NMR examination of gender differences in spinal
cord chemicals must be done to understand if this may be part of MSO’s gender-specificity.
While we have data from the CNS of wild-type and SOD1 mice profiling the course of the
disease and treatment, we do not have liver enzyme and plasma metabolite data from older
mice and are missing part of the story.

Since there are age-related changes in plasma

ammonia and other metabolites, as well as CPSI activity and liver GS activity in SOD1 males,
these metabolite levels and enzyme activities could further change as the disease progresses.
For this reason, plasma metabolite profiles and liver enzyme activities should be examined in
these animals at later time points. It is possible that male metabolism declines faster than that
of females and plays a role in MSO’s gender-specific effects on survival. In addition, obtaining
these data from MSO-treated mice would provide more information about long-term effects of
treatment. Since muscle has been targeted as a major source of glutamine and undergoes
atrophy as the disease progresses, further studies should consider potential defects in muscle
metabolism as well.
Most of the research on MSO has focused on its ability to inhibit glutamine synthetase,
but other targets of the drug have been identified, such as alanine aminotransferase (Pace &
McDermott 1952), ornithine decarboxylase (Di Giacomo et al 1997), and γ-glutamylcysteine
synthetase (Richman et al 1973). In order to understand exactly how this drug works in ALS
mice, these targets should be further characterized.

Further characterization of γ-

glutamylcysteine synthetase is particularly important, as MSO has been shown to inhibit this
enzyme which catalyzes the first step in glutathione synthesis (Richman et al 1973) and our
early data shows that MSO treatment increases glutathione levels in specific brain regions
(Ghoddoussi et al 2010). Increasing glutathione levels in ALS is important to prevent oxidative
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damage, but this conflicting data about MSO’s ability to inhibit glutathione synthesis warrants
further examination.
MSO has been found to alter cytokine levels in a mouse model of acute liver failure
(Jambekar et al 2011) and since some immune cells have been shown to lack GS (Ardawi &
Newsholme 1983; Rohde et al 1996), there may be other potential targets of MSO that have yet
to be identified. Since neuroinflammation has been implicated to play a significant role in the
progression of ALS and peripheral immune cells (which require glutamine) have been found to
infiltrate the CNS, these cell types should be characterized to understand how MSO affects the
immune response in these mice. Basic gender differences in general immune responses have
been characterized and MSO’s impact on these cells may explain its gender-specific effects in
ALS mice.
There is a need to continue ALS research to better understand how motor neurons are
selectively killed, identify biomarkers of the disease for early detection, and to discover better
treatments capable of improving the quality of life of patients. These studies have shown that
MSO has the ability to extend the lifespan and alter plasma metabolites in the most common
mouse model of ALS in a gender-specific manner. Most research on MSO revolves around its
ability to inhibit GS, but it is apparent that its effects in the SOD1 G93A mouse model may
extend beyond its inhibitory effects on GS to other potential targets. In order to make the most
of MSO as a tool for elucidating mechanisms of ALS and other diseases, these other targets
must be identified and better characterized.
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APPENDIX A
50 DAY PLASMA METABOLITE COMPARISONS
Table A-1: List of all mean 50 day mouse plasma metabolite values grouped by genotype and
the corresponding p values obtained from the MANOVA.
WT

SOD1

Metabolite
Mean
SEM
Mean
Phser
14.43
0.84
6.76
Taur
464.48
33.18
429.15
Pea
11.55
1.27
5.57
Urea
9866.08
358.87
8088.85
Asp
18.03
1.51
11.32
Thr
182.68
8.27
161.74
Ser
150.80
5.09
140.31
Asn
38.98
2.09
47.83
Glu
35.32
4.40
26.26
Gln
560.08
13.21
676.66
Sarc
11.91
4.42
11.81
AAAA
25.83
3.16
21.44
Gly
298.53
7.31
285.10
Ala
577.76
23.95
672.69
Citr
109.36
4.91
87.14
Val
247.16
7.71
237.57
Cys
27.91
2.39
0.36
Met
87.38
5.84
65.47
Ile
87.20
3.50
94.00
Leu
144.72
5.12
153.71
Tyr
71.96
3.57
72.78
Phe
60.28
1.63
64.96
Orn
92.02
6.90
72.35
Lys
319.96
12.69
273.63
1-Mhis
11.18
1.16
11.65
His
70.48
2.22
62.56
Trp
59.16
5.74
53.49
Arg
122.45
8.41
86.84
Hypro
14.10
3.45
23.98
Pro
89.27
3.96
105.51
Amino acid levels are expressed as µmoles/L plasma.

SEM
1.24
36.75
2.00
696.89
0.87
12.57
7.29
4.03
2.56
37.19
5.27
3.73
12.89
66.76
5.46
22.61
0.36
7.01
5.91
11.28
5.19
3.13
8.80
16.00
1.17
3.61
9.04
7.51
3.68
10.73

p (MANOVA)
.000009
.488474
.012771
.019385
.001851
.156457
.232226
.041775
.125255
.002029
.988485
.378244
.338465
.136491
.005742
.648060
.000000
.022942
.300051
.426790
.893887
.158838
.085838
.029437
.787789
.057402
.581522
.005630
.065295
.116248
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Table A-2: List of all mean 50 day female plasma metabolite values grouped by genotype and
the corresponding p values obtained from the MANOVA.
WT Female
Mean
SEM

Metabolite
Phser
14.45
Taur
420.15
Pea
12.14
Urea
8,708.96
Asp
15.04
Thr
203.07
Ser
163.93
Asn
42.67
Glu
30.56
Gln
568.60
Sarc
16.02
AAAA
23.28
Gly
290.37
Ala
627.88
Citr
119.86
Val
247.54
Cys
23.32
Met
97.45
Ile
94.29
Leu
152.39
Tyr
79.45
Phe
62.73
Orn
99.00
Lys
356.96
1-Mhis
11.30
His
75.38
Trp
76.56
Arg
138.40
Hypro
9.57
Pro
94.27
Amino acid levels are expressed as

SOD1 Female
Mean
SEM

1.47
8.66
21.83
479.74
1.07
9.30
354.88
8,055.03
2.19
11.45
10.99
131.50
7.19
135.88
3.37
41.08
3.83
26.12
16.63
709.78
7.16
11.19
4.64
19.01
12.12
258.21
40.72
577.55
8.34
72.97
12.37
214.08
3.73
0.77
10.56
47.63
5.54
89.33
8.36
151.51
5.61
62.43
2.19
61.23
8.66
53.06
17.17
255.59
1.50
12.05
2.87
66.22
3.39
62.68
13.63
76.58
4.81
18.79
6.91
77.27
µmoles/L plasma.

1.54
66.56
3.32
450.50
1.42
16.26
13.60
5.71
5.18
74.95
7.43
6.10
22.06
137.36
7.40
18.73
0.77
6.17
8.10
14.46
7.85
5.40
8.53
24.42
2.15
6.47
13.67
11.60
6.91
10.86

p (MANOVA)
.020751
.337043
.356879
.271216
.245272
.002222
.067672
.802155
.493090
.044414
.659119
.581708
.188813
.684298
.001715
.142795
.000329
.003493
.608021
.955598
.092612
.773206
.003171
.003866
.771866
.168983
.257627
.006908
.278058
.187351
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Table A-3: List of all mean 50 day male plasma metabolite values grouped by genotype and the
corresponding p values obtained from the MANOVA.
WT Male
Mean
SEM

Metabolite
Phser
14.40
Taur
504.37
Pea
11.02
Urea
10907.49
Asp
20.73
Thr
164.34
Ser
138.98
Asn
35.65
Glu
39.61
Gln
552.41
Sarc
8.21
AAAA
28.13
Gly
305.88
Ala
532.65
Citr
99.90
Val
246.82
Cys
32.04
Met
78.31
Ile
80.82
Leu
137.81
Tyr
65.22
Phe
58.07
Orn
85.73
Lys
286.65
1-Mhis
11.08
His
66.08
Trp
43.50
Arg
108.09
Hypro
18.17
Pro
84.78
Amino acid levels are expressed as

SOD1 Male
Mean
SEM

0.96
5.13
58.56
385.80
2.28
2.37
366.39
8117.83
1.76
11.20
9.19
187.67
4.92
144.10
2.21
53.62
7.59
26.38
20.70
648.27
5.47
12.33
4.42
23.51
8.56
308.14
19.39
754.24
3.88
99.29
10.17
257.71
2.58
0.00
4.62
80.77
3.51
98.01
5.72
155.59
3.55
81.65
2.25
68.15
10.57
88.89
10.76
289.10
1.82
11.30
2.76
59.43
7.64
45.61
8.47
95.65
4.78
28.43
4.10
129.72
µmoles/L plasma.

1.75
34.25
1.82
1287.87
1.15
12.48
7.75
4.98
2.28
28.90
7.97
4.85
8.79
26.03
4.30
38.76
0.00
8.41
8.78
17.94
5.26
3.44
11.71
20.95
1.31
3.85
12.15
9.25
2.98
11.49

p (MANOVA)
.000158
.140181
.014574
.028406
.000977
.143889
.566131
.002285
.177657
.014115
.664111
.499483
.860338
.000004
.919093
.754715
.000000
.786531
.058409
.293354
.016576
.021428
.846077
.911321
.929296
.169528
.879071
.344685
.122502
.000764
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Table A-4: List of all mean 50 day wild-type mouse plasma metabolite values grouped by
gender and the corresponding p values obtained from the MANOVA.
WT Female
Mean
SEM

WT Male
Mean
SEM

Metabolite
Phser
14.45
1.47
14.40
Taur
420.15
21.83
504.37
Pea
12.14
1.07
11.02
Urea
8708.96
354.88
10907.49
Asp
15.04
2.19
20.73
Thr
203.07
10.99
164.34
Ser
163.93
7.19
138.98
Asn
42.67
3.37
35.65
Glu
30.56
3.83
39.61
Gln
568.60
16.63
552.41
Sarc
16.02
7.16
8.21
AAAA
23.28
4.64
28.13
Gly
290.37
12.12
305.88
Ala
627.88
40.72
532.65
Citr
119.86
8.34
99.90
Val
247.54
12.37
246.82
Cys
23.32
3.73
32.04
Met
97.45
10.56
78.31
Ile
94.29
5.54
80.82
Leu
152.39
8.36
137.81
Tyr
79.45
5.61
65.22
Phe
62.73
2.19
58.07
Orn
99.00
8.66
85.73
Lys
356.96
17.17
286.65
1-Mhis
11.30
1.50
11.08
His
75.38
2.87
66.08
Trp
76.56
3.39
43.50
Arg
138.40
13.63
108.09
Hypro
9.57
4.81
18.17
Pro
94.27
6.91
84.78
Amino acid levels are expressed as µmoles/L plasma.

0.96
58.56
2.28
366.39
1.76
9.19
4.92
2.21
7.59
20.70
5.47
4.42
8.56
19.39
3.88
10.17
2.58
4.62
3.51
5.72
3.55
2.25
10.57
10.76
1.82
2.76
7.64
8.47
4.78
4.10

p (MANOVA)
.977777
.214180
.671958
.000496
.056956
.014481
.009668
.093654
.318440
.555787
.392743
.459507
.302800
.043338
.038316
.963949
.067127
.103217
.051072
.161014
.042666
.157474
.351418
.002484
.929766
.032326
.001420
.070387
.223317
.242627
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Table A-5: List of all mean 50 day SOD1 mouse plasma metabolite values grouped by gender
and the corresponding p values obtained from the MANOVA.
SOD1 Female
SOD1 Male
Metabolite
Mean
SEM
Mean
SEM
Phser
8.66
1.54
5.13
1.75
Taur
479.74
66.56
385.80
34.25
Pea
9.30
3.32
2.37
1.82
Urea
8055.03
450.50
8117.83
1287.87
Asp
11.45
1.42
11.20
1.15
Thr
131.50
16.26
187.67
12.48
Ser
135.88
13.60
144.10
7.75
Asn
41.08
5.71
53.62
4.98
Glu
26.12
5.18
26.38
2.28
Gln
709.78
74.95
648.27
28.90
Sarc
11.19
7.43
12.33
7.97
AAAA
19.01
6.10
23.51
4.85
Gly
258.21
22.06
308.14
8.79
Ala
577.55
137.36
754.24
26.03
Citr
72.97
7.40
99.29
4.30
Val
214.08
18.73
257.71
38.76
Cys
0.77
0.77
0.00
0.00
Met
47.63
6.17
80.77
8.41
Ile
89.33
8.10
98.01
8.78
Leu
151.51
14.46
155.59
17.94
Tyr
62.43
7.85
81.65
5.26
Phe
61.23
5.40
68.15
3.44
Orn
53.06
8.53
88.89
11.71
Lys
255.59
24.42
289.10
20.95
1-Mhis
12.05
2.15
11.30
1.31
His
66.22
6.47
59.43
3.85
Trp
62.68
13.67
45.61
12.15
Arg
76.58
11.60
95.65
9.25
Hypro
18.79
6.91
28.43
2.98
Pro
77.27
10.86
129.72
11.49
Amino acid levels are expressed as µmoles/L plasma.

p (MANOVA)
.165966
.216216
.082722
.966461
.891300
.017791
.596319
.124567
.961401
.433670
.919352
.570300
.047675
.199172
.008607
.358363
.299690
.010443
.488275
.865850
.060810
.288759
.035433
.316951
.765144
.370413
.369072
.219672
.203275
.007326
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APPENDIX B
70 DAY SALINE TREATMENT PLASMA METABOLITE COMPARISONS
Table B-1: List of all mean 70 day saline-treated mouse plasma metabolite values grouped by
genotype and the corresponding p values obtained from the MANOVA.
WT
Metabolite
Mean
Phser
9.61
Taur
328.23
Pea
6.11
Urea
10638.12
Asp
13.06
Thr
200.01
Ser
162.33
Asn
50.48
Glu
14.89
Gln
585.30
Sarc
9.33
AAAA
14.70
Gly
314.52
Ala
720.05
Citr
91.99
Val
311.94
Cys
13.34
Met
98.30
Ile
109.92
Leu
186.02
Tyr
81.54
Phe
73.09
Orn
87.76
Lys
290.03
1-Mhis
12.58
His
74.71
Trp
63.11
Arg
108.90
Hypro
25.60
Pro
116.87
Amino acid levels are expressed as

SOD1
SEM
Mean
2.69
6.09
19.93
320.02
1.74
1.12
460.47
10526.52
1.38
9.15
16.49
183.01
10.15
144.39
5.41
42.92
3.65
10.31
27.18
593.91
5.38
32.38
2.83
10.63
11.57
282.61
52.53
593.61
6.94
80.81
24.77
266.01
5.45
0.00
12.32
82.12
9.01
97.40
15.46
163.87
5.93
73.24
4.88
66.56
11.50
73.53
18.13
280.22
1.16
10.91
2.89
72.94
5.69
57.25
8.30
100.60
6.92
21.00
10.32
75.54
µmoles/L plasma.

SEM
0.97
26.23
0.61
433.47
0.35
7.90
5.37
2.77
3.19
23.94
5.12
1.37
19.13
32.61
3.63
16.11
0.00
6.89
5.14
8.36
5.06
2.21
5.88
18.74
1.35
4.16
8.15
7.59
4.25
11.55

p (MANOVA)
.203497
.810515
.008322
.861584
.006977
.339951
.116629
.206180
.352352
.813428
.004920
.188492
.183576
.045629
.150177
.123330
.013968
.245710
.222863
.202357
.293833
.213174
.261826
.712566
.366192
.738541
.573419
.467178
.564548
.014711
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Table B-2: List of all mean 70 day saline-treated female plasma metabolite values grouped by
genotype and the corresponding p values obtained from the MANOVA.
WT Female
SOD1 Female
Metabolite
Mean
SEM
Mean
SEM
Phser
12.69
5.17
5.51
1.32
Taur
374.83
20.66
348.69
37.23
Pea
11.21
1.40
1.61
1.06
Urea
10150.32
674.15
9447.01
548.05
Asp
13.26
2.35
9.15
0.60
Thr
204.22
30.26
189.55
11.37
Ser
173.98
18.82
151.72
6.30
Asn
56.77
9.42
47.09
3.20
Glu
21.43
5.23
9.55
3.73
Gln
638.99
34.74
646.85
25.91
Sarc
8.90
5.65
37.80
4.86
AAAA
16.12
5.42
11.17
2.71
Gly
303.57
18.83
283.98
39.44
Ala
766.50
102.31
665.88
31.81
Citr
94.21
13.68
84.35
5.54
Val
334.47
41.53
256.47
18.31
Cys
12.43
7.87
0.00
0.00
Met
109.82
18.49
85.19
12.46
Ile
123.89
14.72
102.74
5.14
Leu
210.02
25.28
170.36
9.44
Tyr
84.11
10.23
82.94
6.18
Phe
79.47
8.04
71.48
2.11
Orn
104.78
18.71
74.15
7.35
Lys
317.58
32.62
318.41
17.80
1-Mhis
15.07
1.41
12.13
1.58
His
81.79
3.31
81.73
6.61
Trp
76.07
7.38
71.92
12.69
Arg
119.42
14.41
114.79
8.33
Hypro
18.35
8.31
13.98
5.14
Pro
121.12
20.34
70.32
19.24
Amino acid levels are expressed as µmoles/L plasma.

p (MANOVA)
.176331
.570488
.000168
.430534
.095743
.639083
.256377
.321511
.085281
.856985
.002455
.410276
.679888
.336704
.494238
.097265
.113579
.280868
.176130
.146637
.921283
.323679
.134400
.981690
.198615
.994224
.792300
.777886
.653207
.097402
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Table B-3: List of all mean 70 day saline-treated male plasma metabolite values grouped by
genotype and the corresponding p values obtained from the MANOVA.
WT Male
SOD1 Male
Metabolite
Mean
SEM
Mean
SEM
Phser
6.53
1.14
6.66
1.50
Taur
281.63
21.25
291.36
36.36
Pea
1.02
1.02
0.63
0.63
Urea
11125.92
619.10
11606.02
354.13
Asp
12.86
1.68
9.14
0.41
Thr
195.79
16.55
176.47
11.26
Ser
150.69
6.72
137.06
8.20
Asn
44.20
4.91
38.76
4.14
Glu
8.34
3.75
11.07
5.48
Gln
531.61
29.86
540.98
29.63
Sarc
9.77
9.77
26.97
8.95
AAAA
13.29
2.27
10.10
0.84
Gly
325.48
13.66
281.24
5.40
Ala
673.60
28.49
521.33
43.07
Citr
89.76
4.80
77.27
4.71
Val
289.40
27.79
275.55
27.55
Cys
14.25
8.28
0.00
0.00
Met
86.78
16.53
79.05
6.87
Ile
95.95
7.91
92.07
8.86
Leu
162.02
13.50
157.39
14.14
Tyr
78.98
6.87
63.54
6.43
Phe
66.70
4.90
61.65
2.94
Orn
70.73
10.78
72.91
9.78
Lys
262.49
8.92
242.03
26.80
1-Mhis
10.09
1.22
9.68
2.23
His
67.63
2.41
64.16
2.34
Trp
50.16
4.57
42.58
7.40
Arg
98.38
7.17
86.41
10.63
Hypro
32.85
10.99
28.02
5.96
Pro
112.63
6.91
80.76
14.11
Amino acid levels are expressed as µmoles/L plasma.

p (MANOVA)
.950618
.829347
.742623
.499072
.040910
.343616
.234856
.411383
.699702
.828905
.220481
.189239
.008551
.016112
.091535
.731536
.087854
.656922
.753571
.818810
.129326
.379318
.883197
.513198
.880259
.324544
.421331
.387605
.694851
.081212
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Table B-4: List of all mean 70 day saline-treated wild-type mouse plasma metabolite values
grouped by gender and the corresponding p values obtained from the MANOVA.
WT Female
WT Male
Metabolite
Mean
SEM
Mean
Phser
12.69
5.17
6.53
Taur
374.83
20.66
281.63
Pea
11.21
1.40
1.02
Urea
10150.32
674.15
11125.92
Asp
13.26
2.35
12.86
Thr
204.22
30.26
195.79
Ser
173.98
18.82
150.69
Asn
56.77
9.42
44.20
Glu
21.43
5.23
8.34
Gln
638.99
34.74
531.61
Sarc
8.90
5.65
9.77
AAAA
16.12
5.42
13.29
Gly
303.57
18.83
325.48
Ala
766.50
102.31
673.60
Citr
94.21
13.68
89.76
Val
334.47
41.53
289.40
Cys
12.43
7.87
14.25
Met
109.82
18.49
86.78
Ile
123.89
14.72
95.95
Leu
210.02
25.28
162.02
Tyr
84.11
10.23
78.98
Phe
79.47
8.04
66.70
Orn
104.78
18.71
70.73
Lys
317.58
32.62
262.49
1-Mhis
15.07
1.41
10.09
His
81.79
3.31
67.63
Trp
76.07
7.38
50.16
Arg
119.42
14.41
98.38
Hypro
18.35
8.31
32.85
Pro
121.12
20.34
112.63
Amino acid levels are expressed as µmoles/L plasma.

SEM
1.14
21.25
1.02
619.10
1.68
16.55
6.72
4.91
3.75
29.86
9.77
2.27
13.66
28.49
4.80
27.79
8.28
16.53
7.91
13.50
6.87
4.90
10.78
8.92
1.22
2.41
4.57
7.17
10.99
6.91

p (MANOVA)
.272281
.010420
.000153
.311531
.892935
.811674
.270784
.263843
.069329
.041048
.939669
.640832
.368476
.402286
.765163
.388342
.876291
.374679
.125514
.124917
.686404
.205039
.145856
.134341
.023584
.006124
.013659
.220204
.317249
.700712
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Table B-5: List of all mean 70 day saline-treated SOD1 mouse plasma metabolite values
grouped by gender and the corresponding p values obtained from the MANOVA.
SOD1 Female
SOD1 Male
Metabolite
Mean
SEM
Mean
SEM
Phser
5.51
1.32
6.66
1.50
Taur
348.69
37.23
291.36
36.36
Pea
1.61
1.06
0.63
0.63
Urea
9447.01
548.05
11606.02
354.13
Asp
9.15
0.60
9.14
0.41
Thr
189.55
11.37
176.47
11.26
Ser
151.72
6.30
137.06
8.20
Asn
47.09
3.20
38.76
4.14
Glu
9.55
3.73
11.07
5.48
Gln
646.85
25.91
540.98
29.63
Sarc
37.80
4.86
26.97
8.95
AAAA
11.17
2.71
10.10
0.84
Gly
283.98
39.44
281.24
5.40
Ala
665.88
31.81
521.33
43.07
Citr
84.35
5.54
77.27
4.71
Val
256.47
18.31
275.55
27.55
Cys
0.00
0.00
0.00
0.00
Met
85.19
12.46
79.05
6.87
Ile
102.74
5.14
92.07
8.86
Leu
170.36
9.44
157.39
14.14
Tyr
82.94
6.18
63.54
6.43
Phe
71.48
2.11
61.65
2.94
Orn
74.15
7.35
72.91
9.78
Lys
318.41
17.80
242.03
26.80
1-Mhis
12.13
1.58
9.68
2.23
His
81.73
6.61
64.16
2.34
Trp
71.92
12.69
42.58
7.40
Arg
114.79
8.33
86.41
10.63
Hypro
13.98
5.14
28.02
5.96
Pro
70.32
19.24
80.76
14.11
Amino acid levels are expressed as µmoles/L plasma.

p (MANOVA)
.578220
.292147
.442753
.006238
.988134
.429462
.181758
.136933
.822609
.019677
.308812
.714570
.946299
.019310
.349278
.574656
.673958
.318172
.460239
.050202
.018749
.921026
.035161
.387300
.027537
.068969
.057390
.099441
.669325
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APPENDIX C
70 DAY PLASMA MSO-TREATED METABOLITE COMPARISONS
Table C-1: List of all mean 70 day wild-type mouse plasma metabolite values grouped by
treatment and the corresponding p values obtained from the MANOVA.
WT Saline
WT MSO
Metabolite
Mean
SEM
Mean
SEM
Phser
9.61
2.69
11.43
1.57
Taur
328.23
19.93
395.99
41.42
Pea
6.11
1.74
9.12
1.82
Urea
10638.12
460.47
9146.05
582.81
Asp
13.06
1.38
14.83
1.13
Thr
200.01
16.49
218.26
13.05
Ser
162.33
10.15
176.67
11.16
Asn
50.48
5.41
53.13
4.00
Glu
14.89
3.65
18.79
4.19
Gln
585.30
27.18
557.24
39.21
Sarc
9.33
5.38
10.23
5.42
AAAA
14.70
2.83
16.05
2.77
Gly
314.52
11.57
301.65
19.93
Ala
720.05
52.53
844.44
70.01
Citr
91.99
6.94
96.57
4.91
Val
311.94
24.77
285.58
15.05
Cys
13.34
5.45
26.66
5.34
Met
98.30
12.32
96.64
8.00
Ile
109.92
9.01
107.41
5.43
Leu
186.02
15.46
177.73
8.50
Tyr
81.54
5.93
89.45
6.28
Phe
73.09
4.88
72.20
2.75
Orn
87.76
11.50
86.27
7.31
Lys
290.03
18.13
352.86
17.99
1-Mhis
12.58
1.16
10.83
1.51
His
74.71
2.89
77.23
4.06
Trp
63.11
5.69
50.43
8.38
Arg
108.90
8.30
112.78
7.57
Hypro
25.60
6.92
22.87
4.05
Pro
116.87
10.32
117.75
9.54
Amino acid levels are expressed as µmoles/L plasma.

p (MANOVA)
.574738
.144739
.246880
.055629
.337382
.400963
.351772
.701964
.487941
.557242
.907711
.739149
.574421
.165522
.601330
.384131
.096435
.913104
.817321
.651767
.369783
.879171
.916251
.022960
.364649
.613876
.217336
.735051
.742757
.951244
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Table C-2: List of all mean 70 day SOD1 mouse plasma metabolite values grouped by
treatment and the corresponding p values obtained from the MANOVA.
SOD1 Saline
SOD1 MSO
Metabolite
Mean
SEM
Mean
SEM
Phser
6.09
0.97
7.09
1.58
Taur
320.02
26.23
356.80
17.70
Pea
1.12
0.61
4.68
1.16
Urea
10526.52
433.47
9882.69
432.57
Asp
9.15
0.35
10.40
0.80
Thr
183.01
7.90
209.75
13.59
Ser
144.39
5.37
153.77
7.17
Asn
42.92
2.77
56.49
4.05
Glu
10.31
3.19
17.95
3.40
Gln
593.91
23.94
449.48
29.23
Sarc
32.38
5.12
18.30
3.36
AAAA
10.63
1.37
17.60
1.69
Gly
282.61
19.13
275.32
10.37
Ala
593.61
32.61
743.30
35.23
Citr
80.81
3.63
89.36
4.95
Val
266.01
16.11
302.59
19.68
Cys
0.00
0.00
5.29
2.10
Met
82.12
6.89
96.24
6.69
Ile
97.40
5.14
105.77
4.69
Leu
163.87
8.36
180.33
7.42
Tyr
73.24
5.06
80.91
5.05
Phe
66.56
2.21
70.29
2.72
Orn
73.53
5.88
99.46
7.98
Lys
280.22
18.74
358.42
24.71
1-Mhis
10.91
1.35
9.47
0.75
His
72.94
4.16
73.37
2.40
Trp
57.25
8.15
70.90
6.15
Arg
100.60
7.59
137.16
10.36
Hypro
21.00
4.25
17.40
3.77
Pro
75.54
11.55
96.70
11.63
Amino acid levels are expressed as µmoles/L plasma.

p (MANOVA)
.603230
.244954
.014200
.304200
.184506
.112417
.315400
.011917
.115627
.000808
.025673
.003925
.731411
.004517
.185241
.168868
.025781
.153442
.238197
.150689
.294171
.305675
.016463
.020121
.344738
.927951
.185516
.009664
.529625
.209456
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Table C-3: List of all mean 70 day female wild-type mouse plasma metabolite values grouped
by treatment and the corresponding p values obtained from the MANOVA.
Female Saline
Female MSO
Metabolite
Mean
SEM
Mean
SEM
Phser
12.69
5.17
9.70
2.22
Taur
374.83
20.66
341.62
18.91
Pea
11.21
1.40
9.19
2.39
Urea
10150.32
674.15
8484.25
918.68
Asp
13.26
2.35
13.28
1.72
Thr
204.22
30.26
219.89
24.17
Ser
173.98
18.82
185.62
17.78
Asn
56.77
9.42
55.01
6.65
Glu
21.43
5.23
10.49
3.35
Gln
638.99
34.74
587.33
68.26
Sarc
8.90
5.65
12.24
8.08
AAAA
16.12
5.42
14.28
3.45
Gly
303.57
18.83
267.03
26.05
Ala
766.50
102.31
888.13
100.72
Citr
94.21
13.68
104.92
7.38
Val
334.47
41.53
262.41
18.10
Cys
12.43
7.87
26.71
8.24
Met
109.82
18.49
92.11
14.14
Ile
123.89
14.72
106.26
6.78
Leu
210.02
25.28
169.97
11.29
Tyr
84.11
10.23
89.77
10.82
Phe
79.47
8.04
71.71
3.69
Orn
104.78
18.71
73.23
9.60
Lys
317.58
32.62
377.58
24.88
1-Mhis
15.07
1.41
12.52
2.43
His
81.79
3.31
83.07
2.54
Trp
76.07
7.38
67.40
4.96
Arg
119.42
14.41
117.80
9.74
Hypro
18.35
8.31
19.72
4.55
Pro
121.12
20.34
104.63
11.38
Amino acid levels are expressed as µmoles/L plasma.

p (MANOVA)
.607096
.262994
.483439
.174415
.994428
.694414
.662636
.881851
.108579
.515227
.741493
.781273
.282248
.416684
.506795
.142788
.238523
.464140
.302071
.178631
.711799
.400919
.164447
.174306
.385520
.764741
.352589
.927223
.887539
.495285
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Table C-4: List of all mean 70 day female SOD1 mouse plasma metabolite values grouped by
treatment and the corresponding p values obtained from the MANOVA.
Female Saline
Female MSO
Metabolite
Mean
SEM
Mean
SEM
Phser
5.51
1.32
6.27
1.49
Taur
348.69
37.23
382.35
31.45
Pea
1.61
1.06
3.63
1.59
Urea
9447.01
548.05
9802.29
421.67
Asp
9.15
0.60
9.03
0.61
Thr
189.55
11.37
221.53
21.19
Ser
151.72
6.30
165.77
10.15
Asn
47.09
3.20
61.10
6.39
Glu
9.55
3.73
13.13
5.43
Gln
646.85
25.91
465.34
45.07
Sarc
37.80
4.86
20.18
4.86
AAAA
11.17
2.71
18.44
2.57
Gly
283.98
39.44
260.09
11.90
Ala
665.88
31.81
776.21
46.18
Citr
84.35
5.54
96.07
6.90
Val
256.47
18.31
286.92
19.70
Cys
0.00
0.00
3.61
2.89
Met
85.19
12.46
100.11
9.14
Ile
102.74
5.14
110.23
6.19
Leu
170.36
9.44
180.04
9.99
Tyr
82.94
6.18
83.05
5.94
Phe
71.48
2.11
73.67
3.47
Orn
74.15
7.35
101.76
11.42
Lys
318.41
17.80
400.52
36.11
1-Mhis
12.13
1.58
11.37
0.83
His
81.73
6.61
79.65
2.64
Trp
71.92
12.69
75.79
11.68
Arg
114.79
8.33
152.43
13.55
Hypro
13.98
5.14
11.44
4.56
Pro
70.32
19.24
81.94
20.17
Amino acid levels are expressed as µmoles/L plasma.

p (MANOVA)
.714939
.498940
.321242
.611157
.887741
.225054
.276701
.083888
.606145
.005159
.024089
.073518
.549262
.078419
.216917
.282501
.265627
.343749
.376756
.497543
.990105
.611836
.071060
.073514
.664781
.762944
.826045
.039927
.717204
.685982
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Table C-5: List of all mean 70 day male wild-type mouse plasma metabolite values grouped by
treatment and the corresponding p values obtained from the MANOVA.
Male Saline
Male MSO
Metabolite
Mean
SEM
Mean
SEM
Phser
6.53
1.14
13.50
2.05
Taur
281.63
21.25
461.24
83.37
Pea
1.02
1.02
9.02
3.10
Urea
11125.92
619.10
9940.21
559.60
Asp
12.86
1.68
16.70
1.03
Thr
195.79
16.55
216.30
7.62
Ser
150.69
6.72
165.93
12.59
Asn
44.20
4.91
50.88
4.43
Glu
8.34
3.75
28.75
5.84
Gln
531.61
29.86
521.15
29.52
Sarc
9.77
9.77
7.82
7.82
AAAA
13.29
2.27
18.16
4.73
Gly
325.48
13.66
343.19
19.40
Ala
673.60
28.49
792.01
102.36
Citr
89.76
4.80
86.56
2.18
Val
289.40
27.79
313.39
20.01
Cys
14.25
8.28
26.60
7.41
Met
86.78
16.53
102.09
6.17
Ile
95.95
7.91
108.78
9.60
Leu
162.02
13.50
187.05
12.91
Tyr
78.98
6.87
89.07
6.39
Phe
66.70
4.90
72.80
4.58
Orn
70.73
10.78
101.92
6.61
Lys
262.49
8.92
323.20
21.19
1-Mhis
10.09
1.22
8.80
1.36
His
67.63
2.41
70.22
7.64
Trp
50.16
4.57
30.05
12.61
Arg
98.38
7.17
106.75
12.49
Hypro
32.85
10.99
26.64
7.27
Pro
112.63
6.91
133.49
13.89
Amino acid levels are expressed as µmoles/L plasma.

p (MANOVA)
.012415
.048706
.026201
.196810
.098440
.321409
.290549
.347640
.013997
.810698
.883291
.351081
.463303
.256051
.585681
.517898
.304452
.443573
.324728
.218733
.318011
.394486
.044017
.020005
.497626
.734478
.140806
.558197
.663518
.188968
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Table C-6: List of all mean 70 day male SOD1 mouse plasma metabolite values grouped by
treatment and the corresponding p values obtained from the MANOVA.
Male Saline
Male MSO
Metabolite
Mean
SEM
Mean
SEM
Phser
6.66
1.50
7.92
2.87
Taur
291.36
36.36
331.25
12.93
Pea
0.63
0.63
5.72
1.70
Urea
11606.02
354.13
9963.08
788.85
Asp
9.14
0.41
11.77
1.36
Thr
176.47
11.26
197.97
17.38
Ser
137.06
8.20
141.76
8.73
Asn
38.76
4.14
51.89
4.82
Glu
11.07
5.48
22.76
3.66
Gln
540.98
29.63
433.62
39.49
Sarc
26.97
8.95
16.41
4.87
AAAA
10.10
0.84
16.76
2.33
Gly
281.24
5.40
290.55
15.89
Ala
521.33
43.07
710.40
53.65
Citr
77.27
4.71
82.64
6.67
Val
275.55
27.55
318.25
34.68
Cys
0.00
0.00
6.96
3.11
Met
79.05
6.87
92.37
10.19
Ile
92.07
8.86
101.32
7.09
Leu
157.39
14.14
180.63
11.67
Tyr
63.54
6.43
78.77
8.52
Phe
61.65
2.94
66.91
4.05
Orn
72.91
9.78
97.17
11.88
Lys
242.03
26.80
316.32
28.40
1-Mhis
9.68
2.23
7.56
0.84
His
64.16
2.34
67.09
2.52
Trp
42.58
7.40
66.02
4.31
Arg
86.41
10.63
121.90
14.48
Hypro
28.02
5.96
23.35
5.47
Pro
80.76
14.11
111.47
10.51
Amino acid levels are expressed as µmoles/L plasma.

p (MANOVA)
.715006
.295047
.019937
.093929
.105537
.333528
.703881
.062755
.092641
.053598
.302371
.024692
.609440
.018407
.533401
.362182
.057373
.312487
.424863
.223170
.186732
.324974
.145803
.081930
.365141
.414048
.014299
.076323
.572899
.099526
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APPENDIX D
THE EFFECTS OF OVARIECTOMIZATION ON PLASMA METABOLITES
Table D-1: List of all mean 70 day saline-treated female plasma metabolite values grouped by
intact or removed gonads and the corresponding p values obtained from the MANOVA.
Intact Females
OVR Females
Metabolite
Mean
SEM
Mean
SEM
Phser
5.51
1.32
2.96
0.69
Taur
348.69
37.23
270.76
16.02
Pea
1.61
1.06
1.39
0.71
Urea
9447.01
548.05
8408.40
366.88
Asp
9.15
0.60
4.57
1.67
Thr
189.55
11.37
153.59
10.79
Ser
151.72
6.30
120.88
5.90
Asn
47.09
3.20
43.81
3.17
Glu
9.55
3.73
14.23
0.97
Gln
646.85
25.91
630.12
19.32
Sarc
37.80
4.86
0.00
0.00
AAAA
11.17
2.71
19.59
1.41
Gly
283.98
39.44
253.01
8.86
Ala
665.88
31.81
569.99
40.38
Citr
84.35
5.54
96.22
6.29
Val
256.47
18.31
224.09
17.66
Cys
0.00
0.00
0.00
0.00
Met
85.19
12.46
64.71
5.39
Ile
102.74
5.14
99.05
8.44
Leu
170.36
9.44
152.26
9.79
Tyr
82.94
6.18
85.56
6.33
Phe
71.48
2.11
69.30
3.51
Orn
74.15
7.35
65.25
4.66
Lys
318.41
17.80
249.69
16.00
1-Mhis
12.13
1.58
11.94
1.21
His
81.73
6.61
62.77
2.81
Trp
71.92
12.69
69.96
4.13
Arg
114.79
8.33
101.39
6.38
Hypro
13.98
5.14
8.90
2.57
Pro
70.32
19.24
113.06
6.48
Amino acid levels are expressed as µmoles/L plasma.

p (MANOVA)
.076841
.034264
.974615
.121846
.035407
.056491
.003138
.525487
.184986
.429163
.000000
.006611
.375726
.119981
.189837
.231240
.171933
.701062
.176260
.729931
.730354
.292058
.014590
.950118
.013492
.861269
.230145
.376231
.017115
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Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease
characterized by motor neuron death and a corresponding loss of neuromuscular connections
resulting in muscle atrophy.

Patients become paralyzed shortly after symptom onset and

typically die within one to five years of pulmonary complications.

ALS is a relatively rare

disease, with an overall incidence of approximately 2 in 100,000 people per year and a
prevalence of about 5 in 100,000 people. It is typically associated with increasing age and has
a slight male prevalence, with a male to female ratio of approximately 3:2. ALS is classified as
either familial (the less common form of the disease that has a hereditary component) or
sporadic (the more common form that has no identifiable genetic component), with both forms of
the disease exhibiting a great deal of heterogeneity with respect to causes and underlying
molecular mechanisms. A wide variety of gene mutations have been associated with both
forms of ALS, including mutations in superoxide dismutase 1 (SOD1), TDP-43, and FUS, as
well as several other genes that have yet to be identified. These genes encode a variety of
proteins that encompass several processes within the cell, leading to an array of molecular
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mechanisms that can become dysfunctional during pathogenesis. These mechanisms include,
glutamate excitotoxicity, mitochondrial dysfunction and oxidative stress, dysfunctional protein
quality

control,

aberrant

mRNA

processing,

neurotrophic

factor

dysregulation,

and

neuroinflammation. ALS is difficult to diagnose due to the heterogeneity of symptoms exhibited
by patients and the lack of reliable biomarkers of the disease. As a result, a positive diagnosis
typically takes up to a year from symptom onset, at which time a significant amount of
irreversible damage has occurred.
Since ALS is a neurodegenerative disease, most research focuses on the central
nervous system, however data obtained from ALS patients and animal models suggests that
there are metabolic abnormalities associated with the disease. The experiments conducted in
this study first examined gender differences in the survival response to an irreversible inhibitor
of glutamine synthetase, L-methionine sulfoximine (MSO), which targets excitotoxicity using the
SOD1-G93A transgenic mouse model of ALS.

Human studies have shown that there are

gender differences in basic metabolism, and studies of drug metabolism in rats and humans
suggest that males and females may respond differently to treatment. The results of these
experiments show that female SOD1 mice respond better to MSO treatment, showing both an
extension in the average lifespan as well as improved neuromuscular function with MSO
treatment.

In addition, ovariectomy removes the beneficial effects of MSO treatment on both

survival and neuromuscular function. The second portion of this study was designed to test the
hypothesis that the SOD1 mutation disrupts nitrogen metabolism, specifically the urea cycle.
The results of these studies show that untreated presymptomatic SOD1 mice have altered
nitrogen metabolism and show decreased levels of several urea cycle intermediates in the
plasma compared to their wild-type counterparts. These plasma metabolites also show genderspecific differences in wild-type and SOD1 mice, supporting the idea that male and female mice
have differences in metabolism. Plasma metabolites change with age and suggest that there

262
are compensatory mechanisms that aid in normalizing plasma metabolites in SOD1 mice.
Again, these metabolites show gender-specificity and MSO treatment normalizes the levels of
these metabolites in a gender-specific fashion in SOD1 mice. Studies of nitrogen handling
enzymes also show that there are gender-specific differences in CPSI activity levels that are not
associated with expression of the transgene. Male SOD1 mice begin to show changes in
nitrogen handling enzymes in the liver, specifically glutamine synthetase and CPSI, suggesting
that males may begin to experience alterations in nitrogen metabolism prior to symptom onset
that may help to explain the gender-specific effects of MSO treatment in this mouse model.
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